<!doctype html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover">
  <title>APEX & Trust Prototype</title>
  <link rel="stylesheet" href="../../apex_trust_panel.css">
  <style>
    @keyframes ticker {
      0% { transform: translateX(0); }
      100% { transform: translateX(-50%); }
    }
    @media (max-width: 768px) {
      #scorecard-ticker { animation: ticker 15s linear infinite; }
    }
  </style>
</head>
<body>
  <!-- CONSOLIDATED STICKY HEADER BLOCK -->
  <div style="position: sticky; top: 0; z-index: 9999; margin: 0; padding: 0; width: 100%; overflow: hidden;">
    
    <!-- Page Header -->
    <div style="background: rgb(26, 35, 54); padding: 0.3rem 1.5rem; margin: 0; border-bottom: 1px solid rgba(10, 132, 255, 0.2);">
      <div style="display: flex; align-items: center; gap: 16px;">
        <div style="font-size: 18px; font-weight: 700; color: white;">üî•APEX Intelligence Terminal</div>
      </div>
    </div>

    <!-- Stock Info Header -->
    <div id="stock-info-header" style="margin: 0; padding: 0;">
      <!-- COMPANY INFO HEADER -->
      <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.75rem; background: rgb(26, 35, 54); box-shadow: 0 2px 8px rgba(0,0,0,0.3); border-bottom: 1px solid rgba(10, 132, 255, 0.4); padding: 0.6rem 1.5rem; margin: 0; width: 100%; position: relative; border-radius: 8px 8px 0 0;">
        <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.6rem; width: 100%; overflow: hidden;">
          <!-- Ticker & Company Name (Left) -->
          <div style="flex: 1 1 auto; min-width: 100px; max-width: 180px;">
            <div id="header-ticker" style="color: white; font-size: 0.95rem; font-weight: 800; letter-spacing: 0.5px;">--</div>
            <div id="header-company" style="color: rgba(255,255,255,0.6); font-size: 0.65rem; line-height: 1; margin-top: 1px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</div>
          </div>
          
          <!-- Key Metrics (Center) - 3 columns -->
          <div style="display: flex; gap: 0.5rem; align-items: center; flex: 2 1 auto; overflow: hidden;">
            <!-- Current Price (with currency) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">
                Price <span id="header-currency" style="color: #f59e0b; font-size: 0.5rem; font-weight: 600;">--</span>
              </div>
              <div id="header-price" style="color: white; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Market Cap -->
            <div style="text-align: center; min-width: 55px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Cap</div>
              <div id="header-mcap" style="color: #10b981; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Exchange (combined Market + Exchange) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Exchange</div>
              <div id="header-exchange" style="font-size: 0.75rem; font-weight: 700; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
          </div>
        </div>
      </div>
      
      <!-- Details Row -->
      <div style="display: flex; gap: 1.5rem; font-size: 0.65rem; background: rgb(26, 35, 54); box-shadow: 0 2px 6px rgba(0,0,0,0.2); border-bottom: 1px solid rgba(10, 132, 255, 0.2); padding: 0.35rem 1.5rem 0.4rem 1.5rem; margin: 0; text-align: left; border-radius: 0 0 8px 8px;">
        <div style="display: flex; align-items: center; gap: 0.4rem; min-width: 100px;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Sector:</span>
          <span id="header-sector" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
        <div style="display: flex; align-items: center; gap: 0.4rem; flex: 1; overflow: hidden;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Ind:</span>
          <span id="header-industry" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
      </div>
    </div>

    <!-- Bloomberg Scorecard Ticker -->
    <div style="background: rgb(26, 35, 54); border-left: 3px solid #0a84ff; padding: 0.5rem 0; margin: 0; font-family: 'Courier New', monospace; font-size: 13px; letter-spacing: 0.5px; box-shadow: 0 2px 4px rgba(0,0,0,0.2); overflow: hidden; width: 100%;">
      <div id="scorecard-ticker" style="display: flex; white-space: nowrap; animation: ticker 20s linear infinite; width: max-content;">
        <div class="ticker-content" style="display: flex; align-items: center; gap: 1.5rem; padding: 0 1.5rem; flex-shrink: 0;">
          <span style="color: rgba(255,255,255,0.6); font-size: 11px; text-transform: uppercase; font-weight: 600;">SCORECARD</span>
          <span id="scorecard-apex" style="background: #10b981; color: white; padding: 6px 12px; border-radius: 6px; font-weight: 700; font-size: 13px;">APEX SCORE:--</span>
          <span id="scorecard-setup" style="color: #3B82F6; font-weight: 700;">SETUP:--</span>
          <span id="scorecard-trust" style="color: #8B5CF6; font-weight: 700;">TRUST:--</span>
          <span id="scorecard-panic" style="color: #EF4444; font-weight: 700;">PANIC:--</span>
          <span id="scorecard-comp" style="color: #F59E0B; font-weight: 700;">COMPRESSION:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-timing" style="color: #3b82f6; font-weight: 700;">TIMING:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-action" style="color: #ef4444; font-weight: 700;">ACTION:--</span>
        </div>
      </div>
    </div>
  </div>

  <div class="container">
    <!-- Narrative Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="4" width="16" height="12" stroke="#10B981" stroke-width="1.5" fill="none" rx="2"/>
        <line x1="5" y1="4" x2="5" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="15" y1="4" x2="15" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="2" y1="7" x2="18" y2="7" stroke="#10B981" stroke-width="1.5"/>
        <circle cx="8" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="12" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="16" cy="11" r="1.2" fill="#10B981"/>
      </svg>
      <span style="color: #10B981; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Company in 30 Seconds</span>
    </div>

    <!-- Narrative Card Stack -->
    <div class="card-stack" id="narrative-stack" style="position: relative; min-height: 180px; overflow: visible; touch-action: pan-y; user-select: none; margin-bottom: 30px;">
      <!-- Card 1: What They Do -->
      <div class="card component-card stack-card narrative-card" data-index="0" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(0%) scale(1); opacity: 1; pointer-events: auto; z-index: 10;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <rect x="3" y="3" width="10" height="10" stroke="#10B981" stroke-width="1.5" fill="none" rx="1"/>
            <path d="M6 3 L6 1 M10 3 L10 1 M3 6 L13 6" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
            <circle cx="8" cy="9" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">What They Do <span class="info-icon" data-field="what" data-tooltip="Company business model and core operations" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Company business model and core operations')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-what" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 2: Why It Matters -->
      <div class="card component-card stack-card narrative-card" data-index="1" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <circle cx="8" cy="8" r="6" stroke="#10B981" stroke-width="1.5" fill="none"/>
            <circle cx="8" cy="8" r="2" fill="#10B981"/>
            <path d="M8 2 L8 6 M8 10 L8 14 M2 8 L6 8 M10 8 L14 8" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Why It Matters <span class="info-icon" data-field="why" data-tooltip="Market significance and investment thesis" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Market significance and investment thesis')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-why" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 3: Current State -->
      <div class="card component-card stack-card narrative-card" data-index="2" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <path d="M2 12 L5 9 L8 11 L14 4" stroke="#10B981" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
            <circle cx="5" cy="9" r="1.5" fill="#10B981"/>
            <circle cx="8" cy="11" r="1.5" fill="#10B981"/>
            <circle cx="14" cy="4" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Current State <span class="info-icon" data-field="state" data-tooltip="Latest company situation and metrics" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Latest company situation and metrics')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-state" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Narrative Stack Navigation -->
      <div class="stack-nav" style="bottom: -35px;">
        <div class="stack-dots">
          <span class="stack-dot narrative-dot" data-index="0"></span>
          <span class="stack-dot narrative-dot" data-index="1"></span>
          <span class="stack-dot narrative-dot" data-index="2"></span>
        </div>
        <div class="stack-label" style="color: #10B981;">Company</div>
      </div>
    </div>

    <!-- Scorecard Breakdown Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="6" width="3" height="12" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="7" y="3" width="3" height="15" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="12" y="8" width="3" height="10" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="17" y="5" width="1" height="13" rx="0.5" stroke="#fff" stroke-width="1.5" fill="none"/>
        <circle cx="10" cy="1" r="1.5" fill="#fff"/>
      </svg>
      <span style="color: #fff; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Scorecard Breakdown</span>
    </div>

    <!-- Main swipeable cards -->
    <div id="component-grid"></div>

    <!-- Bloomberg Phase 2: Collapsible Sections -->
    <div class="bloomberg-sections" style="margin-top: 20px;">
      <!-- CrashDash Intelligence -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('crashdash')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(59, 130, 246, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="crashdash-arrow" style="color: #3b82f6; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px;">CrashDash Intelligence</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">INDUSTRY PATTERNS ¬∑ RECOVERY PATHS</span>
        </div>
        <div id="crashdash-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="crashdash-data">Loading...</div>
        </div>
      </div>

      <!-- Catalyst Pipeline -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('catalyst')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(16, 185, 129, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="catalyst-arrow" style="color: #10b981; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #10b981; text-transform: uppercase; letter-spacing: 0.5px;">Catalyst Pipeline</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">UPCOMING EVENTS ¬∑ TIMELINE</span>
        </div>
        <div id="catalyst-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="catalyst-data">Loading...</div>
        </div>
      </div>

      <!-- Market Tape -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('market')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(245, 158, 11, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="market-arrow" style="color: #f59e0b; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #f59e0b; text-transform: uppercase; letter-spacing: 0.5px;">Market Tape</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">SOCIAL SENTIMENT ¬∑ TRENDS</span>
        </div>
        <div id="market-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="market-data">Loading...</div>
        </div>
      </div>

      <!-- Investment Decision -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('decision')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(239, 68, 68, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="decision-arrow" style="color: #ef4444; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #ef4444; text-transform: uppercase; letter-spacing: 0.5px;">Investment Decision</span>
          </div>
          <span id="decision-status" style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">ANALYSIS ¬∑ ACTION</span>
        </div>
        <div id="decision-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="decision-data">Loading...</div>
        </div>
      </div>

      <!-- Top 5 Recent RNS -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('rns')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(6, 182, 212, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="rns-arrow" style="color: #06b6d4; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #06b6d4; text-transform: uppercase; letter-spacing: 0.5px;">Top 5 Recent RNS</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">REGULATORY NEWS ¬∑ ANNOUNCEMENTS</span>
        </div>
        <div id="rns-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="rns-data">Loading...</div>
        </div>
      </div>
    </div>

    <!-- Bloomberg Terminal Footer (Collapsible) -->
    <div id="footer-container" style="margin-top: 40px; background: linear-gradient(180deg, #0a1628 0%, #020617 100%); border: 1px solid #1e293b; border-radius: 12px; overflow: hidden; box-shadow: 0 20px 50px rgba(0,0,0,0.5);">
        <!-- Header Bar (Always Visible) -->
        <div style="background: rgba(59, 130, 246, 0.08); border-bottom: 1px solid rgba(59, 130, 246, 0.2); padding: 12px 16px; cursor: pointer;" onclick="toggleFooter()">
            <div style="display: flex; align-items: center; justify-content: space-between; gap: 8px; width: 100%;">
                <div style="display: flex; align-items: center; gap: 8px; flex: 1; min-width: 0; overflow: hidden;">
                    <div style="width: 8px; height: 8px; background: #3b82f6; border-radius: 50%; box-shadow: 0 0 12px rgba(59, 130, 246, 0.6); flex-shrink: 0;"></div>
                    <span style="font-family: 'Courier New', monospace; font-size: 12px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">APEX Intelligence Terminal</span>
                    <span id="footer-toggle-icon" style="font-size: 14px; color: #3b82f6; transition: transform 0.3s ease; flex-shrink: 0; margin-left: auto;">‚ñº</span>
                </div>
            </div>
            <div style="font-family: 'Courier New', monospace; font-size: 9px; color: rgba(255, 255, 255, 0.4); letter-spacing: 0.3px; margin-top: 6px; overflow: hidden;">
                GENERATED: <span style="color: #06b6d4;" id="footerDate"></span> ‚Ä¢ SESSION: <span style="color: #10b981;">LIVE</span>
            </div>
        </div>
        
        <!-- Collapsible Content Section -->
        <div id="footer-content" style="display: none;">
            <!-- Content Grid -->
            <div style="padding: 24px; display: grid; grid-template-columns: 1fr 1fr; gap: 24px;">
                <!-- Left Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- System Information -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #3b82f6; margin-bottom: 8px; text-transform: uppercase; letter-spacing: 1px;">System Information</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.7); display: flex; gap: 16px; flex-wrap: wrap; align-items: center;">
                            <span><span style="color: rgba(255, 255, 255, 0.4);">VERSION:</span> <span style="color: #06b6d4; font-weight: 700;">APEX v5.0</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">ENGINE:</span> <span style="color: #10b981;">CrashDash Intelligence</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">COVERAGE:</span> <span style="color: #a855f7;">LSE AIM Micro-Caps</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">SOURCES:</span> <span style="color: #ef4444;">RNS ‚Ä¢ Social ‚Ä¢ Trends</span></span>
                        </div>
                    </div>
                    
                    <!-- Risk Disclosure -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #ef4444; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Risk Disclosure</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.5); line-height: 1.6;">
                            This analysis is provided for informational purposes only and does not constitute financial advice. AIM micro-cap securities carry significant volatility and liquidity risks. Past performance does not guarantee future results. Always conduct your own due diligence and consult with a qualified financial advisor before making investment decisions.
                        </div>
                    </div>
                </div>
                
                <!-- Right Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- Platform Overview -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #10b981; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Platform Overview</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.7); line-height: 1.6;">
                            APEX Intelligence Terminal combines technical analysis, sentiment tracking, and regulatory news monitoring to identify high-probability contrarian setups in distressed micro-cap equities. Our proprietary scoring system evaluates setup quality, panic intensity, and compression patterns to surface opportunities before institutional recognition.
                        </div>
                    </div>
                    
                    <!-- Target Users -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #a855f7; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Target Users</div>
                        <div style="display: flex; flex-wrap: wrap; gap: 8px;">
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(168, 85, 247, 0.1); border: 1px solid rgba(168, 85, 247, 0.3); border-radius: 4px; color: #a855f7; font-weight: 600;">PROP TRADERS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(59, 130, 246, 0.1); border: 1px solid rgba(59, 130, 246, 0.3); border-radius: 4px; color: #3b82f6; font-weight: 600;">HEDGE FUNDS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(16, 185, 129, 0.1); border: 1px solid rgba(16, 185, 129, 0.3); border-radius: 4px; color: #10b981; font-weight: 600;">QUANT TEAMS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(239, 68, 68, 0.1); border: 1px solid rgba(239, 68, 68, 0.3); border-radius: 4px; color: #ef4444; font-weight: 600;">RESEARCH DESKS</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Bottom Bar -->
            <div style="background: rgba(2, 6, 23, 0.6); border-top: 1px solid rgba(59, 130, 246, 0.15); padding: 12px 24px;">
                <div style="display: flex; align-items: center; justify-content: space-between; flex-wrap: wrap; gap: 12px; font-family: 'Courier New', monospace; font-size: 10px;">
                    <div style="color: rgba(255, 255, 255, 0.4);">¬© 2026 APEX Intelligence ‚Ä¢ All Rights Reserved</div>
                    <div style="display: flex; align-items: center; gap: 20px; color: rgba(255, 255, 255, 0.5);">
                        <span>STATUS: <span style="color: #10b981; font-weight: 700;">‚óè OPERATIONAL</span></span>
                        <span>LATENCY: <span style="color: #06b6d4; font-weight: 700;">12ms</span></span>
                        <span>BUILD: <span style="color: #a855f7; font-weight: 700;">5.0.2</span></span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function toggleFooter() {
            const content = document.getElementById('footer-content');
            const icon = document.getElementById('footer-toggle-icon');
            
            if (content.style.display === 'none') {
                content.style.display = 'block';
                icon.style.transform = 'rotate(180deg)';
            } else {
                content.style.display = 'none';
                icon.style.transform = 'rotate(0deg)';
            }
        }

        // Mobile-friendly tooltip popover
        function showTooltipPopover(event, tooltipText) {
            event.stopPropagation();
            
            // Close any existing popover
            const existing = document.getElementById('tooltip-popover');
            if (existing) existing.remove();
            
            // Create popover
            const popover = document.createElement('div');
            popover.id = 'tooltip-popover';
            popover.style.cssText = 'position:fixed;background:rgba(20,25,40,0.98);color:#e5e7eb;padding:10px 14px;border-radius:6px;font-size:12px;line-height:1.4;max-width:250px;border:1px solid rgba(16,185,129,0.3);z-index:10000;box-shadow:0 4px 12px rgba(0,0,0,0.4);backdrop-filter:blur(8px);word-wrap:break-word';
            popover.textContent = tooltipText;
            document.body.appendChild(popover);
            
            // Position near clicked element
            const rect = event.target.getBoundingClientRect();
            popover.style.left = Math.min(rect.left, window.innerWidth - 270) + 'px';
            popover.style.top = (rect.bottom + 8) + 'px';
            
            // Close on outside click
            setTimeout(() => {
                document.addEventListener('click', closeTooltip, { once: true });
            }, 0);
        }

        function closeTooltip() {
            const popover = document.getElementById('tooltip-popover');
            if (popover) popover.remove();
        }
    </script>
  </div>
  
  <!-- Mobile Responsive Styles -->
  <style>
    @media(max-width:768px){
        body{padding:10px!important}
        .container{max-width:100%!important}
        #footer-container{margin-top:20px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:12px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:repeat(2,1fr)!important;gap:10px!important}
        div[style*="padding: 24px"]{padding:16px!important}
        div[style*="padding: 12px 16px"]{padding:10px 12px!important}
        div[style*="gap: 20px"]{gap:14px!important}
        div[style*="font-size: 11px"]{font-size:10px!important}
        div[style*="font-size: 12px"]{font-size:11px!important}
        div[style*="font-size: 13px"]{font-size:12px!important}
    }
    @media(max-width:480px){
        body{padding:6px!important}
        .container{padding:0!important;margin:0!important}
        #footer-container{margin-top:16px!important;margin-left:6px!important;margin-right:6px!important}
        #footer-container > div:first-child{padding:8px 10px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:8px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:1fr!important;gap:6px!important;padding:8px 10px!important}
        div[style*="grid-template-columns: repeat(2"]{grid-template-columns:1fr!important;gap:6px!important}
        div[style*="padding: 24px"]{padding:10px!important}
        div[style*="padding: 12px 16px"]{padding:8px 10px!important}
        div[style*="padding: 14px 16px"]{padding:8px 10px!important}
        div[style*="padding: 18px"]{padding:10px!important}
        div[style*="gap: 20px"]{gap:8px!important}
        div[style*="gap: 30px"]{gap:10px!important}
        div[style*="gap: 24px"]{gap:10px!important}
        div[style*="gap: 16px"]{gap:6px!important}
        div[style*="gap: 12px"]{gap:6px!important}
        div[style*="gap: 8px"]{gap:4px!important}
        div[style*="font-size: 9px"]{font-size:8px!important}
        div[style*="font-size: 10px"]{font-size:8px!important}
        div[style*="font-size: 11px"]{font-size:9px!important}
        div[style*="font-size: 12px"]{font-size:10px!important}
        div[style*="font-size: 13px"]{font-size:11px!important}
        div[style*="padding: 6px 12px"]{padding:4px 6px!important;font-size:7px!important}
        div[style*="line-height: 1.8"]{line-height:1.4!important}
        div[style*="line-height: 1.6"]{line-height:1.3!important}
        div[style*="line-height: 1.5"]{line-height:1.2!important}
        /* Footer system info on mobile - stack vertically and shrink */
        div[style*="display: flex; gap: 16px; flex-wrap: wrap; align-items: center"] {
          flex-direction: column!important;
          align-items: flex-start!important;
          gap: 4px!important;
          font-size: 7px!important;
        }
    }
  </style>
  
  <script>window.__APEX_PROFILE = {
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "POLX.L",
  "generated_at": "2026-02-11T23:07:22.400305Z",
  "top_card": {
    "ticker": "POLX.L",
    "company_name": "Polarean Imaging plc",
    "sector": "Healthcare",
    "market_cap_gbp": 965626,
    "days_active": 25,
    "apex_score_100": 52,
    "confidence_score_100": 40,
    "ai_final_score_25": 13,
    "ai_strength": "MODERATE",
    "timing_regime": "TOO_EARLY",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - TOO_EARLY timing with 52/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Polarean Imaging plc",
      "sector": "Healthcare",
      "industry": "Medical Devices",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 965626,
      "current_close_price": 0.08
    },
    "basics": {
      "ticker": "POLX.L",
      "current_price": 0.08,
      "ath": 113.0,
      "atl": 0.06,
      "ath_date": "2021-09-27",
      "atl_date": "2025-12-22",
      "week_52_high": 1.6,
      "week_52_low": 0.06,
      "week_52_high_date": "2025-02-12",
      "week_52_low_date": "2025-12-22",
      "drawdown_from_ath_pct": 99.93,
      "data_start": "2020-01-02",
      "data_end": "2025-12-22",
      "total_bars": 1510
    },
    "latest_signal": {
      "date": "2025-11-27",
      "scan_date": "2026-01-26",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "price": 0.08,
      "drawdown_pct": 95.0,
      "ai_score": 11.0,
      "rsi": 10.5,
      "cycle_position": 0.0282,
      "holding_period_days": 25,
      "current_pnl_pct": -0.0,
      "rally_state": "accumulating",
      "distance_from_high_pct": -62.79,
      "Rally_Count": 2,
      "days_since_last_high": 48,
      "last_high_date": "2025-12-09",
      "lock_in_reached": true,
      "lock_in_date": "2025-12-08",
      "best_rally_pct": 168.75
    },
    "best_historical_signal": {
      "signal_date": "2025-11-24",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "entry_price": 0.08,
      "peak_price": 0.24,
      "peak_date": "2025-12-09",
      "rally_pct": 200.0,
      "days_to_peak": 15,
      "ai_score": 13.0
    },
    "all_historical_signals": [
      {
        "signal_id": "POLX.L_2023-08-02",
        "signal_date": "2023-08-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 16.5,
        "current_price": 0.08,
        "current_return_pct": -99.52,
        "best_rally_pct": 12.12,
        "best_rally_date": "2023-08-07",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -99.57,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 908,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-08-03",
        "signal_date": "2023-08-03",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 15.8,
        "current_price": 0.08,
        "current_return_pct": -99.49,
        "best_rally_pct": 17.09,
        "best_rally_date": "2023-08-07",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -99.57,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 907,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-08-09",
        "signal_date": "2023-08-09",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 15.75,
        "current_price": 0.08,
        "current_return_pct": -99.49,
        "best_rally_pct": -1.59,
        "best_rally_date": "2023-08-10",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 901,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-08-10",
        "signal_date": "2023-08-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 15.5,
        "current_price": 0.08,
        "current_return_pct": -99.48,
        "best_rally_pct": -1.61,
        "best_rally_date": "2023-08-11",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 900,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-08-16",
        "signal_date": "2023-08-16",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.25,
        "current_price": 0.08,
        "current_return_pct": -99.44,
        "best_rally_pct": 7.02,
        "best_rally_date": "2023-08-25",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -99.48,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 894,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-09-07",
        "signal_date": "2023-09-07",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 11.5,
        "current_price": 0.08,
        "current_return_pct": -99.3,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-09-08",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 872,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-09-13",
        "signal_date": "2023-09-13",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.75,
        "current_price": 0.08,
        "current_return_pct": -99.26,
        "best_rally_pct": -3.49,
        "best_rally_date": "2023-09-22",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 866,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-09-14",
        "signal_date": "2023-09-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 9.25,
        "current_price": 0.08,
        "current_return_pct": -99.14,
        "best_rally_pct": 12.16,
        "best_rally_date": "2023-09-22",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -99.23,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 865,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-09-15",
        "signal_date": "2023-09-15",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 10.0,
        "current_price": 0.08,
        "current_return_pct": -99.2,
        "best_rally_pct": 3.75,
        "best_rally_date": "2023-09-22",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -99.23,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 864,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-09-22",
        "signal_date": "2023-09-22",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.375,
        "current_price": 0.08,
        "current_return_pct": -99.23,
        "best_rally_pct": -2.17,
        "best_rally_date": "2023-09-26",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 857,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-10-02",
        "signal_date": "2023-10-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.15,
        "current_price": 0.08,
        "current_return_pct": -99.13,
        "best_rally_pct": -3.83,
        "best_rally_date": "2023-10-03",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 847,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-10-24",
        "signal_date": "2023-10-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 0.08,
        "current_return_pct": -98.93,
        "best_rally_pct": 6.67,
        "best_rally_date": "2023-10-26",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 825,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-02",
        "signal_date": "2023-11-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.75,
        "current_price": 0.08,
        "current_return_pct": -98.97,
        "best_rally_pct": 3.23,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 816,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-09",
        "signal_date": "2023-11-09",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 6.9,
        "current_price": 0.08,
        "current_return_pct": -98.84,
        "best_rally_pct": 15.94,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 809,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-10",
        "signal_date": "2023-11-10",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.9,
        "current_price": 0.08,
        "current_return_pct": -98.84,
        "best_rally_pct": 15.94,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 808,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-16",
        "signal_date": "2023-11-16",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 6.85,
        "current_price": 0.08,
        "current_return_pct": -98.83,
        "best_rally_pct": 16.79,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 802,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-17",
        "signal_date": "2023-11-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 6.85,
        "current_price": 0.08,
        "current_return_pct": -98.83,
        "best_rally_pct": 16.79,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 801,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-20",
        "signal_date": "2023-11-20",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 6.95,
        "current_price": 0.08,
        "current_return_pct": -98.85,
        "best_rally_pct": 15.11,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 798,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-22",
        "signal_date": "2023-11-22",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 6.55,
        "current_price": 0.08,
        "current_return_pct": -98.78,
        "best_rally_pct": 22.14,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 796,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-24",
        "signal_date": "2023-11-24",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 6.1,
        "current_price": 0.08,
        "current_return_pct": -98.69,
        "best_rally_pct": 31.15,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 794,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-27",
        "signal_date": "2023-11-27",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 5.5,
        "current_price": 0.08,
        "current_return_pct": -98.55,
        "best_rally_pct": 45.45,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 791,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-28",
        "signal_date": "2023-11-28",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 4.95,
        "current_price": 0.08,
        "current_return_pct": -98.38,
        "best_rally_pct": 61.62,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 790,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-11-29",
        "signal_date": "2023-11-29",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 5.3,
        "current_price": 0.08,
        "current_return_pct": -98.49,
        "best_rally_pct": 50.94,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 789,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2023-12-01",
        "signal_date": "2023-12-01",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 4.9,
        "current_price": 0.08,
        "current_return_pct": -98.37,
        "best_rally_pct": 63.27,
        "best_rally_date": "2024-01-22",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -99.0,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 787,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-02-08",
        "signal_date": "2024-02-08",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 5.75,
        "current_price": 0.08,
        "current_return_pct": -98.61,
        "best_rally_pct": 21.74,
        "best_rally_date": "2024-02-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -98.86,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 718,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-02-29",
        "signal_date": "2024-02-29",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 3.9,
        "current_price": 0.08,
        "current_return_pct": -97.95,
        "best_rally_pct": 37.18,
        "best_rally_date": "2024-03-06",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -98.5,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 697,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-03-01",
        "signal_date": "2024-03-01",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 4.25,
        "current_price": 0.08,
        "current_return_pct": -98.12,
        "best_rally_pct": 25.88,
        "best_rally_date": "2024-03-06",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -98.5,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 696,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-03-28",
        "signal_date": "2024-03-28",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 4.3,
        "current_price": 0.08,
        "current_return_pct": -98.14,
        "best_rally_pct": 0.0,
        "best_rally_date": "2024-04-02",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -98.14,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 669,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-04-04",
        "signal_date": "2024-04-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 3.9,
        "current_price": 0.08,
        "current_return_pct": -97.95,
        "best_rally_pct": 3.85,
        "best_rally_date": "2024-05-10",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -98.02,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 662,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-05-09",
        "signal_date": "2024-05-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 3.45,
        "current_price": 0.08,
        "current_return_pct": -97.68,
        "best_rally_pct": 17.39,
        "best_rally_date": "2024-05-10",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -98.02,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 627,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-05-22",
        "signal_date": "2024-05-22",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 1.2368,
        "current_price": 0.08,
        "current_return_pct": -93.53,
        "best_rally_pct": 73.84,
        "best_rally_date": "2024-06-20",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -96.28,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 614,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-05-23",
        "signal_date": "2024-05-23",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.35,
        "current_price": 0.08,
        "current_return_pct": -94.07,
        "best_rally_pct": 59.26,
        "best_rally_date": "2024-06-20",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -96.28,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 613,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-10-02",
        "signal_date": "2024-10-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.375,
        "current_price": 0.08,
        "current_return_pct": -94.18,
        "best_rally_pct": 20.0,
        "best_rally_date": "2024-11-07",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.15,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 481,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-10-14",
        "signal_date": "2024-10-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.325,
        "current_price": 0.08,
        "current_return_pct": -93.96,
        "best_rally_pct": 24.53,
        "best_rally_date": "2024-11-07",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.15,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 469,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-10-23",
        "signal_date": "2024-10-23",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.225,
        "current_price": 0.08,
        "current_return_pct": -93.47,
        "best_rally_pct": 34.69,
        "best_rally_date": "2024-11-07",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -95.15,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 460,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-10-24",
        "signal_date": "2024-10-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.225,
        "current_price": 0.08,
        "current_return_pct": -93.47,
        "best_rally_pct": 34.69,
        "best_rally_date": "2024-11-07",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -95.15,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 459,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-12-12",
        "signal_date": "2024-12-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 0.08,
        "current_return_pct": -94.07,
        "best_rally_pct": 11.11,
        "best_rally_date": "2025-02-10",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.67,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 410,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2024-12-17",
        "signal_date": "2024-12-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.3,
        "current_price": 0.08,
        "current_return_pct": -93.85,
        "best_rally_pct": 15.38,
        "best_rally_date": "2025-02-10",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -94.67,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 405,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-01-17",
        "signal_date": "2025-01-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.2,
        "current_price": 0.08,
        "current_return_pct": -93.33,
        "best_rally_pct": 25.0,
        "best_rally_date": "2025-02-10",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -94.67,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 374,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-01-20",
        "signal_date": "2025-01-20",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.175,
        "current_price": 0.08,
        "current_return_pct": -93.19,
        "best_rally_pct": 27.66,
        "best_rally_date": "2025-02-10",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -94.67,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 371,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-01-24",
        "signal_date": "2025-01-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.15,
        "current_price": 0.08,
        "current_return_pct": -93.04,
        "best_rally_pct": 30.43,
        "best_rally_date": "2025-02-10",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -94.67,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 367,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-04-04",
        "signal_date": "2025-04-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.975,
        "current_price": 0.08,
        "current_return_pct": -91.79,
        "best_rally_pct": 48.72,
        "best_rally_date": "2025-06-24",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -94.48,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 297,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-04-07",
        "signal_date": "2025-04-07",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.975,
        "current_price": 0.08,
        "current_return_pct": -91.79,
        "best_rally_pct": 48.72,
        "best_rally_date": "2025-06-24",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -94.48,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 294,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-05-08",
        "signal_date": "2025-05-08",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.925,
        "current_price": 0.08,
        "current_return_pct": -91.35,
        "best_rally_pct": 56.76,
        "best_rally_date": "2025-06-24",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.48,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 263,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-10-22",
        "signal_date": "2025-10-22",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.19,
        "current_price": 0.08,
        "current_return_pct": -57.89,
        "best_rally_pct": 13.16,
        "best_rally_date": "2025-12-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -62.79,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 96,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-10-23",
        "signal_date": "2025-10-23",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.185,
        "current_price": 0.08,
        "current_return_pct": -56.76,
        "best_rally_pct": 16.22,
        "best_rally_date": "2025-12-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -62.79,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 95,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-10-24",
        "signal_date": "2025-10-24",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.18,
        "current_price": 0.08,
        "current_return_pct": -55.56,
        "best_rally_pct": 19.44,
        "best_rally_date": "2025-12-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -62.79,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 94,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-10-29",
        "signal_date": "2025-10-29",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.14,
        "current_price": 0.08,
        "current_return_pct": -42.86,
        "best_rally_pct": 53.57,
        "best_rally_date": "2025-12-08",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -62.79,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 89,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-10-30",
        "signal_date": "2025-10-30",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.16,
        "current_price": 0.08,
        "current_return_pct": -50.0,
        "best_rally_pct": 34.38,
        "best_rally_date": "2025-12-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -62.79,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 88,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-11-10",
        "signal_date": "2025-11-10",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.16,
        "current_price": 0.08,
        "current_return_pct": -50.0,
        "best_rally_pct": 34.38,
        "best_rally_date": "2025-12-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -62.79,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 77,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-11-14",
        "signal_date": "2025-11-14",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.11,
        "current_price": 0.08,
        "current_return_pct": -27.27,
        "best_rally_pct": 95.45,
        "best_rally_date": "2025-12-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -62.79,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 73,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-11-24",
        "signal_date": "2025-11-24",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.08,
        "current_price": 0.08,
        "current_return_pct": -0.0,
        "best_rally_pct": 168.75,
        "best_rally_date": "2025-12-08",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -62.79,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 63,
        "status": "historical"
      },
      {
        "signal_id": "POLX.L_2025-11-27",
        "signal_date": "2025-11-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.08,
        "current_price": 0.08,
        "current_return_pct": -0.0,
        "best_rally_pct": 168.75,
        "best_rally_date": "2025-12-08",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -62.79,
        "days_since_last_high": 48,
        "lock_in_reached": true,
        "age_days": 60,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 53,
      "win_rate_pct": 98.1,
      "avg_rally_pct": 41.95,
      "median_rally_pct": 30.43,
      "best_rally_pct": 200.0,
      "worst_rally_pct": -0.11
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-11 20:06:44 UTC",
    "volatility": {
      "atr_normalized": 8.95,
      "stddev_20d": 0.3466
    },
    "trends": {
      "intelligence_signal": "ACCUMULATION"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 52/100 indicates strong opportunity quality",
      "Timing regime: TOO_EARLY",
      "Historical profile: 2 rallies, 169% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "POLX.L",
      "latest": [
        {
          "title": "Cancellation - Polarean Imaging Plc",
          "announcement_date": "23rd Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "23 Dec 2025 07:00\nRNS Number : 5195M\nAIM\n23 December 2025\nNOTICE\n23/12/2025 - 07:00\nNOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM\nAt the request of the company the following securities have been cancelled from trading on AIM with effect from the time and date of this notice.\nPOLAREAN IMAGING PLC\n213800DGR2BHXJ36OL37\nORDINARY SHARES OF GBP0.00037 EACH, FULLY PAID\n(BF3DT58)(GB00BF3DT583)\nPOLN IMAG/PAR VTG FPD 0.00037\nIf you have any queries or require further information, please contact the company's nominated adviser.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAMOPPGBCPUPAGPP",
          "rns_number": "RNS Number : 5195M"
        },
        {
          "title": "Result of General Meeting",
          "announcement_date": "15th Dec 2025",
          "release_time": "4:03 pm",
          "source": "RNS",
          "content": "15 Dec 2025 16:03\nRNS Number : 6387L\nPolarean Imaging PLC\n15 December 2025\n15 December 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nResult of General Meeting\nInformation on Matched Bargain Facility to assist shareholders\nPolarean Imaging plc (AIM: POLX),\u00a0a commercial-stage medical technology company and global leader in functional lung imaging using hyperpolarised Xenon MRI,\u00a0announces that at the general meeting of the Company (\"\nGeneral Meeting\n\") held earlier today, all resolutions were duly passed on a poll.\nDetails of the poll results are set out below:\nResolution Number\nName\nVotes for\n% of votes for\nVotes against\n% of votes against\nVotes withheld*\n1\nCancellation Resolution\n534,365,742\n80.71%\n127,743,445\n19.29%\n2,347,443\n2\nRe-registration and adoption of new articles of association Resolution\n534,390,927\n80.71%\n127,740,655\n19.29%\n2,325,048\n*\nNote: A 'vote withheld' is not a vote under English law and is not counted in the calcula\nti\non of votes 'for' or 'against' a resolution.\nValid proxy instructions were received in respect of 664,456,630 Ordinary Shares representing approximately 55.05% of the issued share capital of the Company.\nThe total number of Ordinary Shares in issue as at 15 December 2025 is 1,207,032,781.\nThe full text of the Resolutions proposed and passed at the General Meeting can be found in the circular of the Company containing, inter alia, the notice of General Meeting, which was published on 14 November 2025 (the \"\nCircular\n\") and is available on the Company's website\nhere\n. Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular.\nAIM Cancellation\nFollowing approval by Shareholders at the General Meeting, the admission of the Ordinary Shares to trading on AIM will be cancelled. The Cancellation is expected to take place at 7:00 a.m. on 23 December 2025 and, accordingly, the last day of dealings in Ordinary Shares on AIM is expected to be 22 December 2025.\nRe-registration as a private company\nIn accordance with the passing of Resolution 2, the Company will re-register as a private limited company and adopt new articles of association, which is expected to take place by 12 January 2026.\nMatched Bargain Facility\nThe Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (\nwww.polarean.com\n). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation.\nShareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares.\nThe Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders.\nThe indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at\nhttps://jpjenkins.com/\n.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\nTel: +44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please visit the website at\nwww.polarean.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nROMQELFFELLBFBL",
          "rns_number": "RNS Number : 6387L"
        },
        {
          "title": "Chest coil passes Philips compatibility testing",
          "announcement_date": "1st Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "1 Dec 2025 07:00\nRNS Number : 5089J\nPolarean Imaging PLC\n01 December 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nXENOVIEW\u00ae 3T coil passes Philips compatibility testing\nPolarean's FDA cleared coil achieves important milestone, expanding clinical reach\nPolarean Imaging plc (AIM: POLX),\na commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs\n, announces\nthat its FDA-cleared XENOVIEW\u00ae 3T Chest Coil has successfully completed compatibility testing conducted by Philips (Philips Medical Systems Nederland B.V.) and is now confirmed for use with Philips' latest 3T MRI platforms.\nFollowing extensive validation by Philips, the XENOVIEW\u00ae 3T Chest Coil is now confirmed for integration with Philips MRI systems starting in early 2026, including 3.0T platforms such as the\nMR 7700\nand\nIngenia Elition X\n, along with their associated upgrade pathways. Building on Philips' introduction of Xenon MRI compatibility in 2022 with the MR 7700, the addition of the Polarean XENOVIEW 3T Chest Coil expands access to advanced pulmonary imaging and supports a new era of functional lung assessment.\nThis confirmation,\nbuilding on the coil's FDA clearance in 2024, positions the technology for rapid clinical adoption and revenue generation. The XENOVIEW 3T Chest Coil enables healthcare providers to seamlessly adopt advanced functional lung ventilation imaging, supporting broader clinical adoption and advancing the Company's commitment to innovation in pulmonary imaging.\nThis milestone marks a major advance in scaling Polarean's Xenon MRI technology across a major global installed base and enables clinical and research sites using Philips MRI systems to incorporate non-invasive, quantitative assessments of lung function as part of routine care and research. Following this, Polarean is\nwell positioned to accelerate adoption, expand market penetration and enhance significant commercial and clinical value worldwide.\nChristopher von Jako, Ph.D., Chief Executive Officer of Polarean commented:\n\"This milestone marks another important advancement in our vision to optimise lung health and prevent avoidable loss by illuminating hidden disease. Compatibility with Philips' state-of-the-art MRI platforms greatly broadens the accessibility of Xenon MRI and will help more hospitals and imaging centres adopt this powerful technology.\nEqually significant, our FDA-cleared coil's seamless integration with Philips systems positions us to drive adoption by reducing workflow complexity for clinicians, accelerating market penetration and unlocking growth opportunities.\"\nGwenael Herigault, Global MR Clinical Leader at Philips commented:\n\"\nThe compatibility of Polarean's FDA-cleared XENOVIEW\u00ae 3T Chest Coil with Philips' 3T MRI systems reinforces our shared goal of expanding the capabilities of MRI to deliver deeper clinical insights.\nTogether, we're enabling clinicians to access advanced lung imaging tools that help improve diagnostic confidence and patient care.\"\nThe compatibility statement confirms that the FDA-cleared XENOVIEW 3T Chest Coil can be used with Philips MR 7700, Ingenia Elition X, and compatible software upgrade configurations\nfrom 2026 onwards\n. This development significantly expands the potential reach of Polarean's technology and supports its goal of making functional lung MRI more widely available to clinicians and patients worldwide.\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0) 7980541893 /\u00a0+44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW\n\u00ae\nIMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.\nRisk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.\nAdverse Reactions\nAdverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.\nPlease see full prescribing information at\nwww.xenoview.net\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCGZMZMVRFGKZM",
          "rns_number": "RNS Number : 5089J"
        },
        {
          "title": "First Xenon Hyperpolariser in Asia",
          "announcement_date": "25th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "25 Nov 2025 07:00\nRNS Number : 8133I\nPolarean Imaging PLC\n25 November 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nFirst Polarean Xenon Hyperpolariser to be installed in Asia\nCollaboration with Philips and Sumtage to\nbring Xenon MRI technology to Taiwan\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs, announces that the National Taiwan University Hospital (\"NTUH\") has entered into an agreement for a Xenon MRI research system in Taiwan through Polarean's strategic partner, Philips (Philips Medical Systems Nederland B.V.).\nNTUH is widely recognised as Taiwan's leading academic medical centre, with a strong track record in clinical research and advanced patient care. The order will be supported by Polarean's\nnewly appointed Taiwanese distributor\n, Sumtage Enterprise Company Limited (\"Sumtage\"), who will assist in the installation and training at NTUH, and work collaboratively with Polarean on the steps required to secure regulatory approval and reimbursement in Taiwan.\nThis milestone represents Polarean's first entry into Asia and an important step in building the foundations for future adoption of Xenon MRI in the region.\nChristopher von Jako, Ph.D., CEO of Polarean, said:\n\"This first Xenon MRI system in Taiwan, supported by Philips and Sumtage, marks an important milestone in our international strategy. The National Taiwan University Hospital is the country's premier academic medical centre, and this order highlights the recognition of Xenon MRI's potential in lung health. Together with Sumtage, we will focus on ensuring successful installation and training at NTUH while also advancing the regulatory and reimbursement pathways needed for broader adoption in Taiwan.\"\nHui-Lin Su, General Manager of Sumtage, said:\n\"We are excited to partner with Polarean to bring this groundbreaking Xenon MRI technology to Taiwan. Our goal is to support hospitals like NTUH with not only the technology itself, but also the training and long-term support required for success. We look forward to working with Polarean to secure regulatory approval and reimbursement so that physicians and patients across Taiwan can benefit from this innovation.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nFor more information, visit\nwww.xenoview.net\n.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy/ Paul McManus / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0) 7980541893 /\u00a0+44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u2122, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.\nRisk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.\nAdverse Reactions\nAdverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration.\nPlease see full prescribing information at www.XENOVIEW.net\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBZLLLEFLBFBX",
          "rns_number": "RNS Number : 8133I"
        },
        {
          "title": "Korean distributor agreement with DK Healthcare",
          "announcement_date": "24th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "24 Nov 2025 07:00\nRNS Number : 6022I\nPolarean Imaging PLC\n24 November 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nKorean distributor agreement with DK Healthcare in South Korea\nExpanding commercial reach and advancing lung imaging innovation in Asia-Pacific\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, announces it has signed an exclusive distribution agreement with DK Healthcare Co., Ltd. (\"DK Healthcare\") for the distribution of Polarean's Xenon MRI platform in South Korea.\nThis agreement represents Polarean's second international distribution partnership,\nstrengthening the Company's commercial presence across the Asia-Pacific region.\nThrough this partnership, Polarean is\nstrategically positioning its innovative Xenon MRI platform for entry\ninto one of the world's most advanced medical imaging markets\n.\nThe Company will collaborate with DK Healthcare to obtain the necessary regulatory clearances ahead of commercial launch in South Korea.\nDK was founded in 1986 and is headquartered in Seoul. They are a leading provider of diagnostic radiology systems and imaging technologies in Korea, and DK Healthcare is one of the affiliates of DK. Through long-standing partnerships with global medical device manufacturers, DK Healthcare has built a reputation for delivering cutting-edge imaging solutions, along with comprehensive technical, clinical, and maintenance support.\nChristopher von Jako, Ph.D., CEO of Polarean, said:\n\"We are delighted to partner with DK Healthcare, one of South Korea's most respected medical imaging distributors, to expand access to our Xenon MRI platform.\nSouth Korea's strong emphasis on early detection and precision medicine makes it an ideal growth market, and\nthis agreement accelerates\nour dual-track strategy\nto grow internationally through high-quality regional partners while our U.S. team continues to drive adoption domestically.\"\nJoonhyuk Lee, CEO of DK Healthcare, said:\n\"We are excited to introduce Polarean's Xenon MRI technology to Korea's leading hospitals and imaging centers. This platform offers clinicians a new dimension in lung function assessment by enabling visualisation of ventilation and gas-exchange that was previously impossible with conventional imaging. We believe Xenon MRI will play a vital role in\ntransforming respiratory care in South Korea through enhancing early detection and outcomes for patients with lung cancer, COPD and beyond.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\n/ Paul McManus / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0) 7980541893 /\u00a0+44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW\n\u00ae\nIMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.\nRisk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.\nAdverse Reactions\nAdverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.\nPlease see full prescribing information at\nwww.xenoview.net\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRKZMZMKMVGKZM",
          "rns_number": "RNS Number : 6022I"
        }
      ],
      "themes": [
        "drilling"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 775,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "ACCUMULATION"
    },
    "volatility": {
      "atr_normalized": 8.95,
      "stddev_20d": 0.3466
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-23rd Dec 2025-cancella",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.826571Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Cancellation - Polarean Imaging Plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/cancellation-polarean-imaging-plc-u2s9vwvpfq0aw29.html",
          "rns_number": "RNS Number : 5195M",
          "full_content": "23 Dec 2025 07:00\nRNS Number : 5195M\nAIM\n23 December 2025\nNOTICE\n23/12/2025 - 07:00\nNOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM\nAt the request of the company the following securities have been cancelled from trading on AIM with effect from the time and date of this notice.\nPOLAREAN IMAGING PLC\n213800DGR2BHXJ36OL37\nORDINARY SHARES OF GBP0.00037 EACH, FULLY PAID\n(BF3DT58)(GB00BF3DT583)\nPOLN IMAG/PAR VTG FPD 0.00037\nIf you have any queries or require further information, please contact the company's nominated adviser.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAMOPPGBCPUPAGPP",
          "content_length": 1310
        },
        "ingested_at": "2026-01-12T21:58:06.826615Z"
      },
      {
        "event_id": "RNS-15th Dec 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.826646Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/result-of-general-meeting-o4l59uemyrgzplg.html",
          "rns_number": "RNS Number : 6387L",
          "full_content": "15 Dec 2025 16:03\nRNS Number : 6387L\nPolarean Imaging PLC\n15 December 2025\n15 December 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nResult of General Meeting\nInformation on Matched Bargain Facility to assist shareholders\nPolarean Imaging plc (AIM: POLX),\u00a0a commercial-stage medical technology company and global leader in functional lung imaging using hyperpolarised Xenon MRI,\u00a0announces that at the general meeting of the Company (\"\nGeneral Meeting\n\") held earlier today, all resolutions were duly passed on a poll.\nDetails of the poll results are set out below:\nResolution Number\nName\nVotes for\n% of votes for\nVotes against\n% of votes against\nVotes withheld*\n1\nCancellation Resolution\n534,365,742\n80.71%\n127,743,445\n19.29%\n2,347,443\n2\nRe-registration and adoption of new articles of association Resolution\n534,390,927\n80.71%\n127,740,655\n19.29%\n2,325,048\n*\nNote: A 'vote withheld' is not a vote under English law and is not counted in the calcula\nti\non of votes 'for' or 'against' a resolution.\nValid proxy instructions were received in respect of 664,456,630 Ordinary Shares representing approximately 55.05% of the issued share capital of the Company.\nThe total number of Ordinary Shares in issue as at 15 December 2025 is 1,207,032,781.\nThe full text of the Resolutions proposed and passed at the General Meeting can be found in the circular of the Company containing, inter alia, the notice of General Meeting, which was published on 14 November 2025 (the \"\nCircular\n\") and is available on the Company's website\nhere\n. Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular.\nAIM Cancellation\nFollowing approval by Shareholders at the General Meeting, the admission of the Ordinary Shares to trading on AIM will be cancelled. The Cancellation is expected to take place at 7:00 a.m. on 23 December 2025 and, accordingly, the last day of dealings in Ordinary Shares on AIM is expected to be 22 December 2025.\nRe-registration as a private company\nIn accordance with the passing of Resolution 2, the Company will re-register as a private limited company and adopt new articles of association, which is expected to take place by 12 January 2026.\nMatched Bargain Facility\nThe Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (\nwww.polarean.com\n). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation.\nShareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares.\nThe Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders.\nThe indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at\nhttps://jpjenkins.com/\n.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\nTel: +44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine",
          "content_length": 7136
        },
        "ingested_at": "2026-01-12T21:58:06.826680Z"
      },
      {
        "event_id": "RNS-1st Dec 2025-chestcoi",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.826707Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Chest coil passes Philips compatibility testing",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/chest-coil-passes-philips-compatibility-testing-1mbtl2yurs2j32d.html",
          "rns_number": "RNS Number : 5089J",
          "full_content": "1 Dec 2025 07:00\nRNS Number : 5089J\nPolarean Imaging PLC\n01 December 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nXENOVIEW\u00ae 3T coil passes Philips compatibility testing\nPolarean's FDA cleared coil achieves important milestone, expanding clinical reach\nPolarean Imaging plc (AIM: POLX),\na commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs\n, announces\nthat its FDA-cleared XENOVIEW\u00ae 3T Chest Coil has successfully completed compatibility testing conducted by Philips (Philips Medical Systems Nederland B.V.) and is now confirmed for use with Philips' latest 3T MRI platforms.\nFollowing extensive validation by Philips, the XENOVIEW\u00ae 3T Chest Coil is now confirmed for integration with Philips MRI systems starting in early 2026, including 3.0T platforms such as the\nMR 7700\nand\nIngenia Elition X\n, along with their associated upgrade pathways. Building on Philips' introduction of Xenon MRI compatibility in 2022 with the MR 7700, the addition of the Polarean XENOVIEW 3T Chest Coil expands access to advanced pulmonary imaging and supports a new era of functional lung assessment.\nThis confirmation,\nbuilding on the coil's FDA clearance in 2024, positions the technology for rapid clinical adoption and revenue generation. The XENOVIEW 3T Chest Coil enables healthcare providers to seamlessly adopt advanced functional lung ventilation imaging, supporting broader clinical adoption and advancing the Company's commitment to innovation in pulmonary imaging.\nThis milestone marks a major advance in scaling Polarean's Xenon MRI technology across a major global installed base and enables clinical and research sites using Philips MRI systems to incorporate non-invasive, quantitative assessments of lung function as part of routine care and research. Following this, Polarean is\nwell positioned to accelerate adoption, expand market penetration and enhance significant commercial and clinical value worldwide.\nChristopher von Jako, Ph.D., Chief Executive Officer of Polarean commented:\n\"This milestone marks another important advancement in our vision to optimise lung health and prevent avoidable loss by illuminating hidden disease. Compatibility with Philips' state-of-the-art MRI platforms greatly broadens the accessibility of Xenon MRI and will help more hospitals and imaging centres adopt this powerful technology.\nEqually significant, our FDA-cleared coil's seamless integration with Philips systems positions us to drive adoption by reducing workflow complexity for clinicians, accelerating market penetration and unlocking growth opportunities.\"\nGwenael Herigault, Global MR Clinical Leader at Philips commented:\n\"\nThe compatibility of Polarean's FDA-cleared XENOVIEW\u00ae 3T Chest Coil with Philips' 3T MRI systems reinforces our shared goal of expanding the capabilities of MRI to deliver deeper clinical insights.\nTogether, we're enabling clinicians to access advanced lung imaging tools that help improve diagnostic confidence and patient care.\"\nThe compatibility statement confirms that the FDA-cleared XENOVIEW 3T Chest Coil can be used with Philips MR 7700, Ingenia Elition X, and compatible software upgrade configurations\nfrom 2026 onwards\n. This development significantly expands the potential reach of Polarean's technology and supports its goal of making functional lung MRI more widely available to clinicians and patients worldwide.\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0) 7980541893 /\u00a0+44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive",
          "content_length": 8105
        },
        "ingested_at": "2026-01-12T21:58:06.826735Z"
      },
      {
        "event_id": "RNS-25th Nov 2025-firstxen",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.826762Z",
        "source": "LSE_RNS",
        "data": {
          "title": "First Xenon Hyperpolariser in Asia",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/first-xenon-hyperpolariser-in-asia-pjsgx0ltqthl1gl.html",
          "rns_number": "RNS Number : 8133I",
          "full_content": "25 Nov 2025 07:00\nRNS Number : 8133I\nPolarean Imaging PLC\n25 November 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nFirst Polarean Xenon Hyperpolariser to be installed in Asia\nCollaboration with Philips and Sumtage to\nbring Xenon MRI technology to Taiwan\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs, announces that the National Taiwan University Hospital (\"NTUH\") has entered into an agreement for a Xenon MRI research system in Taiwan through Polarean's strategic partner, Philips (Philips Medical Systems Nederland B.V.).\nNTUH is widely recognised as Taiwan's leading academic medical centre, with a strong track record in clinical research and advanced patient care. The order will be supported by Polarean's\nnewly appointed Taiwanese distributor\n, Sumtage Enterprise Company Limited (\"Sumtage\"), who will assist in the installation and training at NTUH, and work collaboratively with Polarean on the steps required to secure regulatory approval and reimbursement in Taiwan.\nThis milestone represents Polarean's first entry into Asia and an important step in building the foundations for future adoption of Xenon MRI in the region.\nChristopher von Jako, Ph.D., CEO of Polarean, said:\n\"This first Xenon MRI system in Taiwan, supported by Philips and Sumtage, marks an important milestone in our international strategy. The National Taiwan University Hospital is the country's premier academic medical centre, and this order highlights the recognition of Xenon MRI's potential in lung health. Together with Sumtage, we will focus on ensuring successful installation and training at NTUH while also advancing the regulatory and reimbursement pathways needed for broader adoption in Taiwan.\"\nHui-Lin Su, General Manager of Sumtage, said:\n\"We are excited to partner with Polarean to bring this groundbreaking Xenon MRI technology to Taiwan. Our goal is to support hospitals like NTUH with not only the technology itself, but also the training and long-term support required for success. We look forward to working with Polarean to secure regulatory approval and reimbursement so that physicians and patients across Taiwan can benefit from this innovation.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nFor more information, visit\nwww.xenoview.net\n.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy/ Paul McManus / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0) 7980541893 /\u00a0+44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u2122, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can caus",
          "content_length": 6911
        },
        "ingested_at": "2026-01-12T21:58:06.826797Z"
      },
      {
        "event_id": "RNS-24th Nov 2025-koreandi",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.826822Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Korean distributor agreement with DK Healthcare",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/korean-distributor-agreement-with-dk-healthcare-7snopepnnq89j1v.html",
          "rns_number": "RNS Number : 6022I",
          "full_content": "24 Nov 2025 07:00\nRNS Number : 6022I\nPolarean Imaging PLC\n24 November 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nKorean distributor agreement with DK Healthcare in South Korea\nExpanding commercial reach and advancing lung imaging innovation in Asia-Pacific\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, announces it has signed an exclusive distribution agreement with DK Healthcare Co., Ltd. (\"DK Healthcare\") for the distribution of Polarean's Xenon MRI platform in South Korea.\nThis agreement represents Polarean's second international distribution partnership,\nstrengthening the Company's commercial presence across the Asia-Pacific region.\nThrough this partnership, Polarean is\nstrategically positioning its innovative Xenon MRI platform for entry\ninto one of the world's most advanced medical imaging markets\n.\nThe Company will collaborate with DK Healthcare to obtain the necessary regulatory clearances ahead of commercial launch in South Korea.\nDK was founded in 1986 and is headquartered in Seoul. They are a leading provider of diagnostic radiology systems and imaging technologies in Korea, and DK Healthcare is one of the affiliates of DK. Through long-standing partnerships with global medical device manufacturers, DK Healthcare has built a reputation for delivering cutting-edge imaging solutions, along with comprehensive technical, clinical, and maintenance support.\nChristopher von Jako, Ph.D., CEO of Polarean, said:\n\"We are delighted to partner with DK Healthcare, one of South Korea's most respected medical imaging distributors, to expand access to our Xenon MRI platform.\nSouth Korea's strong emphasis on early detection and precision medicine makes it an ideal growth market, and\nthis agreement accelerates\nour dual-track strategy\nto grow internationally through high-quality regional partners while our U.S. team continues to drive adoption domestically.\"\nJoonhyuk Lee, CEO of DK Healthcare, said:\n\"We are excited to introduce Polarean's Xenon MRI technology to Korea's leading hospitals and imaging centers. This platform offers clinicians a new dimension in lung function assessment by enabling visualisation of ventilation and gas-exchange that was previously impossible with conventional imaging. We believe Xenon MRI will play a vital role in\ntransforming respiratory care in South Korea through enhancing early detection and outcomes for patients with lung cancer, COPD and beyond.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\n/ Paul McManus / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0) 7980541893 /\u00a0+44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW\n\u00ae\nIMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use",
          "content_length": 7213
        },
        "ingested_at": "2026-01-12T21:58:06.826850Z"
      },
      {
        "event_id": "RNS-14th Nov 2025-proposed",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.826876Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Proposed Cancellation of Admission & Notice of GM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/proposed-cancellation-of-admission-notice-of-gm-po0x9dt6xrpi44d.html",
          "rns_number": "RNS Number : 4911H",
          "full_content": "14 Nov 2025 07:00\nRNS Number : 4911H\nPolarean Imaging PLC\n14 November 2025\nThis announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.\n14 November 2025\nPolarean Imaging Plc(\"Polarean\" or the \"Company\")\nProposed Cancellation of Admission of Ordinary Shares to Trading on AIMRe-registration as a Private Limited CompanyAdoption of New Articles of AssociationandNotice of General Meeting\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical technology company and global leader in functional lung imaging using hyperpolarised Xenon MRI, announces that it intends to seek shareholder approval for the cancellation of the admission of its Ordinary Shares to trading on AIM with effect from 7:00 a.m. on 23 December 2025 and the re-registration of the Company as a private limited company.\nThe Company's current cash balance is anticipated to fund the Company through the second quarter of 2026. The Company needs to raise additional capital from strategic or financial investors during the current cash runway. The Board has been evaluating all available options to maximise long-term shareholder value, including identifying opportunities to further reduce operational costs while maintaining strict financial discipline. After careful consideration, the Board believes that, under certain circumstances, a transition to a private company structure could reduce operational expenses, provide greater strategic flexibility, and broaden access to capital on more favourable terms. The Directors believe that the Proposals are in the best interests of the Company and its Shareholders as a whole.\nIn reaching this conclusion the Board has considered the following key factors:\n\u00b7\nStronger Access to Capital:\nAs the Company has publicly stated, it requires approximately $20 million additional funding to execute its business plan to achieve profitability. Based on feedback received following engagement with a number of potential strategic and financial investors, they typically prefer companies to be private before making an investment in them. Therefore, being a private company could improve the Company's ability to access the capital it needs in order to execute its strategy.\n\u00b7\nListing and Compliance Costs\n:\nThe costs of being a public company, both in terms of financial and management time are significant. Cancellation would eliminate the annual expenditure associated with maintaining a listing on AIM and thus enable the business to reallocate that expenditure to core business activities and free up management time to achieve its strategic objectives.\n\u00b7\nPublic Market Undervaluation:\nThe Directors believe that the public markets are not fairly valuing the Company, and the Directors do not believe that this disconnect will change in the short-to-medium term. Based on the current public market valuation, raising the required capital would be significantly dilutive to current shareholders. The Company believes that becoming a private company could potentially provide access to capital at a higher valuation.\n\u00b7\nCurrent Funding Environment:\nThe Directors believe that the UK public market environment for small-cap MedTech companies remains highly challenging, characterised by persistent undervaluation, limited liquidity and the ongoing costs associated with maintaining a public listing. With shares frequently trading below their intrinsic value and market activity remaining subdued, investors continue to face difficulties executing trades efficiently. At the same time, the Company requires additional capital to advance the development and commercialisation of its technology.\nA circular (\"Circular\") that provides shareholders with the background to and the reasons for the proposed Cancellation, explains the consequences of the Cancellation, sets out the views of the directors of the Company on the Cancellation, and sets out why the directors of the Company consider the Cancellation to be in the best interests of the Company and its shareholders as a whole, together with a notice convening the General Meeting, will be posted to shareholders today and will also be made available on the Company's website (with a copy of the proposed new articles of association) at www.polarean.com. Capitalised terms in this announcement, unless otherwise defined, have the same meanings given to them in the Circular.\nThe Takeover Code currently applies to the Company, however, if the Cancellation is approved by Shareholders at the General Meeting and becomes effective, the Takeover Code will continue to apply to the Company for a period of two years after the Cancellation, following which it will cease to apply and Shareholders will no longer be afforded the protections provided by the Takeover Code. For furthe",
          "content_length": 48710
        },
        "ingested_at": "2026-01-12T21:58:06.826909Z"
      },
      {
        "event_id": "RNS-27th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.826937Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/holdings-in-company-aakqst6zs0ypj1o.html",
          "rns_number": "RNS Number : 9878E",
          "full_content": "27 Oct 2025 15:37\nRNS Number : 9878E\nPolarean Imaging PLC\n27 October 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BF3DT583\nIssuer Name\nPOLAREAN IMAGING PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nMaven Capital Partners UK LLP\nCity of registered office (if applicable)\nGlasgow\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nMeinom Limited\nGlasgow\nScotland\nMaven Renovar VCT PLC\nLondon\nEngland and Wales\nMaven Income and Growth VCT 5 PLC\nLondon\nEngland and Wales\nMaven Income and Growth VCT 4 PLC\nGlasgow\nScotland\nMaven Income and Growth VCT 3 PLC\nLondon\nEngland and Wales\nMaven Income and Growth VCT PLC\nLondon\nEngland and Wales\n5. Date on which the threshold was crossed or reached\n23-Oct-2025\n6. Date on which Issuer notified\n27-Oct-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n2.753901\n0.000000\n2.753901\n33240487\nPosition of previous notification (if applicable)\n3.044000\n0.000000\n3.044000\n36740487\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BF3DT583\n33240487\n2.753901\nSub Total 8.A\n33240487\n2.753901%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n27-Oct-2025\n13. Place Of Completion\nGlasgow\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUBOVRVSURUAA",
          "content_length": 4008
        },
        "ingested_at": "2026-01-12T21:58:06.826962Z"
      },
      {
        "event_id": "RNS-22nd Oct 2025-strategi",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.826987Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Strategic review and consideration of AIM listing",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/strategic-review-and-consideration-of-aim-listing-fpni45hcur824sn.html",
          "rns_number": "RNS Number : 2856E",
          "full_content": "22 Oct 2025 07:00\nRNS Number : 2856E\nPolarean Imaging PLC\n22 October 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nStrategic Review and Consideration of AIM Listing Status\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical technology company and global leader in functional lung imaging using hyperpolarised Xenon MRI, announces that its Board of Directors is undertaking a strategic review of the Company's future direction and organisational structure.\nThe Board recognises that the UK public market environment for small-cap MedTech companies remains highly challenging, characterised by persistent undervaluation, limited liquidity, and the ongoing costs associated with maintaining a public listing. With shares frequently trading below their intrinsic value and market activity remaining subdued, investors continue to face difficulties executing trades efficiently. At the same time, the Company requires additional capital to advance the development and commercialisation of its technology.\nIn light of these factors, the Board is evaluating all available options to maximise long-term shareholder value, including identifying opportunities to further reduce operational costs while maintaining strict financial discipline. Among the options under consideration is the potential cancellation of the admission of the Company's ordinary shares to trading on AIM (\"Cancellation\"). After careful deliberation, the Board believes that, under certain circumstances, a transition to a private company structure could reduce operational expenses, provide greater strategic flexibility, and broaden access to capital on more favourable terms.\nNo decision\nhas been made at this stage.\u00a0Should the Board determine that pursuing a Cancellation and re-registration of the Company as a private company is in the best interests of shareholders, a detailed circular setting out the background, rationale, and implications of such a proposal will be sent to shareholders. Any Cancellation would require the approval of not less than\u00a075 percent of votes cast by shareholders\u00a0at a duly convened general meeting, in accordance with Rule 41 of the AIM Rules for Companies.\nThe Company remains committed to advancing its mission of revolutionising pulmonary medicine through Xenon MRI and to continuing commercial growth while this review is ongoing. A further announcement will be made if and when the Board decides to proceed with any specific course of action.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0) 7980541893 /\u00a0+44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our ",
          "content_length": 5178
        },
        "ingested_at": "2026-01-12T21:58:06.827014Z"
      },
      {
        "event_id": "RNS-6th Oct 2025-ascendim",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827041Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Ascend Imaging agreement expansion",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/ascend-imaging-agreement-expansion-v8naciibq91b14h.html",
          "rns_number": "RNS Number : 0813C",
          "full_content": "6 Oct 2025 07:00\nRNS Number : 0813C\nPolarean Imaging PLC\n06 October 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nAscend Imaging agreement expansion\nExtended commercial partnership to accelerate US market growth\nPolarean Imaging plc (AIM: POLX),\na commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs\n, announces that it has expanded its\nRepresentative Agreement\nwith Ascend Imaging LLC (\"Ascend Imaging\") which will enable extending coverage into additional US states.\nUnder the expanded agreement, Ascend Imaging will continue to act as a non-exclusive, independent manufacturer's representative, supporting the promotion and sale of the Company's Xenon MRI platform. The expansion will increase the footprint to 19 US states, up from four states in the original agreement. Ascend Imaging will continue to complement Polarean's existing commercial team by identifying new prospective customers, driving engagement, and supporting the negotiation and closure of sales opportunities.\nAscend Imaging specialises in radiology and radiation oncology solutions, including advanced imaging hardware and artificial intelligence (AI) technologies. Their team brings deep expertise and long-standing relationships with healthcare providers across their regions, making them a strong strategic fit for Polarean's targeted expansion in functional lung imaging.\nChristopher von Jako\n, Ph.D., Chief Executive Officer for Polarean, said:\n\"Our collaboration with Ascend Imaging has already proven highly productive, and we see clear value in their ability to connect us with the right decision-makers at leading institutions. By expanding this partnership into additional states, we can further strengthen our commercial reach and accelerate adoption of Xenon MRI, advancing our mission to transform pulmonary medicine and ultimately improving outcomes for patients across the country.\"\nWesley Adams, President of Ascend Imaging,\nsaid:\n\"\nXenon MRI is gaining momentum as institutions recognise the value of regional functional lung imaging. With hospitals increasingly seeking innovative solutions that are supported by reimbursement, we are excited to expand our partnership with Polarean and help bring this important technology to more patients and providers.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0) 7980541893 /\u00a0+44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW\n\u00ae\nIMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can",
          "content_length": 7000
        },
        "ingested_at": "2026-01-12T21:58:06.827074Z"
      },
      {
        "event_id": "RNS-29th Sep 2025-universi",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827118Z",
        "source": "LSE_RNS",
        "data": {
          "title": "University of Virginia Health Hospital agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/university-of-virginia-health-hospital-agreement-fpoofn5yzxbxc3a.html",
          "rns_number": "RNS Number : 1086B",
          "full_content": "29 Sep 2025 07:00\nRNS Number : 1086B\nPolarean Imaging PLC\n29 September 2025\n29 September 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nUniversity of Virginia Health Hospital new supply agreement\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs, announces that it has entered into a new supply agreement with the University of Virginia Health (\"UVA Health\") to complete the implementation of full clinical Xenon MRI capabilities.\nUVA Health holds a unique place in medical imaging history as the site where the first human patient was scanned using hyperpolarised Xenon MRI. The institution upgraded its two research-grade hyperpolarisers to clinical-grade systems in 2024 provided by Polarean, and UVA Health required some essential additional equipment from Polarean to enable clinical Xenon MRI scans\nin their clinical imaging area.\nUVA Health is an integrated health system anchored by a world-class academic medical center that includes a nationally recognised Comprehensive Cancer Center and UVA Health Children's, the leading pediatric hospital in Virginia. Its Hyperpolarized Xenon MRI Center faculty pioneered applications for a variety of lung diseases, including asthma, cystic fibrosis, and bronchopulmonary dysplasia. Their research programme was recently strengthened by a $7.4 million US National Institutes of Health grant, awarded to evaluate lung transplant rejection and abnormalities in the lungs of electronic cigarette users using Xenon MRI, focusing on improving diagnosis and treatment monitoring.\nProfessor Colin Derdeyn, MD, Interim Dean of the UVA School of Medicine and previously Chair of the Department of Radiology and Medical Imaging at UVA Health, said\n:\n\"UVA Health has been a leader in Xenon MRI research for nearly three decades, beginning with the world's first human lung scan using this technology in 1996. Since then, our teams have made significant contributions to its development and application across a range of pulmonary diseases. Advancing to clinical implementation is a major step, not only for UVA Health, but for the patients who will benefit from safer, more detailed evaluation of lung disease. We are pleased to work with Polarean to bring this innovation into routine care.\"\nChristopher von Jako, PhD, CEO of Polarean, said: \"\nWe are delighted to support UVA Health as they prepare to launch their first clinical Xenon MRI scan, anticipated to occur later this year. Their deep and sustained commitment to advancing pulmonary imaging - from early research breakthroughs to today's clinical transition - perfectly aligns with Polarean's mission to provide critical imaging solutions for chronic lung disease.\n\"UVA Health's decades-long leadership in Xenon MRI has been instrumental in shaping the field, and we look forward to continuing our partnership to improve lung health for patients everywhere.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please v",
          "content_length": 7499
        },
        "ingested_at": "2026-01-12T21:58:06.827148Z"
      },
      {
        "event_id": "RNS-25th Sep 2025-national",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827174Z",
        "source": "LSE_RNS",
        "data": {
          "title": "National Institutes of Health system order",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/national-institutes-of-health-system-order-az0drz49g7dlmzs.html",
          "rns_number": "RNS Number : 8562A",
          "full_content": "25 Sep 2025 12:14\nRNS Number : 8562A\nPolarean Imaging PLC\n25 September 2025\n25 September 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nNational Institutes of Health orders Polarean's HPX Hyperpolarisation system\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs, announces that it has received an order for a new Xenon MRI System from the\nNational Institutes of Health (\"NIH\") Clinical Center in Bethesda, Maryland, USA. This\nis the world's largest hospital dedicated exclusively to clinical research, and this is the first system to be purchased directly from Polarean by the NIH.\nSince opening in 1953, the NIH Clinical Center has been recognised for serving as a model research hospital, providing innovative therapy and high-quality patient care, treating rare and severe diseases, and producing outstanding clinician-scientists whose collective work has set a standard of excellence in biomedical research.\nChristopher von Jako, Ph.D, CEO of Polarean, said:\n\"\nThe\nNIH Clinical Center is the nation's largest hospital devoted entirely to clinical research. It is a key resource for trials on rare diseases, experimental therapies, and cutting-edge medical research. The advantages of owning a clinical Xenon MRI system will allow for high performance polarization of Xenon for studies of innovative MRI techniques to better characterise lung disease.\n\"We\nare delighted to be working alongside Dr.\nCampbell-Washburn, a true pioneer in the lung imaging field, and her team, to conduct in-depth research on the most serious of respiratory conditions and find new ways to improve the lives of patients everywhere.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Fred Walsh / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nMob: +44 (0)7876741001 / +44 (0) 7980541893 /\u00a0+44 (0)7867984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW\n\u00ae\nIMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.\nRisk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.\nAdverse Reactions\nAdverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, hea",
          "content_length": 6404
        },
        "ingested_at": "2026-01-12T21:58:06.827202Z"
      },
      {
        "event_id": "RNS-25th Sep 2025-half-yea",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827226Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half-year Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/half-year-report-760482d298t5ddq.html",
          "rns_number": "RNS Number : 7166A",
          "full_content": "25 Sep 2025 07:00\nRNS Number : 7166A\nPolarean Imaging PLC\n25 September 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\" or the \"Group\")\nHalf-year Report\nPolarean Imaging plc (AIM: POLX),\na commercial-stage medical device leader in advanced magnetic resonance imaging (\"MRI\") of the lungs, announces\nits unaudited interim results for the six months ended 30 June 2025 and update to guidance for 2025\n.\nAwareness of the benefits of Xenon MRI continues to grow within the scientific and medical community, and Polarean expanded its commercial partnerships and broadened its regulatory approvals. However, as noted in the Company's Final Results announcement on 8 May 2025, reductions in United States (\"US\") National Institute of Health (\"NIH\") grant funding created headwinds for our customers in our target market. These challenges have since been compounded by the passing of the US One Big Beautiful Bill Act (\"OBBBA\"), which introduced significant Medicaid cuts for hospitals. Together, these two factors have created increased levels of uncertainty in the sector and contributed to delays in 2025 sales. However, we are starting to see potential customers adapting to the new funding environment and finding creative ways to adopt new technologies. Further detail relating to the pipeline is outlined below.\nFinancial Highlights\n\u00b7\nIncreased consumable sales for H1 2025 by 36% compared to H1 2024, reflecting greater utilization by existing customers; however, there were no Xenon MRI system sales in H1 2025, compared with one in H1 2024\n\u00b7\nGroup revenues for H1 2025 were US$0.6m (H1 2024: US$1.1m), reflecting the challenging US market for capital equipment in H1 2025\n\u00b7\nOperating expenses for H1 2025 of US$5.6m (H1 2024: US$4.6m), reflecting the increase in the non-cash share-based payment expense. Excluding the non-cash share-based payment costs, operating expenses were US$0.1m higher than H1-2024 as the higher selling and distribution costs for 2025 (H1 2025: US$1.5m versus H1 2024: US$0.8m) were largely offset by strict cost controls in other areas\n\u00b7\nCash and cash equivalents of US$7.3m as at 30 June 2025 (31 December 2024: US$12.1m). Management continues to expect this funding to support operations through the end of Q2 2026\nOperational Highlights\n\u00b7\nApproval from the US Food and Drug Administration (\"FDA\") of the Company's Supplemental New Drug Application (\"NDA\") to expand the indication of XENOVIEW\u00ae. This approval lowered the minimum patient age from 12 to six years old, significantly broadening access to this technology and expanding Polarean's total addressable market by approximately one million additional patients. The Company is still on track to launch a controlled market release of the paediatric product at Cincinnati Children's prior to year end\n\u00b7\nType C meeting with the FDA in March 2025 to discuss the proposed design of a clinical trial to expand the XENOVIEW\u00ae label to include gas exchange indications, representing a major opportunity to increase the clinical and commercial value of the platform. Based on FDA feedback and de-risking from a 230+ subject proof-of-concept study, the Company now expects the trial to be significantly smaller and completed at an estimated cost of US$4.0m to US$4.5m, down from prior estimates of US$9.0m to US$11.0m\n\u00b7\nExpansion of the Philips and Polarean strategic partnership announced on 14 May 2025 which seeks to increase access to advanced, radiation-free lung MRI for patients with obstructive lung diseases. By expanding multi-nuclei imaging with Xenon MRI, the collaboration enables clinicians to better detect and monitor lung conditions like asthma and cystic fibrosis\n\u00b7\nExpansion of a new imaging service model, in collaboration with VIDA Diagnostics, to support pharma-sponsored research using Xenon MRI. This announcement coincided with the Company's inclusion of their clinical trial imaging platform in a sub-study within a global, multicentre investigational trial for a novel lung therapy, run by a leading global pharmaceutical company. Preparations have been ongoing for this trial, and it should begin in the new year\n\u00b7\nRepresentative agreement signed with Ascend Imaging LLC (\"Ascend Imaging\"), for the promotion and sale of Polarean's products in specific US states. Under the agreement, Ascend Imaging will act as a non-exclusive, independent manufacturer's representative in four US states, with the potential for this to be expanded, supporting the promotion and sale of the Company's Xenon MRI platform. Ascend Imaging will complement Polarean's existing commercial team by identifying new prospective customers, driving engagement and supporting the negotiation and closure of sales opportunities\n\u00b7\nIssuance of second Chinese patent, covering the use of the Xenon MRI platform to visualise global and regional pulmonary gas exchange and microvascular blood flow in real time. This patent strengthens the Company's intellectual property portfolio in Asia and supports potential future ent",
          "content_length": 34064
        },
        "ingested_at": "2026-01-12T21:58:06.827253Z"
      },
      {
        "event_id": "RNS-16th Sep 2025-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827280Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/notice-of-results-2pjqvjxxvimmdnv.html",
          "rns_number": "RNS Number : 4116Z",
          "full_content": "16 Sep 2025 07:00\nRNS Number : 4116Z\nPolarean Imaging PLC\n16 September 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nNotice of results\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\nconfirms that it will be announcing its half year results for the six months ended 30 June 2025 on Thursday, 25 September 2025.\nChristopher von Jako, PhD, Chief Executive Officer, and Charles Osborne, Chief Financial Officer, will be hosting a live online presentation\nrelating to the results via the Investor Meet Company platform on\nThursday, 25 September 2025\nat 15.00 BST.\nThe presentation is open to all existing and potential shareholders.\nQuestions can be submitted pre-event\nvia your IMC dashboard up until 9.00 BST the day before the meeting\nor in real time during the presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet Polarean Imaging Plc\nhere\n.\nInvestors who already follow Polarean on the Investor Meet Company platform will automatically be invited.\nWhilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation will be available on the Investor Meet Company platform afterwards.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or polarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nMob: +44 (0)7876 741 001 / +44 (0) 7980 541 893 /\u00a0+44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORKZGMLVKMGKZM",
          "content_length": 4117
        },
        "ingested_at": "2026-01-12T21:58:06.827304Z"
      },
      {
        "event_id": "RNS-11th Sep 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827329Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/holdings-in-company-9lggxc4psb6at6t.html",
          "rns_number": "RNS Number : 0249Z",
          "full_content": "11 Sep 2025 16:36\nRNS Number : 0249Z\nPolarean Imaging PLC\n11 September 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BF3DT583\nIssuer Name\nPOLAREAN IMAGING PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nDavid and Monique Newlands\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\nName\nCity of registered office\nCountry of registered office\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n11-Sep-2025\n6. Date on which Issuer notified\n11-Sep-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n4.598\n0.0\n4.598\n55,500,000\nPosition of previous notification (if applicable)\n5.016\n0.0\n5.016\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BF3DT583\n55,500,000\n4.598\nSub Total 8.A\n55,500,000\n4.598%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n11-Sep-2025\n13. Place Of Completion\nUK\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUAOVRVOUKAAR",
          "content_length": 3836
        },
        "ingested_at": "2026-01-12T21:58:06.827354Z"
      },
      {
        "event_id": "RNS-12th Aug 2025-submissi",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827383Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Submission of new Phase III study protocol to FDA",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/submission-of-new-phase-iii-study-protocol-to-fda-hpazblssmzyh5ph.html",
          "rns_number": "RNS Number : 8813U",
          "full_content": "12 Aug 2025 07:00\nRNS Number : 8813U\nPolarean Imaging PLC\n12 August 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nSubmission of new Phase III study protocol to FDA for expanded indication of XENOVIEW\nGas exchange protocol submitted for final feedback is key to finalising the plan for this trial\nPolarean Imaging plc (AIM: POLX),\na commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs\n, announces\nthe submission of a new Phase III clinical trial protocol to the U.S. Food and Drug Administration (FDA) to support an expanded indication for XENOVIEW\n\u00ae\n(xenon Xe 129 hyperpolarised). XENOVIEW\n\u00ae\nis the Company's FDA-approved contrast agent for MRI of the lungs. The proposed expansion would include quantitative gas-exchange imaging in addition to the currently approved ventilation imaging indication.\nAs part of the submission, Polarean has formally requested written feedback from the FDA under a Type C meeting to guide development and alignment on the Phase III study design. The FDA review of the proposed clinical trial should be completed by Q4 2025.\nThe new protocol aims to evaluate the safety and diagnostic performance of XENOVIEW in assessing how effectively the lungs can transfer gas from the air into the bloodstream (pulmonary function), as compared to the standard of care test which is currently used. There is a substantial need to quantify and visualise gas-exchange abnormalities across a range of chronic obstructive, interstitial and pulmonary-vascular diseases\n. If approved, the expanded indication would significantly broaden the clinical utility of XENOVIEW by enabling clinicians to obtain a more comprehensive picture of lung function through non-invasive imaging.\nChristopher von Jako, Ph.D., Chief Executive Officer of Polarean said:\n\"Submission of this new protocol and our Type C meeting request marks a critical milestone in Polarean's clinical development programme and mission to transform pulmonary imaging.\n\"Embarking on a multi-center trial to add gas-exchange to the existing ventilation indication is key to our growth strategy. If successful, this expanded utility of XENOVIEW will have the potential to provide a comprehensive, multi-compartment assessment of deep lung function, information that is not currently with conventional imaging or pulmonary function tests, all in a single breath hold.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nFor more information, visit\nwww.xenoview.net\n.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\u00a0/ Paul McManus / Marcus Ulker\nMob: +44 (0)7876 741 001\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u2122, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental O",
          "content_length": 6999
        },
        "ingested_at": "2026-01-12T21:58:06.827413Z"
      },
      {
        "event_id": "RNS-24th Jul 2025-blocklis",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827430Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block Listing Six Monthly Return",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/block-listing-six-monthly-return-4zkaateof2ipzmp.html",
          "rns_number": "RNS Number : 7176R",
          "full_content": "24 Jul 2025 07:00\nRNS Number : 7176R\nPolarean Imaging PLC\n24 July 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nBlock Listing Six Monthly Return\nPolarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\ntoday\nmakes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:\nName of applicant:\nPolarean Imaging Plc\nName of scheme:\nPolarean Share Option Plan\nNumber and class of securities originally admitted:\n8,000,000 ordinary shares of \u00a30.00037 each\nDate of admission:\n29 July 2021\nPeriod of return:\nFrom:\n25 January 2025\nTo:\n24 July 2025\nBalance of unallotted securities under scheme(s) from previous return:\n808,917\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\n0\nLess:\nNumber of securities issued/allotted under scheme(s) during period (see LR3.5.7G):\n0\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n808,917\nTotal number of\u00a0securities\u00a0in issue at the end of the period\n1,207,032,781\nName of contact:\nCharles F. Osborne, Jr., Chief Financial Officer\nTelephone number of contact:\n+\n44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy /Paul McManus / Marcus Ulker\nAbout Polarean\n(\nwww.polarean.com\n)\nPolarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBLRPKFBBBBKDOOD",
          "content_length": 4001
        },
        "ingested_at": "2026-01-12T21:58:06.827445Z"
      },
      {
        "event_id": "RNS-24th Jun 2025-promotio",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827459Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Promotion & sales representative agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/promotion-sales-representative-agreement-xb2wlsuspd20i95.html",
          "rns_number": "RNS Number : 0359O",
          "full_content": "24 Jun 2025 07:00\nRNS Number : 0359O\nPolarean Imaging PLC\n24 June 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nPromotion & Sales Representative Agreement\nNew commercial partnership to accelerate US market growth\nPolarean Imaging plc (AIM: POLX),\na commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs\n, announces that it has signed a Representative Agreement with Ascend Imaging LLC (\"Ascend\nImaging\n\"), for the promotion and sale of Polarean products in\nspecific US states\n.\nUnder the agreement, Ascend Imaging will act as a non-exclusive, independent manufacturer's representative in four US states, supporting the promotion and sale of the Company's Xenon MRI platform. Ascend will complement Polarean's existing commercial team by identifying new prospective customers, driving engagement, and supporting the negotiation and closure of sales opportunities.\nAscend Imaging specialises in radiology and radiation oncology solutions, including advanced imaging hardware and artificial intelligence (AI) technologies. Their team brings deep expertise and long-standing relationships with healthcare providers across their regions - making them a strong strategic fit for Polarean's targeted expansion in functional lung imaging.\nAlan Huang\n, Ph.D., Vice President of Sales for Polarean, said:\n\"We are pleased to welcome Ascend Imaging as a strategic sales partner. Their focus on radiology and radiation oncology, combined with a deep understanding of imaging workflows and strong customer relationships, aligns well with our commercial strategy. This partnership enhances our reach in key US regions while maintaining operational efficiency, and we expect it to support meaningful commercial momentum in the second half of 2025 and beyond.\"\nWesley Adams, President of Ascend Imaging,\nsaid:\n\"We are excited to partner with Polarean to help bring their groundbreaking Xenon MRI technology to more healthcare providers. Our experience in radiology and AI solutions, combined with long-standing customer relationships, positions us well to support Polarean's mission of revolutionizing pulmonary medicine. We look forward to expanding access to this important imaging innovation.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.\nFor the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW\n\u00ae\nIMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW",
          "content_length": 6866
        },
        "ingested_at": "2026-01-12T21:58:06.827475Z"
      },
      {
        "event_id": "RNS-9th Jun 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827491Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/result-of-agm-r4cpoamgqyyz41s.html",
          "rns_number": "RNS Number : 0656M",
          "full_content": "9 Jun 2025 16:16\nRNS Number : 0656M\nPolarean Imaging PLC\n09 June 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nResult of AGM\nPolarean Imaging plc (AIM: POLX),\na commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs\n,\nannounces that at the AGM held earlier today, all resolutions were duly passed.\nDetails of the proxy votes received on each resolution by Polarean's Registrar are set out below:\nResolution\nFor\nAgainst\n01\n572,589,782\n33,404\n02\n522,618,153\n49,986,337\n03\n572,211,914\n85,763\n04\n532,209,384\n38,679,812\n05\n533,474,486\n38,667,157\n06\n525,097,507\n38,679,812\n07\n570,603,589\n899,739\n08\n570,264,453\n1,959,346\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGSSIFIUEISEFM",
          "content_length": 3329
        },
        "ingested_at": "2026-01-12T21:58:06.827504Z"
      },
      {
        "event_id": "RNS-2nd Jun 2025-fdaexpan",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827519Z",
        "source": "LSE_RNS",
        "data": {
          "title": "FDA expands XENOVIEW indication",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/fda-expands-xenoview-indication-u9am04um21maq9o.html",
          "rns_number": "RNS Number : 8945K",
          "full_content": "2 Jun 2025 07:00\nRNS Number : 8945K\nPolarean Imaging PLC\n02 June 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nFDA expands XENOVIEW\u00ae indication to include children from six years of age\nIncreases number of eligible patients by approximately one million\nPolarean Imaging plc (AIM: POLX),\na commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (\"MRI\") of the lungs\n, announces that the US Food and Drug Administration (\"FDA\") has approved the Company's Supplemental New Drug Application (\"NDA\") to\nexpand the indication of\nXENOVIEW\u00ae\n. This approval immediately lowers the minimum patient age from 12 to six years old, significantly broadening access to this technology\nand expanding Polarean's total addressable market\n.\nThe approval means that XENOVIEW can now be used with MRI for evaluation of lung ventilation in adults and paediatric patients aged six years and older, representing an increase in the number of eligible patients by approximately one million.\nThe FDA supplement approval also includes the introduction of new XENOVIEW Dose Delivery Bag sizes tailored for smaller lungs of younger patients and corresponding updates to the HPX Polarisation Measurement Station to measure various bag sizes.\nThis approval reinforces Polarean's dedication to advancing functional lung imaging and increasing access to its technology, enabling enhanced care for a broader patient population.\nChristopher von Jako, Ph.D., Chief Executive Officer of Polarean, said:\n\"We are delighted that the FDA has approved our Supplemental NDA, allowing XENOVIEW to be used in younger paediatric patients, increasing the number of patients eligible to use our technology by approximately one million. This expanded indication further enhances our technology's clinical utility, offering clinicians an advanced tool to assess the lungs in children with chronic respiratory conditions, and strengthens its return on investment for hospitals. We look forward to launching a controlled US market release of the paediatric Dose Delivery Bags later this year, starting with Cincinnati Children's.\"\nEric Hysinger, MD, Paediatric Pulmonologist from Cincinnati Children's, said:\n\"\nThis approval is an exciting step for children with chronic lung diseases, such as cystic fibrosis, asthma, bronchopulmonary dysplasia, and inflammation following bone-marrow transplant. For years, I've studied Xenon MRI in children ages 6 to 12, and expanding access to younger patients offers clinicians a powerful tool to characterise disease progression, monitor response to therapy, and guide interventions like airway dilation or tissue removal. This imaging platform enhances our ability to deliver more personalised, precise care for children with complex respiratory conditions\n.\"\nFor more information, visit\nwww.xenoview.net\n.\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW\n\u00ae\nIMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW, prepared from the Xenon Xe 129 Gas Ble",
          "content_length": 7458
        },
        "ingested_at": "2026-01-12T21:58:06.827535Z"
      },
      {
        "event_id": "RNS-21st May 2025-dr.basti",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827550Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Dr. Bastiaan Driehuys awarded by ATS",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/dr-bastiaan-driehuys-awarded-by-ats-d6xca7nfoo8p0hp.html",
          "rns_number": "RNS Number : 4631J",
          "full_content": "21 May 2025 07:00\nRNS Number : 4631J\nPolarean Imaging PLC\n21 May 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nAmerican Thoracic Society honours Dr. Bastiaan Driehuys for pioneering work in Xenon MRI\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function\n, announces that Bastiaan Driehuys, PhD, has received a 2025 American Thoracic Society (\"ATS\") Respiratory Health Award for his\ntranslational work in bringing Xenon MRI from the bench to the clinic.\nDr. Driehuys has been presented with ATS's Research Innovation and Translation Achievement Award\u00a0for his exemplary accomplishments in respiratory health based on his work at Duke University Medical Center.\nDr. Driehuys invented hyperpolarised gas MRI while completing his Doctorate in Atomic Physics at Princeton University, and co-founded Polarean. He and his team developed the underlying technology of Xenon-129 hyperpolarisation, as well as novel MR image acquisition, reconstruction, and analysis strategies and how to apply them to problems in pulmonary medicine. He currently holds the position of Chief Scientific Officer at Polarean. Much of Dr. Driehuys' work resulted in the core Xenon MRI technology being commercialised by Polarean. His later work on utilising Xenon MRI for the study of gas exchange and cardiopulmonary indications while at Duke are exclusively licensed to Polarean.\nBastiaan Driehuys,\nPhD\n, Chief Scientific Officer of Polarean said:\n\"I am deeply honoured to receive the 2025 Research Innovation and Translation Achievement Award. This recognition reflects the dedication of an incredible community of interdisciplinary scientists and physicians who have advanced Xenon MRI into a transformative tool for 3D assessment of pulmonary function. I'm excited to continue working with my ATS colleagues to bring this technology to bear on improving the care of patients worldwide.\"\nChristopher von Jako, PhD, CEO of Polarean, added:\n\"We were delighted to learn that Dr. Driehuys has been recognised by the American Thoracic Society for his groundbreaking contributions to pulmonary imaging. His work is not only advancing the science-it is directly benefiting patients by enabling earlier detection, improved treatment planning, and better outcomes for those with serious respiratory conditions. Bastiaan is a vital part of our team at Polarean, and we are proud to see his impact acknowledged with such a prestigious award. Honours like this reflect the highest standards in science and clinical care, and we look forward to continuing to build on his expertise to transform respiratory health.\"\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\n\u00ae\n, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u00ae, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Suppl",
          "content_length": 7100
        },
        "ingested_at": "2026-01-12T21:58:06.827565Z"
      },
      {
        "event_id": "RNS-15th May 2025-xenonmri",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827580Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Xenon MRI featured prominently at ATS 2025",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/xenon-mri-featured-prominently-at-ats-2025-n7gwfecme7kck9h.html",
          "rns_number": "RNS Number : 8739I",
          "full_content": "15 May 2025 12:48\nRNS Number : 8739I\nPolarean Imaging PLC\n15 May 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nXenon MRI featured prominently at ATS 2025 across broad clinical spectrum\n30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function\n, will be featured at the\nAmerican Thoracic Society's (ATS) 2025 Respiratory Innovation Summit (RIS)\n, taking place May 16-17 at the Marriott Marquis in San Francisco, California. Polarean will also attend the\nATS 2025 International Conference\nfrom May 18-21, continuing its active engagement\nwith leaders across pulmonary medicine.\nPolarean's selection as a featured company at RIS 2025 underscores the growing recognition of the company's Xenon MRI platform as an innovative tool for both clinical imaging and pharmaceutical drug development.\nRIS brings together key innovators, investors, clinicians, and patient advocacy groups for cross-sector dialogue on the future of respiratory care.\nAt the ATS 2025 International Conference, Xenon MRI will be featured in over 30 posters and presentations from more than 10 leading clinical sites. This robust presence reinforces the sustained momentum behind Xenon MRI as a powerful and enduring technology in pulmonary medicine. The breadth and depth of research presented this year further demonstrate its expanding role in both clinical care and clinical trials - signaling that Xenon MRI is not just innovative, but a lasting part of the respiratory care landscape.\nThe presentations listed below will highlight Xenon MRI's versatility across a wide spectrum of respiratory conditions, including asthma, bronchopulmonary dysplasia, COPD, COVID-19, cystic fibrosis, pulmonary arterial hypertension, radiation-induced lung injury, and post-transplant lung monitoring.\nPolarean representatives will be on-site throughout RIS and the ATS International Conference to connect with clinicians, researchers, industry partners, and patient advocates.\nAs excitement continues to build around functional lung imaging, Polarean remains at the forefront - visualizing hidden disease, personalizing treatment, and accelerating the future of respiratory medicine.\nChristopher von Jako, PhD, CEO of Polarean, said:\n\"We are honoured to return as a featured company at the Respiratory Innovation Summit. RIS and the ATS International Conference provide vital opportunities to engage with thought leaders, strengthen partnerships, and highlight the growing body of clinical evidence supporting Xenon MRI. With over 30 presentations this year, it's clear that Xenon MRI is not only gaining traction-it's shaping the future of functional lung imaging and respiratory care.\"\nSee the listing below for details on the presentation title, abstract number, session time, and location.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or polarean@walbrookpr.com\nAnna Dunphy / Paul McManus / Marcus Ulker\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u00ae, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (M",
          "content_length": 15272
        },
        "ingested_at": "2026-01-12T21:58:06.827597Z"
      },
      {
        "event_id": "RNS-14th May 2025-ongoingc",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827623Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Ongoing collaboration with Philips",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/ongoing-collaboration-with-philips-4sjqiz4eoqg5u92.html",
          "rns_number": "RNS Number : 6917I",
          "full_content": "14 May 2025 14:25\nRNS Number : 6917I\nPolarean Imaging PLC\n14 May 2025\n14 May 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nOngoing collaboration with Philips\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function\n,\nnotes the announcement by its partner Philips\nto bring\nadvanced Xenon lung MRI to more children with chronic obstructive lung disease.\nFor the full announcement by Philips, please see here:\nPhilips and Polarean advance Xenon MRI for children's lung disease | Philips\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging Plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, PhD, Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\u00a0/ Paul McManus\nMob: +44 (0)7876 741 001 / +44 (0) 7980 541 893\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCFLFFVEFISLIE",
          "content_length": 3481
        },
        "ingested_at": "2026-01-12T21:58:06.827650Z"
      },
      {
        "event_id": "RNS-8th May 2025-finalres",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827676Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Final Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/final-results-j8vmlp76d427xs3.html",
          "rns_number": "RNS Number : 7780H",
          "full_content": "8 May 2025 07:00\nRNS Number : 7780H\nPolarean Imaging PLC\n08 May 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nFinal Results\nNotice of Annual General Meeting\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, ann\nounces its audited final results for the year ended 31 December 2024.\nIn addition, Polarean\u00a0confirms that the Annual Report and Accounts for the year ended 31 December 2024, the Notice of the Annual General Meeting (\"AGM\") and a Form of Proxy are now available on the Company's website (\nhttp://www.polarean-ir.com/content/investors/annual-reports.asp\n) and will be posted to shareholders shortly.\nThe AGM will be held at the Company's office at 2500 Meridian Parkway, Durham, NC 27713 USA at 2:00 p.m. BST / 9:00 a.m. EDT on Monday, 9 June 2025.\nHighlights\n\u00b7\nReported audited revenue for FY24 of US$3.1 million (FY23: US$891k), exceeding the previously issued guidance of US$2.5 million to US$3.0 million\n\u00b7\nSales of proprietary Xenon gas blend cylinders and other consumables increased by more than 50% year-on-year, reflecting the growing number of Xenon MRI scans being performed across clinical and research sites\n\u00b7\nRaised gross proceeds of US$12.6 million (\u00a39.9 million), with strong participation from strategic partners Bracco Imaging S.p.A. and NUKEM Isotopes GmbH, as well as Directors and members of the management team. The Company values its close working relationships with both Bracco and NUKEM. Based on updated plans, this funding is expected to support operations through to Q2 2026, absent further financing\n\u00b7\nInstalled a new Xenon MRI system at the University of Alabama at Birmingham, a leading academic medical centre in the south-eastern United States (\"US\") and a de novo site for Polarean\n\u00b7\nCompleted trade-in system upgrades at Cincinnati Children's, the University of Virginia Health System, and the University of Kansas Medical Center, enabling these institutions to replace research-only hyperpolarisers with clinical-grade systems capable of both research and clinical scanning\n\u00b7\nAppointed Dr. Alan Huang as Vice President of Sales and Dr. Chase Hall as Chief Medical Advisor, strengthening the Company's leadership team\n\u00b7\nSubmitted a Supplemental New Drug Application to the US Food and Drug Administration (\"FDA\") in July 2024 to lower the minimum patient age for XENOVIEW\u00ae from 12 years to six years. Approval would significantly increase paediatric access to Xenon MRI and expand the Company's total addressable market\n\u00b7\nContinued growth in Xenon MRI visibility with presentations and posters by the Company, academic researchers, and industry collaborators at key annual conferences including the Xenon Clinical Trials Consortium, American Thoracic Society, Radiological Society of North America, CHEST, and American Society for Radiation Oncology. This ongoing exposure is expanding awareness and understanding of Xenon MRI across multiple clinical domains\n\u00b7\nGranted a key US patent for dynamic cardiopulmonary blood flow imaging with Xenon MRI, enhancing its application in pulmonary vascular disease. The Company's portfolio now includes more than 20 active patents, supporting long-term protection of its core technology\n\u00b7\nNet cash of US$12.1 million as of 31 December 2024 (31 December 2023: US$6.2 million)\nPost period end highlights\n\u00b7\nThe Company reaffirmed its revenue guidance for 2025, maintaining the previously stated range of US$5.0 million to US$6.0 million\n\u00b7\nAnnounced the expansion of a new imaging service model, in collaboration with VIDA Diagnostics, to support pharma-sponsored research using Xenon MRI. This announcement coincided with the Company's inclusion of their clinical trial imaging platform in a sub-study within a global, multicentre investigational trial for a novel lung therapy, run by a leading global pharmaceutical company\n\u00b7\nHeld a Type C meeting with the FDA in March 2025 to discuss the proposed design of a clinical trial to expand the XENOVIEW\u00ae label to include gas exchange indications, representing a major opportunity to increase the clinical and commercial value of the platform. Based on FDA feedback and de-risking from a 230+ subject proof-of-concept study, the Company now expects the trial to be significantly smaller and completed at an estimated cost of US$4.0 million to US$4.5 million, down from prior estimates of US$9.0 million to US$11.0 million\n\u00b7\nEntered into a strategic collaboration with SimonMed Imaging, one of the largest outpatient imaging providers in the US, to expand access to Polarean's Xenon MRI platform. This collaboration will integrate Polarean's technology within SimonMed's network, enhancing diagnostic capabilities and advancing the standard of care for patients with pulmonary diseases\n\u00b7\nAnnounced the issuance of another Chinese patent, covering the use of the Xenon MRI platform to visualise global and regional pulmonary gas exchange and microvascular blood flow in real ",
          "content_length": 36758
        },
        "ingested_at": "2026-01-12T21:58:06.827712Z"
      },
      {
        "event_id": "RNS-6th May 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827741Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/holdings-in-company-03vg80f5ovfg5zc.html",
          "rns_number": "RNS Number : 5454H",
          "full_content": "6 May 2025 14:59\nRNS Number : 5454H\nPolarean Imaging PLC\n06 May 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BF3DT583\nIssuer Name\nPOLAREAN IMAGING PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn event changing the breakdown of voting rights\n3. Details of person subject to the notification obligation\nName\nMaven Capital Partners UK LLP\nCity of registered office (if applicable)\nGlasgow\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nMeinom Limited\nGlasgow\nScotland\nMaven Renovar VCT PLC\nLondon\nEngland and Wales\nMaven Income and Growth VCT 5 PLC\nLondon\nEngland and Wales\nMaven Income and Growth VCT 4 PLC\nGlasgow\nScotland\nMaven Income and Growth VCT 3 PLC\nLondon\nEngland and Wales\nMaven Income and Growth VCT PLC\nLondon\nEngland and Wales\n5. Date on which the threshold was crossed or reached\n01-May-2025\n6. Date on which Issuer notified\n06-May-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n3.044000\n0.000000\n3.044000\n36740487\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BF3DT583\n36740487\n3.044000\nSub Total 8.A\n36740487\n3.044000 %\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nMaven Renovar VCT PLC was previously Amati AIM VCT plc.\nThe name change occurred following a change of Investment Manager from Amati Global Investors (AGI) to Maven Capital Partners UK LLP (Maven).\n12. Date of Completion\n06-May-2025\n13. Place Of Completion\nGlasgow\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUNVORVBUVRAR",
          "content_length": 4171
        },
        "ingested_at": "2026-01-12T21:58:06.827770Z"
      },
      {
        "event_id": "RNS-25th Apr 2025-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827801Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/notice-of-results-psgk54t6rdjpunp.html",
          "rns_number": "RNS Number : 1055G",
          "full_content": "25 Apr 2025 07:00\nRNS Number : 1055G\nPolarean Imaging PLC\n25 April 2025\n25 April 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nNotice of results\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function\n,\nconfirms that it will be announcing its full year results for the year ended 30 December 2024 on Thursday, 8 May 2025.\nChristopher von Jako, PhD, Chief Executive Officer, and Charles Osborne, Chief Financial Officer, will be hosting a live online presentation\nrelating to the results via the Investor Meet Company platform on Thursday, 8 May 2025 at 15.00 BST.\nThe presentation is open to all existing and potential shareholders.\nQuestions can be submitted pre-event\nvia your IMC dashboard up until 9.00 BST the day before the meeting\nor in real time during the presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet Polarean Imaging Plc\nhere\n.\nInvestors who already follow Polarean on the Investor Meet Company platform will automatically be invited.\nWhilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation will be available on the Investor Meet Company platform afterwards.\nEnquiries:\nPolarean Imaging Plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, PhD, Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Brough Ransom / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\u00a0/ Paul McManus\nMob: +44 (0)7876 741 001 / +44 (0) 7980 541 893\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORKZGZDFDRGKZM",
          "content_length": 4109
        },
        "ingested_at": "2026-01-12T21:58:06.827829Z"
      },
      {
        "event_id": "RNS-10th Mar 2025-expansio",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827859Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Expansion of Xenon MRI imaging platform",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/expansion-of-xenon-mri-imaging-platform-hk9gxipmpgb9mng.html",
          "rns_number": "RNS Number : 9086Z",
          "full_content": "10 Mar 2025 07:00\nRNS Number : 9086Z\nPolarean Imaging PLC\n10 March 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nExpansion of Xenon MRI imaging platform for pharma-sponsored research\nA leading global pharmaceutical collaborator has selected Polarean's Xenon MRI clinical trial support services for a multicenter\nstudy\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\nannounces the successful expansion of a new imaging service model to enable the use of Xenon MRI in pharma-sponsored research, alongside its partner VIDA Diagnostics (\"VIDA\"). This coincides with its selection by a leading global pharmaceutical (\"pharma\") partner to utilise the new Xenon MRI clinical trial support services platform as part of a sub-study within a worldwide multicenter study trial testing an investigational lung therapy.\nAs the interest in using Xenon MRI as a sensitive marker of pulmonary treatment effects has grown, there remains an unmet need for a Xenon MRI imaging platform to streamline pulmonary drug development. This unmet need includes harmonised image acquisition and processing and ensuring high-quality image controls for pharma trials to run with potentially fewer patients and/or at a faster pace to accelerate new drug time-to-market. Polarean's partnership with\nVIDA\n, a leader in lung imaging intelligence, has enabled the establishment of an imaging services platform and catalysed Polarean's capability to expand this new business vertical, underlined by its selection in the multicenter clinical trial.\nThe double-blind, randomised, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the investigational therapy. The Xenon MRI sub-study will provide valuable additional insights into ventilation, membrane conductance, and red blood cell transfer in the lungs. The trial is expected to initiate in the fourth quarter of 2025 at selected sites in the U.S. and Canada that have a Xenon MRI system. Enrolled patients will undergo scans at baseline and at the study's conclusion to evaluate drug-induced changes on various components of alveolar gas-exchange.\nTogether, Polarean and VIDA will provide site qualification and training, image harmonisation, and Xenon MRI biomarker analysis for the sub-study as part of this pharma partnership.\nThis new revenue-generating service model builds upon initial experience last year with an industry partner who selected Xenon MRI ventilation defect percentage (VDP) as the primary endpoint in testing different inhaled drug-delivery devices at a single site. Xenon MRI offers a non-invasive, radiation-free imaging approach that enables direct visualisation of lung function through a single breath hold of the inhaled hyperpolarized gas. Compared to traditional pulmonary function tests such as spirometry, Xenon MRI provides a more sensitive and repeatable assessment of lung function, making it an invaluable tool for reducing sample size and/or achieving greater power to detect subtle treatment-induced changes in the evaluation of new therapeutic interventions.\nChristopher von Jako, Ph.D., CEO of Polarean, said:\n\"We previously identified pharma-sponsored trials as a new business vertical for us, and participation in this multi-center clinical trial underscores the growing recognition of Xenon MRI as a powerful tool in advancing the understanding and treatment of lung diseases. Our ongoing collaboration with VIDA has enabled us to launch our imaging services platform, enhancing the value proposition of Xenon MRI for pharma partners and accelerating the expansion of this vertical. By delivering precise and reproducible lung function measurements, our platform can help drive innovation in respiratory medicine and support the development of novel therapies that improve patient outcomes.\"\nAlex Dusek, Chief Business Officer of Polarean, said:\n\"Beyond sales of our Xenon MRI system and proprietary gas blend, pharma-sponsored trials using our unique imaging platform represent a key area of strategic growth for Polarean. Being selected for these services by a renowned pharmaceutical company is a key milestone for us. With VIDA as a partner, we have accelerated our ability to establish Xenon MRI as an advanced imaging modality that provides attractive biomarkers for pharmaceutical research. Providing a robust imaging service platform for drug development trials also enhances the value proposition for academic sites to build Xenon MRI programmes and be part of a growing network of expert centres able to provide Xenon MRI and recruit subjects for pulmonary drug trials.\"\nAs previously announced, the Company will hold a Virtual Investor Day on Wednesday, 12 March 2025 at 2:00pm GMT. To register for the webinar, please use this link:\nZoom Webinar - Register\n.\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 5",
          "content_length": 9846
        },
        "ingested_at": "2026-01-12T21:58:06.827892Z"
      },
      {
        "event_id": "RNS-27th Feb 2025-fy24trad",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827923Z",
        "source": "LSE_RNS",
        "data": {
          "title": "FY24 trading update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/fy24-trading-update-7xoqduaenv9pt5k.html",
          "rns_number": "RNS Number : 6081Y",
          "full_content": "27 Feb 2025 07:00\nRNS Number : 6081Y\nPolarean Imaging PLC\n27 February 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nFY24 Trading Update\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, provides a full year unaudited trading update for the year ended 31 December 2024 (\"FY24\") and a commercial update.\nThe Company expects to report FY24 unaudited revenue of between US$3.0 million and $3.1 million (audited 2023: $891k), exceeding the upper end of revenue guidance of US$2.5 million to US$3.0 million.\nAs of the date hereof, the Company has 22 Xenon MRI platform customers, seven sites of which have either received or pending clinical hyperpolariser systems. This represents an increase of four customers with installed or pending clinical hyperpolariser systems compared to the prior year, demonstrating continued progress in the commercialisation of the Company's platform.\nProprietary\nXenon gas blend cylinders and other consumables sales increased more than 50% from FY23 to FY24, highlighting the growing number of Xenon MRI scans occurring.\nDuring the second half of the year, a key focus for the Company was recruiting top-tier sales talent, with Dr. Alan Huang joining as VP of Sales in Q3 FY24. The sales team is currently comprised of six people providing coverage across the U.S. and allowing for an enhanced sales pipeline, as evidenced by the aforementioned year-on-year increase in sales.\nPost-period end, the Company has continued to make commercial traction demonstrated by the recently announced distribution agreement with a Taiwanese company, Sumtage, to distribute Polarean's products in Taiwan. This agreement is the first distribution agreement signed by the Company and the first step in commercialising its products outside of the U.S., pending regulatory clearance.\nThe Company's unaudited cash and cash equivalents balance as of 31 December 2024 was US$12.1 million, a cash runway that extends through Q1 FY26.\nChristopher von Jako, Ph.D., CEO of Polarean, said\n:\n\"The financing we completed in June 2024 was key for Polarean in the early phase of our commercialisation strategy, allowing us to attract some top sales and medical talent and execute on further key aspects of our five-pillar commercial strategy.\n\"With our enhanced team and clear strategy, we were able to exceed our revenue target for FY24 beyond the upper end of our increased guidance, more than tripling our revenues from 2023. Our pipeline is now building nicely, including further expected de novo sales.\n\"Alongside the strategic progress the Company has made, including our recent entry into the APAC region evidenced by the recently announced Taiwanese partnership, Polarean is well positioned for 2025 and to demonstrate further commercial progress in advancing our Xenon MRI platform.\"\nAs previously announced, the Company will hold a Virtual Investor Day on Wednesday, 12 March 2025 at 2:00pm GMT. To register for the webinar, please use this link:\nZoom Webinar - Register\n. The Company will provide additional updates as appropriate.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\n\u00ae\n, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news a",
          "content_length": 7618
        },
        "ingested_at": "2026-01-12T21:58:06.827957Z"
      },
      {
        "event_id": "RNS-19th Feb 2025-virtuali",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.827986Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Virtual Investor Day",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/virtual-investor-day-ycxc7a8f4fho0z3.html",
          "rns_number": "RNS Number : 5794X",
          "full_content": "19 Feb 2025 07:00\nRNS Number : 5794X\nPolarean Imaging PLC\n19 February 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nVirtual Investor Day\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\nannounces it will be hosting a virtual investor day on Wednesday 12 March 2025, at 2.00pm GMT / 10.00am EDT.\nThe event will be held via a Zoom webinar and will feature presentations on Polarean's lung functional Xenon MRI platform, its current clinical use at leading academic medical centres, as well as the Company's expanded sales team and commercial strategy. The event is open to all who wish to learn more about the story.\nA welcome and introduction will be given by\nChristopher von Jako, Ph.D., CEO of Polarean\n. The afternoon will also feature presentations by:\n\u00b7\nDr. Laura Walkup, Associate Professor, Cincinnati Children's\n\u00b7\nDr. Alan Huang, Vice President of Global Sales, Polarean\nThe presentations will be followed by a Q&A session where attendees can submit questions to the management team.\nTo register for the webinar, please use this link:\nZoom Webinar - Register\n.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or polarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u00ae, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.\nRisk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.\nAdverse Reactions\nAdverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.\nPlease see full prescribing information at www.XENOVIEW.net\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary In",
          "content_length": 5622
        },
        "ingested_at": "2026-01-12T21:58:06.828003Z"
      },
      {
        "event_id": "RNS-3rd Feb 2025-taiwanes",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828019Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Taiwanese distributor agreement with Sumtage",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/taiwanese-distributor-agreement-with-sumtage-wnjt47e09cev726.html",
          "rns_number": "RNS Number : 5550V",
          "full_content": "3 Feb 2025 07:00\nRNS Number : 5550V\nPolarean Imaging PLC\n03 February 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nTaiwanese distributor agreement with Sumtage\nFirst distribution agreement, expanding Polarean's international reach\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\nannounces it has signed a distribution agreement with Sumtage Enterprise Company Limited (\"Sumtage\") for the distribution of Polarean's Xenon MRI platform in Taiwan.\nThis agreement represents the Company's first distribution deal,\nexpanding Polarean's international reach and paving the way for Polarean's innovative Xenon MRI platform to\nbe sold and used in Taiwan. Polarean will work collaboratively with Sumtage to achieve the necessary regulatory clearances necessary for commercial launch in Taiwan.\nSumtage is a medical distributor with 30 years of experience in introducing the latest and most advanced medical equipment from overseas into the Taiwanese market, and offers customers additional maintenance and clinical support service post-sale. Sumtage has a comprehensive portfolio of medical imaging and diagnostic technologies, catering to the diverse needs of healthcare professionals.\nChristopher von Jako, Ph.D., CEO of Polarean, said:\n\"Sumtage are highly experienced in selling cutting-edge\nmedical technology in Taiwan, making them the ideal partner to help us expand access to our innovative Xenon MRI platform into this market. While our own sales team remains focused on expanding the number of user sites within the United States, I am pleased to see our first commercial entry into the Asia-Pacific region via a high-quality distributor, where we believe our platform can provide great benefit to pulmonary patients and their physicians. We will work with Sumtage to achieve regulatory approval for our platform in Taiwan ahead of commercial launch, and look forward to further updating the market in due course.\"\nHui-Lin Su, General Manager of Sumtage, said:\n'We are excited to work with Polarean to bring this groundbreaking Xenon MRI technology to Taiwan to help address lung diseases such as lung cancer, COPD, and asthma. The Polarean Xenon MRI platform enables advanced lung function assessments, allowing physicians to identify affected regions at earlier stages and facilitate timely treatment. We have already seen strong interest from leading academic medical centers, highlighting the significant potential of this technology to improve lung health in Taiwan.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\n\u00ae\n, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u00ae, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evalua",
          "content_length": 7222
        },
        "ingested_at": "2026-01-12T21:58:06.828036Z"
      },
      {
        "event_id": "RNS-30th Jan 2025-keypaten",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828050Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Key patent in China secured",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/key-patent-in-china-secured-towk7ozro4zapyn.html",
          "rns_number": "RNS Number : 1689V",
          "full_content": "30 Jan 2025 07:00\nRNS Number : 1689V\nPolarean Imaging PLC\n30 January 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nKey Patent in China Secured\nNew patent covers the use of Xenon MRI to non-invasively visualise pulmonary gas exchange and vascular function\nPolarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, announces the issuance of Chinese patent ZL201980047729.5.\nThe new Chinese patent covers the use of Polarean's Xenon MRI platform to visualise global and regional pulmonary gas exchange and microvascular blood flow in real time, helping position the Company for a potential future entry into the Chinese market and underscoring the Company's commitment to tackling the global burden of lung disease.\nChina has one of the highest burdens of lung disease globally, driven by factors such as air pollution, smoking, and an aging population, accounting for nearly a quarter of all chronic obstructive pulmonary disease (COPD) cases and 40% of new lung cancer cases globally. Chronic conditions like interstitial lung disease (ILD) and pulmonary hypertension are major challenges, particularly when symptoms such as unexplained dyspnea (breathlessness) cannot be clearly diagnosed using conventional tools. By illuminating hidden aspects of lung function, Polarean's Xenon MRI platform offers clinicians valuable new insights into complex lung diseases.\nChristopher von Jako, Ph.D., CEO of Polarean, commented:\n\"This new patent represents another step forward in our mission to optimise lung health globally. China faces an immense burden of respiratory diseases, and the addition of this patent will enable us, when the time is right, to bring our innovative, non-invasive Xenon MRI platform to a country that urgently needs it. With our cutting-edge Xenon MRI platform, we aim to deliver novel diagnostic tools that can improve outcomes for millions of patients with lung disease.\"\nChase Hall, M.D., Chief Medical Advisor at Polarean, added:\n\"China's burden of chronic lung disease is exacerbated by late diagnoses and inadequate screening. Our newly granted patent for gas exchange imaging will help expand the use of Xenon MRI in China to visualise lung function and vascular health - potentially enabling earlier detection, better monitoring of disease progression, and providing a new tool to help clinicians improve the long-term outlook for conditions like COPD, asthma, and ILD.\"\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u2122, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental ox",
          "content_length": 6870
        },
        "ingested_at": "2026-01-12T21:58:06.828069Z"
      },
      {
        "event_id": "RNS-28th Jan 2025-collabor",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828084Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Collaboration to Advance Lung Imaging Innovation",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/collaboration-to-advance-lung-imaging-innovation-72e1og5byep6tdk.html",
          "rns_number": "RNS Number : 8630U",
          "full_content": "28 Jan 2025 07:00\nRNS Number : 8630U\nPolarean Imaging PLC\n28 January 2025\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nPolarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation\nOne of the largest US outpatient medical imaging providers to introduce Xenon MRI platform to its network\nPolarean Imaging plc (AIM: POLX),\na commercial-stage leader in advanced medical imaging focused on functional Magnetic Resonance Imaging (\"MRI\") of the lungs\n, announces a strategic collaboration with SimonMed Imaging, one of the largest outpatient medical imaging providers in the United States, to expand access to Polarean's cutting-edge Xenon MRI platform.\nSimonMed Imaging operates in over 170 facilities across 11 states, offering comprehensive medical imaging with cutting-edge technology and artificial intelligence, all with an emphasis on affordability and accessibility. This collaboration will integrate Polarean's innovative Xenon MRI platform within SimonMed's network, enhancing diagnostic capabilities and advancing the standard of care for patients with pulmonary diseases.\nThe first SimonMed site to adopt Polarean's Xenon MRI platform will be in Scottsdale, Arizona, which is expected to be installed later this year, with scope to increase the number of sites installing systems as the collaboration matures.\nThe integration of Polarean's Xenon MRI platform into SimonMed's facilities represents a new business opportunity to expand the availability of functional lung imaging. This collaboration underscores both organisations' dedication to advancing medical technologies that enhance patient care and improve clinical outcomes.\nDr. John Simon, Founder and CEO of SimonMed Imaging, stated\n:\n\"At SimonMed, our mission is to bring the newest diagnostic imaging technologies to the community in a way that is both accessible and affordable. Polarean's groundbreaking work with Xenon MRI aligns perfectly with our mantra, 'See Tomorrow Today'. This technology provides an unparalleled ability to visualise lung function, offering critical insights for patients with respiratory conditions such as asthma, COPD, and unexplained dyspnea. Together, we are committed to delivering innovative solutions that have the potential to improve diagnostic accuracy and patient outcomes.\"\nChristopher von Jako, Ph.D., CEO of Polarean, added\n:\n\"SimonMed's dedication to making imaging technologies widely accessible mirrors Polarean's vision of optimising lung health and illuminating hidden disease, making SimonMed an ideal collaboration partner. Together, we aim to bring a much-needed imaging tool to clinicians, enabling them to see lung function with unprecedented clarity and precision to help them manage their patients' disease. We look forward to establishing a strong program in Scottsdale to serve as a model for potential expansion to several additional SimonMed's sites.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nSimondMed PR\nMichelle Kafka\nmichelle.kafka@kafkamediagroup.com\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\n\u00ae\n, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information abo",
          "content_length": 8410
        },
        "ingested_at": "2026-01-12T21:58:06.828123Z"
      },
      {
        "event_id": "RNS-24th Jan 2025-blocklis",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828142Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block Listing Six Monthly Return",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/block-listing-six-monthly-return-45lq3q43yl77zsf.html",
          "rns_number": "RNS Number : 3364U",
          "full_content": "24 Jan 2025 07:00\nRNS Number : 3364U\nPolarean Imaging PLC\n24 January 2025\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nBlock Listing Six Monthly Return\nPolarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\ntoday\nmakes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:\nName of applicant:\nPolarean Imaging Plc\nName of scheme:\nPolarean Share Option Plan\nNumber and class of securities originally admitted:\n8,000,000 ordinary shares of \u00a30.00037 each\nDate of admission:\n29 July 2021\nPeriod of return:\nFrom:\n27 July 2024\nTo:\n24 January 2025\nBalance of unallotted securities under scheme(s) from previous return:\n808,917\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\n0\nLess:\nNumber of securities issued/allotted under scheme(s) during period (see LR3.5.7G):\n0\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n808,917\nTotal number of\u00a0securities\u00a0in issue at the end of the period\n1,207,032,781\nName of contact:\nCharles F. Osborne, Jr., Chief Financial Officer\nTelephone number of contact:\n+\n44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy /Phillip Marriage\nMob: +44 (0)7876 741 001 /\n+44 (0) 7867 984 082\nAbout Polarean\n(\nwww.polarean.com\n)\nPolarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBLRPKBBQQBKDCDB",
          "content_length": 4025
        },
        "ingested_at": "2026-01-12T21:58:06.828156Z"
      },
      {
        "event_id": "RNS-11th Dec 2024-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828171Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/holdings-in-company-8zt2rsn0biuyft8.html",
          "rns_number": "RNS Number : 7392P",
          "full_content": "11 Dec 2024 14:52\nRNS Number : 7392P\nPolarean Imaging PLC\n11 December 2024\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BF3DT583\nIssuer Name\nPOLAREAN IMAGING PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nAmati Global Investors Limited\nCity of registered office (if applicable)\nEdinburgh\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nAmati AIM VCT plc\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n10-Dec-2024\n6. Date on which Issuer notified\n11-Dec-2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n2.930000\n0.000000\n2.930000\n35468967\nPosition of previous notification (if applicable)\n3.680000\n0.000000\n3.680000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BF3DT583\n35468967\n2.930000\nSub Total 8.A\n35468967\n2.930000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n11-Dec-2024\n13. Place Of Completion\nEdinburgh, UK\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUASSRSKUUAAA",
          "content_length": 3744
        },
        "ingested_at": "2026-01-12T21:58:06.828184Z"
      },
      {
        "event_id": "RNS-21st Nov 2024-fdaclear",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828200Z",
        "source": "LSE_RNS",
        "data": {
          "title": "FDA clears Chest Coil in GE HealthCare MRI Systems",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/fda-clears-chest-coil-in-ge-healthcare-mri-systems-mnj525d7i22bwjn.html",
          "rns_number": "RNS Number : 0374N",
          "full_content": "21 Nov 2024 07:00\nRNS Number : 0374N\nPolarean Imaging PLC\n21 November 2024\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nFDA clears XENOVIEW\u00ae 3T Chest Coil in GE HealthCare MRI Systems\nExpands accessibility for institutions utilising GE HealthCare MRI systems\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\nannounces that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company's specialised MRI Chest Coil to now include GE HealthCare 3 Tesla (3T) MRI scanners for the visualisation of Xenon-129 nuclei. With this new introduction, the Company now supports Xenon MRI scanning of both clinical and research patients on all three major MRI scanner vendors: GE HealthCare, Philips, and Siemens Healthineers.\nPolarean's GE HealthCare compatible XENOVIEW\u00ae 3T Chest Coil is a flexible, single-channel, transmit-receive radiofrequency coil tuned to image Xenon-129 nuclei while a patient is positioned inside a GE HealthCare SIGNA\u2122 Premier 3T or Discovery MR750 3T MRI scanner equipped with their Multi-Nuclear Spectroscopy capability. The XENOVIEW 3T Chest Coil is indicated to be used in conjunction with hyperpolarised Xenon-129 for oral inhalation for the evaluation of lung ventilation in adults and paediatric patients, aged 12 years and older. The addition of the new Chest Coil seamlessly supports institutions with GE HealthCare compatible MRI systems looking to adopt Xenon MRI, with safety and effectiveness confirmed through testing and FDA clearance.\nChristopher von Jako, Ph.D., CEO of Polarean, commented:\n\"GE HealthCare is a global leader in MRI technology and we are delighted to now offer our XENOVIEW 3T Chest Coil for use on their cutting-edge 3T MRI systems. Expanding our FDA clearance to include GE HealthCare's platforms, following our previous clearance for Philips and Siemens systems, ensures that more institutions and clinicians across the U.S. can access our innovative Xenon MRI technology. This expansion further enhances our ability to provide advanced imaging solutions to support patients and clinicians in the detection and ongoing monitoring of lung disease.\"\nClick\nhere\nto view an interview with Christopher von Jako on the 510(k) clearance and other recent Company milestones.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or polarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u00ae, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u00ae, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately followi",
          "content_length": 6803
        },
        "ingested_at": "2026-01-12T21:58:06.828217Z"
      },
      {
        "event_id": "RNS-25th Sep 2024-virtuali",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828232Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Virtual investor day",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/virtual-investor-day-7w4acv936c5f5nv.html",
          "rns_number": "RNS Number : 4849F",
          "full_content": "25 Sep 2024 07:00\nRNS Number : 4849F\nPolarean Imaging PLC\n25 September 2024\n25 September 2024\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nVirtual Investor Day\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\nannounces it will be hosting a virtual investor day on Wednesday 9 October 2024, at 2.00pm BST / 9.00am EST.\nThe event will be held via a Zoom webinar and will feature presentations on Polarean's lung functional Xenon MRI platform, its clinical use and future utility, as well as the Company's commercial strategy and future plans. The event is open to all.\nA welcome and introduction will be given by\nChristopher von Jako, Ph.D., CEO of Polarean Imaging\n. The afternoon will also feature presentations by:\n\u00b7\nDr. Chase Hall,\nChief Medical Advisor\n\u00b7\nDr. Bastiaan Driehuys,\nChief Scientific Officer and founder of Polarean\n\u00b7\nAlex Dusek, Chief Commercial Officer\nThe presentations will be followed by a Q&A session where attendees can submit questions to the management team.\nTo register for the webinar, please use this link:\nWebinar Registration - Zoom\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\n\u00ae\n, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u00ae, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.\nRisk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.\nAdverse Reactions\nAdverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.\nPlease see full prescribing information at www.XENOVIEW.net\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in",
          "content_length": 5601
        },
        "ingested_at": "2026-01-12T21:58:06.828248Z"
      },
      {
        "event_id": "RNS-4th Sep 2024-half-yea",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828262Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half-year Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/half-year-report-s9mmes99nyv5u0s.html",
          "rns_number": "RNS Number : 7701C",
          "full_content": "4 Sep 2024 07:00\nRNS Number : 7701C\nPolarean Imaging PLC\n04 September 2024\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\" or the \"Group\")\nHalf-year Report\nPolarean Imaging plc (AIM: POLX),\na commercial-stage medical device leader in advanced magnetic resonance imaging (\"MRI\") of the lungs, announces\nits unaudited interim results for the six months ended 30 June 2024\n.\nHighlights\n\u00b7\nGroup revenues for H1 2024 of US$1.1m (H1 2023: US$0.1m), reflecting increased commercial traction\n\u00b7\nOperating expenses for H1 2024 of US$4.6m (H1 2023 US$7.7m), reflecting the focus of expenditures in the highest value areas\n\u00b7\nSuccessfully raised gross proceeds of US$12.6m (\u00a39.9m), including the participation of existing strategic partners NUKEM Isotopes GmbH and Bracco Imaging S.p.A., and certain Directors and management of the Company, extending cash runway until at least Q1 2026\n\u00b7\nReceived de novo Xenon MRI System order from the University of Alabama at Birmingham (\"UAB\") Hospital, a top-tier academic medical hospital in the southeastern region of the U.S.\n\u00b7\nReceived and installed Cincinnati Children's trade-in agreement order, which exchanged their existing research hyperpolariser for a new clinical-grade Xenon MRI hyperpolariser system, thereby providing them additional flexibility for both research and clinical Xenon MRI scanning\n\u00b7\nA significant U.S. patent was granted for dynamic cardiopulmonary blood flow imaging with Xenon MRI, expanding its utility in the diagnosis and monitoring of diseases of the pulmonary vasculature\nPost period end\n\u00b7\nWith the H1 2024 revenue and orders received to date, the Company is raising its revenue guidance for 2024 to a range of $2.5m to $3.0m\n\u00b7\nThe Company now has 21 sites that have either installed or ordered hyperpolariser systems and five dedicated salespeople who will continue to drive sales for the remainder of 2024 and secure orders for 2025\n\u00b7\nReceived a trade-in agreement order to exchange the University of Virginia Health System's (\"UVA Health\") existing two research hyperpolarisers for two new clinical-grade Xenon MRI hyperpolariser systems\n\u00b7\nReceived a trade-in agreement order to exchange the University of Kansas Medical Center's (\"KUMC\") existing research hyperpolariser for a new clinical-grade Xenon MRI hyperpolariser system\n\u00b7\nAppointed Alan Huang, Ph.D., as Vice President of Sales\n\u00b7\nAppointed Chase Hall, M.D., as Chief Medical Advisor\n\u00b7\nSubmitted a New Drug Application (\"NDA\") supplement to the US Food and Drug Administration (\"FDA\"), to allow the administration of XENOVIEW\u2122 to paediatric patients aged six years and older\nChristopher von Jako, Ph.D., CEO of Polarean, commented:\n\"We are very pleased with the results for the first half of 2024. The revenue is tangible proof that our five-pillar growth strategy to revolutionise pulmonary medicine is starting to produce results. The installation of the new hyperpolariser system at Cincinnati Children's and the receipt of the de novo order from UAB Hospital, expected to be installed later this year, are important milestones for the Company toward achieving the revenue targets laid out in our\nFebruary 2024 strategy update\n. Additionally, the orders from UVA Health and KUMC in July 2024 further our progress toward converting legacy research sites to performing both research and clinical scans, and this continues to highlight the growing interest in this important technology from pulmonary clinicians.\n\"The first half of 2024 was marked by our efforts to successfully raise capital for the commercialisation of our pulmonary functional Xenon MRI platform. With gross proceeds of US$12.6m received in June 2024, we are now well-positioned to expand our sales team, as evidenced by the addition of Dr. Huang as our new VP of Sales, to help broaden our discussions with prospective sites. Additionally, we continue to advance the clinical applications of our technology. If our NDA supplement, filed at the end of July 2024, is approved by the FDA, it would significantly broaden our XENOVIEW label to include patients as young as six years old, greatly enhancing our clinical utility in the critical paediatric population.\n\"I would like to extend my gratitude to the Polarean team, our customers and investors who are helping us bring this important technology to patients suffering from chronic lung conditions.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, PhD, Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\u00a0/ Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue",
          "content_length": 29178
        },
        "ingested_at": "2026-01-12T21:58:06.828280Z"
      },
      {
        "event_id": "RNS-3rd Sep 2024-appointm",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828294Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Appointment of Vice President of Sales",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/appointment-of-vice-president-of-sales-dj277cc2esp5zu2.html",
          "rns_number": "RNS Number : 5963C",
          "full_content": "3 Sep 2024 07:00\nRNS Number : 5963C\nPolarean Imaging PLC\n03 September 2024\n3 September 2024\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nAppointment of Alan Huang, Ph.D., as Vice President of Sales\nExperienced business leader with extensive commercial experience in Magnetic Resonance Imaging\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, is pleased to announce the appointment of Alan Huang, Ph.D. as Vice President of Sales.\nDr. Huang brings extensive knowledge and 15 years of experience in the medical device industry, with specific expertise in MRI and MRI-based technologies. He is skilled in executing strategic plans and driving revenue growth of novel technologies. Dr. Huang joins Polarean after nearly 12 years at Philips Healthcare, where he held various roles, most recently as North American Business Leader for the MRI business unit. In this role, he was directly responsible for P&L management and directing the sales and marketing teams. Dr. Huang also developed strategic plans for market growth, supported the reorganisation of the commercial organisation to sharpen its focus on key markets, and hired channel partners to assist in the management of the business in non-core markets.\nAs VP of Sales, Dr. Huang will be responsible for driving Polarean's sales strategy and leading the Company's expanding sales team as it accelerates the market adoption of its\npulmonary functional Xenon MRI platform technology\n. He will focus on expanding the technology's footprint in academic medical centers and driving utilization across the growing install base, enabling improved characterisation and management of chronic lung disease for patients and their clinicians.\nDr. Huang holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine in Baltimore, MD, and a double Bachelor of Science degree in Neurobiology and Electrical and Computer Engineering from the University of Texas at Austin.\nChristopher von Jako, Ph.D., CEO of Polarean, said:\n\"I am extremely delighted to welcome Alan to the Polarean team as our VP of Sales. Having gotten to know him over the past year during our collaboration with Philips, I am confident that he brings a wealth of experience and insights that will greatly complement our current commercial team. This appointment comes at an ideal time following our recent financing, as we aim to expand our sales infrastructure with best-in-class talent to accelerate the adoption of our Xenon MRI technology. Alan's extensive experience at Philips, where he successfully grew their MR business and built strong relationships with a large number of academic medical centres and clinicians across the US, makes him a tremendous asset to Polarean.\"\nAlan Huang, Ph.D., VP of Sales at Polarean, said\n:\n\"In my previous roles in diagnostic MRI and Radiation Therapy solutions, I recognised the potential of Polarean's Xenon MRI technology to significantly improve the characterisation and management of chronic lung diseases. Through the Philips partnership with Polarean and numerous conversations with customers, I became more aware of the significant unmet clinical need and was impressed by the Company's innovative approach. I am excited to join Polarean and work with the team to expand the reach of Xenon MRI platform technology across the pulmonary clinical community.\"\nClick\nhere\nfor an interview with Christopher von Jako on the appointments of Alan Huang, Ph.D., VP of Sales, and Chase Hall, M.D., Chief Medical Advisor.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehen",
          "content_length": 8033
        },
        "ingested_at": "2026-01-12T21:58:06.828312Z"
      },
      {
        "event_id": "RNS-28th Aug 2024-appointm",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828327Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Appointment of Chief Medical Advisor",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/appointment-of-chief-medical-advisor-2yxf0brf4pja4y4.html",
          "rns_number": "RNS Number : 8706B",
          "full_content": "28 Aug 2024 07:00\nRNS Number : 8706B\nPolarean Imaging PLC\n28 August 2024\n28 August 2024\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nAppointment of Chase Hall, M.D., as Chief Medical Advisor\nAdds significant pulmonary expertise to help drive engagement with the medical community\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, announces that it has appointed Chase Hall, M.D., as Chief Medical Advisor.\nDr. Hall is an Associate Professor, Pulmonary, Critical Care and Sleep Medicine, at the University of Kansas Medical Center in the Division of Pulmonary and Critical Care. He also serves as Associate Director at the University of Kansas Interstitial Lung Disease and Rare Lung Disease Clinic. Dr. Hall's research focus has been on establishing imaging biomarkers in respiratory disease, utilising Xenon MRI. In his lab, he is currently working to utilise Xenon MRI as a sensitive measure of treatment response in a number of respiratory diseases, as well as rapid image acquisition protocols and fully automated image analysis programmes. In addition, Dr. Hall is a member of the Xenon MRI Clinical Trials Consortium, a growing collaboration of 13 clinical research sites; its activities include the harmonisation and standardisation of Xenon imaging protocols for multi-center clinical trials, training of new sites establishing Xenon MRI programmes, and growing awareness and expertise in the field.\nIn his role as Chief Medical Advisor, Dr. Hall will assist in guiding Polarean's clinical development strategy and medical education initiatives with fellow clinicians and professional societies. He will leverage his experience while maintaining his clinical pulmonology practice, providing valuable insights to help Polarean address unmet medical needs in pulmonary care.\nDr. Hall received his medical degree from the University of Kansas School of Medicine and completed his residency in Internal Medicine and fellowship training in Pulmonary and Critical Care at Washington University School of Medicine in St. Louis. He serves as a peer-reviewer for many prestigious journals, such as Academic Radiology and The American Journal of Respiratory and Critical Care Medicine.\nChristopher von Jako, Ph.D, CEO of Polarean, said:\n\"I am delighted to welcome Dr. Hall to Polarean as our new Chief Medical Advisor. As a leading expert in pulmonary medicine as well as a champion of our Xenon MRI technology platform, Dr. Hall is a perfect fit for the Company. His appointment represents\na significant step in growing the Polarean team\nas we look to expand Xenon MRI\nto more clinical and research sites.\"\nChase Hall, M.D., CMA of Polarean, said:\n\"\nFor several years, I have been deeply interested in the potential of Xenon MRI to assist pulmonary clinicians and the patients we treat. There is a significant unmet need in pulmonary medicine for imaging technology that can better characterise disease, monitor response to therapy, and guide interventional procedures. I am excited to join Polarean to help guide the clinical development and implementation of this unique technology in pulmonary medicine.\"\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D, Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platfo",
          "content_length": 7643
        },
        "ingested_at": "2026-01-12T21:58:06.828345Z"
      },
      {
        "event_id": "RNS-21st Aug 2024-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828360Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/notice-of-results-fygvffopbdsngr2.html",
          "rns_number": "RNS Number : 1391B",
          "full_content": "21 Aug 2024 07:00\nRNS Number : 1391B\nPolarean Imaging PLC\n21 August 2024\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nNotice of results\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\nconfirms that it will be announcing its half year results for the six months ended 30 June 2024 on Wednesday, 4 September 2024.\nChristopher von Jako, Ph.D., Chief Executive Officer, and Charles Osborne, Chief Financial Officer, will be hosting a live online presentation relating to the results via the Investor Meet Company platform on Wednesday, 4 September 2024 at 17.30 BST.\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your IMC dashboard up until 09:00 BST the day before the meeting or in real time during the presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet Polarean Imaging plc\nhere\n.\nInvestors who already follow Polarean on the Investor Meet Company platform will automatically be invited.\nWhilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation will be available on the Investor Meet Company platform afterwards.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Nick Harland / Ben Good\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\u00a0/ Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORGZGZRFGZGDZM",
          "content_length": 4067
        },
        "ingested_at": "2026-01-12T21:58:06.828374Z"
      },
      {
        "event_id": "RNS-15th Aug 2024-appointm",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828388Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Appointment of Bastiaan Driehuys as consultant",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/appointment-of-bastiaan-driehuys-as-consultant-y6mecu8b6tu5ymf.html",
          "rns_number": "RNS Number : 4852A",
          "full_content": "15 Aug 2024 07:00\nRNS Number : 4852A\nPolarean Imaging PLC\n15 August 2024\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nAppointment of Bastiaan Driehuys as consultant\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, announces the appointment of Bastiaan Driehuys Ph.D., previously a Board member and Chief Scientific Officer of Polarean, as a consultant to the Company with immediate effect.\nAs announced in the Company's preliminary results on 28 June 2024, Bastiaan stepped down from his position on the Board effective 24 July 2024 but will retain his position as Chief Scientific Officer of the Company, which he will serve on a consultancy basis.\nBastiaan Driehuys invented hyperpolarised gas MRI while completing his Doctorate in Atomic Physics at Princeton University, and co-founded Polarean Imaging in 2011. He and his team developed the underlying technology of\u00a0129Xe hyperpolarisation, as well as novel MR image acquisition, reconstruction and analysis strategies and how to apply them to problems in pulmonary medicine.\nUnder the terms of the consultancy contract, Polarean will pay Dr. Driehuys an annual fee of US$36,500.\nChristopher von Jako, Ph.D., CEO of Polarean, said:\n\"We are delighted to be able to retain Bastiaan as a consultant to the Company, and that he will remain our Chief Scientific Officer. We are excited to continue to capitalise on his expertise as a founder and key member of the Polarean team.\"\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)\nNick Harland (Corporate Broking)\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\u00a0/ Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u2122, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.\nRisk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.\nAdverse Reactions\nAdverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to",
          "content_length": 6064
        },
        "ingested_at": "2026-01-12T21:58:06.828406Z"
      },
      {
        "event_id": "RNS-1st Aug 2024-fdasubmi",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828424Z",
        "source": "LSE_RNS",
        "data": {
          "title": "FDA submission to expand minimum age for XENOVIEW\u2122",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/fda-submission-to-expand-minimum-age-for-xenoview8482-nvtspz2p6cn5a1a.html",
          "rns_number": "RNS Number : 7522Y",
          "full_content": "1 Aug 2024 07:00\nRNS Number : 7522Y\nPolarean Imaging PLC\n01 August 2024\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nFDA submission to expand minimum age for\nXENOVIEW\n\u2122\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function\n, announces that it has submitted a New Drug Application (\"NDA\") supplement to the US Food and Drug Administration (\"FDA\"), to allow the administration of XENOVIEW\u2122 to paediatric patients aged six years and older. This supplement includes updates\nto the HPX Polarisation Measurement Station and new XENOVIEW\n\u2122\nDose Delivery Bag sizes.\nCurrently XENOVIEW\u2122, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and paediatric patients aged 12 years and older.\nChristopher von Jako, Ph.D, Chief Executive Officer of Polarean, said:\n\"I am pleased to have submitted our NDA supplement to the FDA to expand the minimum age of XENOVIEW\n\u2122\nto paediatric patients six years and older. If granted, this will allow our technology to help even more children with chronic lung conditions and their clinicians, allowing for better management of their disease. I look forward to further updating the market in due course.\"\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D, Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)\nNick Harland (Corporate Broking)\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\u00a0/ Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\n\u200b\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrat\ned modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u2122, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.\nRisk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.\nAdverse Reactions\nAdverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in",
          "content_length": 5886
        },
        "ingested_at": "2026-01-12T21:58:06.828441Z"
      },
      {
        "event_id": "RNS-31st Jul 2024-newxenon",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828456Z",
        "source": "LSE_RNS",
        "data": {
          "title": "New Xenon MRI System trade-in agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/new-xenon-mri-system-trade-in-agreement-t0arayf290cx7cv.html",
          "rns_number": "RNS Number : 5460Y",
          "full_content": "31 Jul 2024 07:00\nRNS Number : 5460Y\nPolarean Imaging PLC\n31 July 2024\n31 July 2024\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nNew Xenon MRI System trade-in agreement entered with the University of Kansas Medical Center\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, announces\nit has entered into a trade-in agreement to exchange the University of Kansas Medical Center's (\"KUMC\") existing research hyperpolariser for a new clinical-grade Xenon MRI hyperpolariser system to be provided by Polarean.\nKUMC is a top-tier academic centre that has pioneered Xenon MRI research across multiple therapeutic areas. The new hyperpolariser will advance the already strong programme that includes clinical research in asthma, cystic fibrosis, long COVID, pulmonary hypertension, interstitial lung disease, and scleroderma. KUMC researcher Dr. Peter Niedbalski recently received a grant to lead a multi-centre study initiative to use Xenon MRI to identify structural determinants of low lung function and respiratory symptoms in young adults.\nThe new equipment is being purchased as part of a device trade-in in which KUMC will trade in an earlier research hyperpolariser for the latest FDA-approved system, suitable for clinical scans. Polarean expects to install the new system later this year and will work closely with KUMC to advance clinical imaging, NIH-funded research, and pharmaceutical-sponsored trials.\nWorld-renowned pulmonologist Mario Castro, M.D., MPH, at KUMC, said\n:\n\"My team and I have been using Xenon MRI for research purposes for nearly eight years now. We believe that it offers unique insights into disease characterization and monitoring response to treatment. I look forward to receiving the upgraded Polarean hyperpolariser, continuing our research, and planning clinical scans in the future.\"\nChristopher von Jako, Ph.D, CEO of Polarean, said:\n\"The team at KUMC has been a valued champion of our pulmonary functional Xenon MRI platform technology for a number of years, pioneering its\nuse across multiple disease areas with their research-grade hyperpolariser. We are delighted to see KUMC upgrading its hyperpolariser as part of its broader expansion of pulmonary imaging capabilities. This underscores the growing importance that top-tier institutions are placing on Xenon MRI technology.\"\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D., Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)\nNick Adams / Nick Harland (Corporate Broking)\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u2122, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. F",
          "content_length": 6960
        },
        "ingested_at": "2026-01-12T21:58:06.828473Z"
      },
      {
        "event_id": "RNS-29th Jul 2024-repricin",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828488Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Repricing of Options and Grant of Options",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/repricing-of-options-and-grant-of-options-qm62wvlrx120dw5.html",
          "rns_number": "RNS Number : 0985Y",
          "full_content": "29 Jul 2024 07:00\nRNS Number : 0985Y\nPolarean Imaging PLC\n29 July 2024\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nRepricing of Options and Grant of Options\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function\n, announces that upon the recommendation of the Company's Remuneration Committee, it has repriced existing options over\nordinary\u00a0shares of \u00a30.00037 each in the capital of the Company\u00a0(\"Ordinary Shares\") (\"\nShare Options\") over an aggregate of 19,849,965 Ordinary Shares and granted Share Options over an aggregate 121,022,451 Ordinary Shares to certain Directors, employees, and consultants of the Company.\nThe Company's Remuneration Committee recognises the importance of share options to appropriately incentivise and retain Directors and employees as well as to ensure their interests are aligned with that of Company and its shareholders. Following a review of incentive plans, the Remuneration Committee of the Board recommended that, given the reduction in the Company's share price and the changes in the share capital following the recent fundraising, the existing awards of share options were no longer a reasonable incentive and should be amended to re-align the option scheme with the current share price and share capital.\nThe Company contracted with a third-party compensation firm to perform a benchmarking analysis of Share Options at comparable companies. The Remuneration Committee and Board used the third-party report in determining the number of new Share Options to be issued.\nThe repricing and granting of Share Options is pursuant to the terms of the Company's existing Stock Option Plan. 25% of the new Share Options will vest on 26 July 2025 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 August 2025. The Share Options will be exercisable at a price of 1.83p each per Ordinary Share, being the share price as at close of business on Friday 26 July 2024. The repriced Share Options retain their original vesting and expiration terms.\n17,462,194 Share Options have been repriced and 104,810,222 Share Options were granted to the 11 PDMRs listed in the table below. 2,387,771 Share Options have been repriced and\n16,212,229 new Share Options were granted, to non-PDMR employees and a consultant.\nName\nShare Options Repriced\nShare Options Granted\nTotal no. of options over ordinary shares now held\nChristopher von Jako\n5,325,000\n24,368,006\n29,693,006\nBastiaan Driehuys\n1,686,000\n20,040,590\n21,726,590\nKenneth West\n2,263,218\n15,842,273\n18,105,491\nCharles Osborne\n1,700,000\n7,956,262\n9,656,262\nCyrille Petit\n500,000\n4,448,834\n4,948,834\nJuergen Laucht\n884,400\n4,064,434\n4,948,834\nFrank Schulkes\n500,000\n2,879,691\n3,379,691\nDaniel Brague\n500,000\n2,879,691\n3,379,691\nAlexander Dusek\n1,500,000\n8,156,262\n9,656,262\nNeil Wadehra\n1,568,988\n7,242,351\n8,811,339\nKiarash Emami\n1,034,588\n6,931,828\n7,966,416\nTotal\n17,462,194\n104,810,222\n122,272,416\nNon-PDMR Employees and Consultant\n2,387,771\n17,412,229\n19,800,000\nTotal (PDMR, Non-PDMR Employees and Consultant)\n19,849,965\n122,222,451\n142,072,416\nThe award and repricing of Share Options to the Directors of the Company are deemed to be Related Party Transactions under Rule 13 of the AIM Rules. As there are no Directors independent of the transactions to provide a fair and reasonable statement because all of the Directors are participating in the award of Options, Stifel (in its capacity as nominated adviser for the purposes of the AIM Rules) considers the Directors' participation to be fair and reasonable insofar as Shareholders are concerned.\nFollowing the grant of Share Options referred above, there are 143,473,216 outstanding Share Options over Polarean's Ordinary Shares, representing 11.9% of the Company's total voting rights.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com / www.polarean-ir.com\nChristopher von Jako, PhD, Chief Executive Officer\nCharles Osborne, Chief Financial Officer\nVia Walbrook PR\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)\nNick Harland (Corporate Broking)\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy\u00a0/ Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polar",
          "content_length": 6662
        },
        "ingested_at": "2026-01-12T21:58:06.828507Z"
      },
      {
        "event_id": "RNS-26th Jul 2024-blocklis",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828522Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block Listing Six Monthly Return",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/block-listing-six-monthly-return-hp15edkwscj71a9.html",
          "rns_number": "RNS Number : 8723X",
          "full_content": "26 Jul 2024 07:00\nRNS Number : 8723X\nPolarean Imaging PLC\n26 July 2024\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nBlock Listing Six Monthly Return\nPolarean Imaging plc (AIM: POLX a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function\n,\ntoday\nmakes\nthe following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:\nName of applicant:\nPolarean Imaging Plc\nName of scheme:\nPolarean Share Option Plan\nNumber and class of securities originally admitted:\n8,000,000 ordinary shares of \u00a30.00037 each\nDate of admission:\n29 July 2021\nPeriod of return:\nFrom:\n27 January 2024\nTo:\n26 July 2024\nBalance of unallotted securities under scheme(s) from previous return:\n1,224,573\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\n0\nLess:\nNumber of securities issued/allotted under scheme(s) during period (see LR3.5.7G):\n415,656\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n808,917\nTotal number of\u00a0securities\u00a0in issue at the end of the period\n1,207,032,781\nName of contact:\nCharles F. Osborne, Jr., Chief Financial Officer\nTelephone number of contact:\n+\n44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)\nNick Harland (Corporate Broking)\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy /Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0) 7867 984 082\nAbout Polarean (\nwww.polarean.com\n)\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBLRSEIFSIELSEIW",
          "content_length": 4104
        },
        "ingested_at": "2026-01-12T21:58:06.828536Z"
      },
      {
        "event_id": "RNS-24th Jul 2024-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828550Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/result-of-agm-9cx4snw2062vd2s.html",
          "rns_number": "RNS Number : 7028X",
          "full_content": "24 Jul 2024 14:36\nRNS Number : 7028X\nPolarean Imaging PLC\n24 July 2024\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nResult of AGM\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function,\nannounces that at the AGM held earlier today, all resolutions were duly passed.\nDetails of the proxy votes received on each resolution by Polarean's Registrar are set out below:\nResolution\nFor\nAgainst\n01\n542,592,425\n501,837\n02\n502,233,241\n40,851,639\n03\n535,480,548\n156,837\n04\n540,895,665\n1,754,284\n05\n541,339,768\n1,754,284\n06\n542,446,417\n647,635\n07\n447,099,699\n44,443,774\n08\n491,438,034\n44,534,613\n09\n542,149,864\n942,744\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com\n/\nwww.polarean-ir.com\nChristopher von Jako, Ph.D, Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)\nNick Harland (Corporate Broking)\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGSELFDLELSEDW",
          "content_length": 3458
        },
        "ingested_at": "2026-01-12T21:58:06.828564Z"
      },
      {
        "event_id": "RNS-19th Jul 2024-xenonmri",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828578Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Xenon MRI System trade-in agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/xenon-mri-system-trade-in-agreement-7tqaosx8eofbn2e.html",
          "rns_number": "RNS Number : 0197X",
          "full_content": "19 Jul 2024 10:36\nRNS Number : 0197X\nPolarean Imaging PLC\n19 July 2024\n19 July 2024\nPolarean Imaging plc\n(\"Polarean\" or the \"Company\")\nXenon MRI System trade-in agreement entered with the\nUniversity of Virginia Health Hospital\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, announces that it has entered into a trade-in agreement to exchange the University of Virginia Health System's (\"UVA Health\") existing two research hyperpolarisers for two new clinical-grade hyperpolariser systems to be provided by Polarean.\nUVA Health is an integrated health system with a world-class academic medical center that includes a Level 1 Trauma Centre, an NCI-designated Comprehensive Cancer Center, and UVA Health Children's, the number one pediatric hospital in Virginia.\nUVA Health's Hyperpolarized Gas MR Imaging Center faculty pioneered the application of Xenon MRI for a variety of lung diseases, including asthma, cystic fibrosis, and bronchopulmonary dysplasia.\nReplacing these research hyperpolarisers is the first step to UVA Health advancing its leadership position in the Mid-Atlantic as a centre of excellence for NIH grants, industry-sponsored trials, and clinical patient referrals for this novel imaging modality.\nPolarean expects to install the new systems later this year and will collaborate closely with UVA Health to ensure a successful implementation that enhances the Xenon MRI research program and establishes the foundation for clinical Xenon MRI capabilities.\nChristopher von Jako, Ph.D, CEO of Polarean, said:\n\"We are delighted to see UVA Health upgrade both of their hyperpolariser systems to clinical grade. This milestone underscores the increasing adoption of Polarean's technology and the continued progress in our strategy to convert previously research-only centres to clinical-grade, in addition to establishing de novo sites\n. We look forward to working with the team at UVA Health to ensure that their implementation of\nour Xenon MRI technology\nis successful as it continues to advance research and move into clinical use.\"\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D, Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)\nNick Harland (Corporate Broking)\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\npolarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nXENOVIEW IMPORTANT SAFETY INFORMATION\nIndication\nXENOVIEW\u2122, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.\nLimitations of Use\nXENOVIEW has not been evaluated for use with lung perfusion imaging.\nCONTRAINDICATIONS\nNone.\nWarnings and Precautions\nRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to X",
          "content_length": 6871
        },
        "ingested_at": "2026-01-12T21:58:06.828597Z"
      },
      {
        "event_id": "RNS-18th Jul 2024-pdmrdeal",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828611Z",
        "source": "LSE_RNS",
        "data": {
          "title": "PDMR Dealing",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/pdmr-dealing-0vzmeyobnwnqlsy.html",
          "rns_number": "RNS Number : 0116X",
          "full_content": "18 Jul 2024 17:33\nRNS Number : 0116X\nPolarean Imaging PLC\n18 July 2024\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nPDMR Dealing\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, announces it has received notification today from Bill Blair, an Independent Non-Executive Director (\"NED\") who is considered by the Company to be a person discharging managerial responsibility (\"PDMR\"), that he sold 650,000 ordinary\u00a0shares of \u00a30.00037 each in the capital of the Company (\"Ordinary Shares\") on 17 July 2024 and 2,039 Ordinary Shares on 18 July 2024, all at a price of 1.8p per Ordinary Share.\nNotifications have been made in accordance with the requirements of the UK Market Abuse Regulation in respect of the PDMR and further details can be found by following this link:\nhttps://www.polarean-ir.com/content/investors/shareholder-information\nEnquiries:\nPolarean Imaging plc\nwww.polarean.com /\nwww.polarean-ir.com\nChristopher von Jako, Ph.D, Chief Executive Officer\nVia Walbrook PR\nCharles Osborne, Chief Financial Officer\nStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)\n+44 (0)20 7710 7600\nNicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)\nNick Harland (Corporate Broking)\nWalbrook PR\nTel: +44 (0)20 7933 8780 or polarean@walbrookpr.com\nAnna Dunphy / Phillip Marriage\nMob: +44 (0)7876 741 001 / +44 (0)7867 984 082\nAbout Polarean\nPolarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW\u2122, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit\nwww.polarean.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHQKFBNABKDBOD",
          "content_length": 3695
        },
        "ingested_at": "2026-01-12T21:58:06.828625Z"
      },
      {
        "event_id": "RNS-28th Jun 2024-finalres",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828639Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Final Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/final-results-cyxmlzdt0u8hxe1.html",
          "rns_number": "RNS Number : 2465U",
          "full_content": "28 Jun 2024 07:00\nRNS Number : 2465U\nPolarean Imaging PLC\n28 June 2024\n28 June 2024\nPolarean Imaging Plc\n(\"Polarean\" or the \"Company\")\nFinal Results and Directorate Changes\nNotice of Annual General Meeting\nPolarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (\"MRI\") of lung function, ann\nounces its audited final results for the year ended 31 December 2023.\nIn addition, Polarean\u00a0confirms that the Annual Report and Accounts for the year ended 31 December 2023, the Notice of the Annual General Meeting (\"AGM\") and a Form of Proxy are now available on the Company's website (\nhttp://www.polarean-ir.com/content/investors/annual-reports.asp\n) and will be posted to shareholders shortly.\nThe AGM will be held at 2500 Meridian Parkway, Suite 175, Durham, NC 27713, USA at 2:00 p.m. BST / 9:00 a.m. EDT on 24 July 2024.\nHighlights\n\u00b7\nAppointed Christopher von Jako, Ph.D. as new Chief Executive Officer and Board Director, following the retirement of Richard Hullihen\n\u00b7\nReceived first de novo XENOVIEW\u2122 (Xenon Xe 129 hyperpolarised) polariser order from a top-tier U.S. academic medical centre located in the north-eastern region of the U.S.\n\u00b7\nSecured first order for a Xenon gas blend cylinder for the production of XENOVIEW from Cincinnati Children's Hospital Medical Center, enabling the first clinical scan utilising the technology in the U.S.\n\u00b7\nUpgraded the University of Missouri Health Care polariser\nsystem to a clinical configuration accompanied by the sale of an initial xenon gas blend cylinder for the production of XENOVIEW\n\u00b7\nEntered into a collaboration agreement with multinational medical imaging technology company, Philips to advance the field of hyperpolarised Xenon MRI\n\u00b7\nSubmitted a post-marketing commitment plan to the US Food and Drug Administration (\"FDA\") to seek approval to expand the minimum current age of XENOVIEW MRI in children from twelve to six years\n\u00b7\nGranted New Chemical Entity designation for XENOVIEW by the FDA, with a five-year market exclusivity period\n\u00b7\nReceived 510(k) clearance from the FDA for the Company's specialised MRI chest coil to now include Philips 3.0T MRI scanners for visualisation of\nthe\nXenon 129\nnuclei\n\u00b7\nNew reimbursement C-code (C9791) from the US Centers for Medicare & Medicaid Services (\"CMS\") for the XENOVIEW MRI technology which corresponds to a payment range of between US$1,201 to US$1,300\n\u00b7\nRequested and granted a formal Type B meeting in October 2023 with the FDA's Center for Drug Evaluation and Research division to seek guidance on the clinical plan related to the XENOVIEW indication expansion, which includes both regional visualisation and quantitative assessment of gas exchange and microvascular haemodynamics for both pulmonary and cardio-pulmonary diseases\n\u00b7\nPartnered with VIDA Diagnostics (\"VIDA\") to further enable the Polarean Xenon 129 MRI platform to accelerate clinical and research use\n\u00b7\nNet cash of $6.2 million as of 31 December 2023 (31 December 2022: $16.4 million)\nPost period end highlights\n\u00b7\nSuccessfully raised gross proceeds of US$\n12.6\nmillion\n(\u00a3\n9.9\nmillion)\n, including participation of\nexisting strategic partners NUKEM Isotopes GmbH and Bracco\nImaging S.p.A., and certain Directors and management of the Company demonstrating their continued support and extending cash runway until at least Q1 2026\n\u00b7\nReceived first de novo XENOVIEW (Xenon Xe 129 hyperpolarised) polariser order from the University of Alabama at Birmingham, a top-tier academic hospital in the south-eastern region of the U.S.\n\u00b7\nU.S. Patent granted for dynamic cardiopulmonary blood flow imaging with Xenon MRI\n\u00b7\nReceived an order from\nCincinnati Children's Hospital Medical Center for a new polariser to upgrade its existing research system to provide additional flexibility for research and clinical scanning\n\u00b7\nBastiaan Driehuys, Ph.D., Marcella Ruddy, M.D. and William Blair notified the Company of their intention to resign from their roles as Directors of the Board, with effect from 24 July 2024. Dr. Driehuys will retain his role as Chief Scientific Officer. Departures will result in a seven-member Board, an appropriate size and skill set for the Company\nChristopher von Jako, Ph.D., CEO of Polarean, commented\n:\n\"\nIt is now one year since I joined the excellent team at Polarean and I am very pleased with the progress we have made so far. Most recently in May, we announced a successful Placing, Subscription and Open Offer where we raised gross proceeds of\nUS$\n12.6\nmillion\n(\u00a3\n9.9\nmillion), which we will use\nto accelerate the commercialisation of XENOVIEW, support our continued investment in research and development including, amongst other developments, finalisation of the FDA plan to expand indications to gas exchange, and continue to develop strategic partnerships. The fundraise\nwill enable us to substantially progress implementation of our five-pillar growth strategy in pursuit of its mission to revolutionise pulmonary medicine.\n\"We also achiev",
          "content_length": 26168
        },
        "ingested_at": "2026-01-12T21:58:06.828656Z"
      },
      {
        "event_id": "RNS-19th Jun 2024-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828670Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/holdings-in-company-kw1xjho8719hev2.html",
          "rns_number": "RNS Number : 1207T",
          "full_content": "19 Jun 2024 17:23\nRNS Number : 1207T\nPolarean Imaging PLC\n19 June 2024\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BF3DT583\nIssuer Name\nPOLAREAN IMAGING PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nRathbones Investment Management Ltd\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\nName\nCity of registered office\nCountry of registered office\nInvestec Wealth & Investment Limited\nLondon\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nHero Nominees Limited\nSt Peter Port\nGuernsey\nFerlim Nominees Limited\nLondon\nUnited Kingdom\nRathbone Nominees Limited\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n18-Jun-2024\n6. Date on which Issuer notified\n19-Jun-2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n4.991900\n0.000000\n4.991900\n60254082\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BF3DT583\n60254082\n4.991900\nSub Total 8.A\n60254082\n4.991900%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nRathbones Group PLC\nRathbones Investment Management Limited\n4.970900\n4.970900%\nRathbones Group PLC\nInvestec Wealth & Investment Limited\n0.021100\n0.021100%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNone\n12. Date of Completion\n19-Jun-2024\n13. Place Of Completion\nPort of Liverpool Building, Liverpool L3 1NW\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUKUNRSAUNAAR",
          "content_length": 4143
        },
        "ingested_at": "2026-01-12T21:58:06.828684Z"
      },
      {
        "event_id": "RNS-19th Jun 2024-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T21:58:06.828698Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLX/holdings-in-company-7kr5prblalahiv9.html",
          "rns_number": "RNS Number : 1203T",
          "full_content": "19 Jun 2024 17:23\nRNS Number : 1203T\nPolarean Imaging PLC\n19 June 2024\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BF3DT583\nIssuer Name\nPOLAREAN IMAGING PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nRathbones Investment Management Ltd\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\nName\nCity of registered office\nCountry of registered office\nInvestec Wealth & Investment Limited\nLondon\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nHero Nominees Limited\nSt Peter Port\nGuernsey\nFerlim Nominees Limited\nLondon\nUnited Kingdom\nRathbone Nominees Limited\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n17-Jun-2024\n6. Date on which Issuer notified\n19-Jun-2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n15.140900\n0.000000\n15.140900\n60163200\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BF3DT583\n60163200\n15.140900\nSub Total 8.A\n60163200\n15.140900%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nRathbones Group PLC\nRathbones Investment Management Limited\n15.099900\n15.099900%\nRathbones Group PLC\nInvestec Wealth & Investment Limited\n0.041100\n0.041100%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNone\n12. Date of Completion\n19-Jun-2024\n13. Place Of Completion\nPort of Liverpool Building, Liverpool L3 1NW\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUKUNRSRUNAAR",
          "content_length": 4149
        },
        "ingested_at": "2026-01-12T21:58:06.828712Z"
      },
      {
        "event_id": "SOCIAL-15Dec20251405-loadofbo-50014120",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.897078",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why on earth would someone buy 7m shares when its de listing?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.13",
          "thread_title": "RE: And... delisted from AIM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=8E783F9A-4C63-461E-ACA1-4513E80D78C0"
        },
        "ingested_at": "2026-01-22T21:08:46.907901+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251406-Doppo59--8527543",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.896669",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Such a shame, but no surprise! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.13",
          "thread_title": "No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-22T21:08:46.907883+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-bassman7--5221629",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.896254",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Judging by your recent comments Doppo, you seemed to think this would come good, even congratulating otheres on their holdings just a week ago... \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-22T21:08:46.907864+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-Shpunken--7503514",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.895832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Yep it is a shame that ppl will miss out on this and big companies again will be the winners",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-22T21:08:46.907846+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251437-Ilovesus-24837869",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.895359",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Down 99.8% over the last 5 years. Even though some may have just made 100% . Often these type of rises are meaningless for most. Who honestly got in on the bottom and how long have they been invested? As the company can no longer get away with another placing it would have to issue too many shares and then only raise small amounts. That it now wants to delist is very telling. Its reach the end of the road. Its in a place where raising more through selling shares will not work. This is where most companies on AIM delist. They cannot sell any more shares. PYC is a company like this that may also delist. Seems some on that company post here. AIM companies list in order to raise money. PYC has had so many placings and  has a history of raising unlike this company. That too like this one will no doubt delist. Beware guys AIM is a cesspit.",
          "sentiment": 0.0,
          "engagement": "7,718",
          "price_at_post": "0.11",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-22T21:08:46.907828+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251519-2reincar--7120610",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.894913",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Question of only when.",
          "sentiment": 0.0,
          "engagement": "5,828",
          "price_at_post": "0.10",
          "thread_title": "Genedrive will eventually go the same way!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=EF81FBC2-AF85-428C-BBE4-906724917774"
        },
        "ingested_at": "2026-01-22T21:08:46.907810+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251534-share4--5046899",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.894506",
        "source": "LSE_CHAT",
        "data": {
          "author": "share4",
          "content": "These are going to end up being known as \"green box\" shares",
          "sentiment": 0.0,
          "engagement": "1,738",
          "price_at_post": "0.10",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-22T21:08:46.907792+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251535-Laura202--5176930",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.894075",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Confirmation or otherwise This drop is on very low volume Mmmmmm",
          "sentiment": 0.0,
          "engagement": "15,164",
          "price_at_post": "0.10",
          "thread_title": "Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-22T21:08:46.907774+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251539-bassman7-28857587",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.893655",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Did you not zoom the meeting? They said information would be up on their website \"in due course\".  The meeting was about 5 mins long. It was agreed the company is being delisted. Hearing it from the company live in a zoom call (jiopning details below) was enough confirmation for me \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-22T21:08:46.907756+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251541-loadofbo-25760405",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.893246",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people still buying here?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-22T21:08:46.907738+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251545-shamI89-28990363",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.892824",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Managed to get another \"p&d\" away......",
          "sentiment": 0.0,
          "engagement": "5,435",
          "price_at_post": "0.10",
          "thread_title": "Looks like Laura has",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=95DBDD4A-508B-4205-B71E-4DC15152341B"
        },
        "ingested_at": "2026-01-22T21:08:46.907720+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251555-tuan6--8489469",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.892414",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "No RNS is good news as if they pass they have published  it by now.  400% rise next month.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-22T21:08:46.907702+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251558-loadofbo--8768308",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.891997",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-22T21:08:46.907685+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-loadofbo-79027299",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.891586",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "If they don\u2019t de list they will go bust because they are out of money, can\u2019t raise anymore and can\u2019t sell the company.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-22T21:08:46.907667+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-bassman7-75858229",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.891177",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "I mean... they announced it live in an advertised public call. Are you honestly putting your posts through googletranslate and back. You know those translation programmes don't make spelling mistakes?",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-22T21:08:46.907649+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-tuan6--6077783",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.890755",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Dont worry  as peoples dont sell when they are  reading in .  only sell when they dont see any value left .  this comoany have more money in its bank account  than its market CAP so there are still  pretty  things left for sell .  even  someone  will jump in  to buy this company  so dont worry  for shareholders as this is thier money and they dont give up that easy.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-22T21:08:46.907631+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-Laura202-63594561",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.890349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected but the 20% tried Will the 80% continue to buy ?",
          "sentiment": 0.0,
          "engagement": "15,164",
          "price_at_post": "0.10",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-01-22T21:08:46.907613+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-loadofbo--7277940",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.889922",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-22T21:08:46.907595+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251617-loadofbo-79968960",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.889509",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "This is de listing in 8 days, why are people still buying?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-01-22T21:08:46.907577+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251636-Safi123--4144057",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.889085",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "We were close, certainly winning the vote was on the cards but it seems a large number of PIs were apathetic. Does anyone know if any large stakeholders opposed the move to going private? This company is growing, with international expansion, upcoming trial and proven technology. It will have no issue raising cash. In my view a much better chance of success than most small med tech businesses (some of whom valued in 10s of millions) I\u2019m not convinced ultradilution as a private business is inevitable. For one thing, there\u2019s no guarantee either Nukem or Bracco are willing to fully finance this business further to the tune of 20 million, already owning healthy portions. If a third party wants a stake it will be at a much higher valuation (business is realistically worth at the very least 10-20 million looking at similar AIM businesses) Secondly, 524 million votes in favour suggests Nukem and Bracco somehow obtained the support of other large shareholders. These shareholders would never agree to going private if it means their stakes are obliterated.",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.105",
          "thread_title": "Company valuation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=43B57842-8C07-4F9A-B3B1-1EE524148282"
        },
        "ingested_at": "2026-01-22T21:08:46.907559+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251650-trunky--4056265",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.888652",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will this mean we lose all our investment ?or will we be allocated new shares in the private company?",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.105",
          "thread_title": "Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-22T21:08:46.907541+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251656-Mikewinv-43747195",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.888240",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikewinvest",
          "content": "TR1s...the dogs that haven't barked!",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "0.105",
          "thread_title": "TR1s",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=698AFB22-A50E-487C-B919-75F58340736B"
        },
        "ingested_at": "2026-01-22T21:08:46.907523+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251720-loadofbo--3450113",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.887811",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Yes, probably 1 new share for every 100 old ones, that\u2019s the usual practice.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-22T21:08:46.907504+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251845-shamI89-42419319",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.887393",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Company has been survining on placings and would do so in near future, so you can imagine what will happen.It is a trend where share holders spend the money and company uses that money to develop a technology to get delisted at the end leaving shareholders high and dry.",
          "sentiment": 0.0,
          "engagement": "5,435",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-22T21:08:46.907485+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251947-Doppo59--9664318",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:46.886939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunky. I believe that any shares you own, remain yours. It will be harder to trade them though.However I did hear a rumour that polx are setting up something on their website to help. Maybe stick around and hope they don't go bust!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-22T21:08:46.907466+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252025-Jacobjoh-44985398",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.275026",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "In a sad old death threesome here.  Dopper and spunky has to admit and apologise now and they should have listened to me and saved some money.  I tried....you can lead a dopper to water lop .. You nasty people deserve every misfortune you get here.",
          "sentiment": -0.5,
          "engagement": "1,274",
          "price_at_post": "0.105",
          "thread_title": "Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-22T21:08:46.907448+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252026-Jacobjoh--3834627",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.274609",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "With laura.",
          "sentiment": -0.5,
          "engagement": "1,274",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-22T21:08:46.907430+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252113-shamI89-81782924",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.274197",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "There will be other mini spikes to let traped traders out , although I believe last \"p&d\" was orchestrated to let Laura excape with a profit.",
          "sentiment": 0.0,
          "engagement": "5,435",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-22T21:08:46.907412+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250815-Laura202--4378865",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.273783",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The matched bargain facilty is at bottom of yesterday RNS",
          "sentiment": 0.0,
          "engagement": "15,164",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-22T21:08:46.907394+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250921-2reincar-59911652",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.273371",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Say hello to Genedrive when you meet in hell!",
          "sentiment": 0.0,
          "engagement": "5,828",
          "price_at_post": "0.09",
          "thread_title": "Goodbye Polarean",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=28001004-0D99-46D9-AF63-BB068E80A726"
        },
        "ingested_at": "2026-01-22T21:08:46.907375+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251015-Latino--4729203",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.272953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yesterday RNS extract: The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "19,349",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-22T21:08:46.907357+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251111-Doppo59--7951573",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.272520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Thanks Latino. I did speak to my broker (HL) this morning who confirmed those details. They will be writing to me in the next few days to confirm my holding and advising the next step with J P Jenkins. POLX have funds until H2, lets see what happens next. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-22T21:08:46.907339+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251141-ironknut-28186976",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.272091",
        "source": "LSE_CHAT",
        "data": {
          "author": "ironknut",
          "content": "At last we mugs who invested here are put out of our misery. At least the losses will reduce capital gains tax donations to Westminster.",
          "sentiment": 0.0,
          "engagement": "1,660",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-22T21:08:46.907321+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251259-bassman7--9144125",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.271678",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "What happened to the poster here who said he bought in after a tip from his Harley St eye surgeon's mate? \ud83d\ude02 Hope he didn't lose too much",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.075",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-22T21:08:46.907303+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-PYUECK--8511903",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.271266",
        "source": "LSE_CHAT",
        "data": {
          "author": "PYUECK",
          "content": "I am assuming everybody is now just selling their shares before the 23rd. If you hold in a nominee account I suspect they wont even hold these shares for you in a private company so effectively they will be lost. Even if you keep, assuming the company survives any future fundraising is going to almost completely wipe out existing shareholders anyway. Even if this company has a rosey future, which I doubt, existing shareholders wont be part of it.",
          "sentiment": 0.0,
          "engagement": "773",
          "price_at_post": "0.08",
          "thread_title": "Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-22T21:08:46.907284+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251437-Doppo59--1624045",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.270843",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Pyueck, I'm not selling yet, I'm too stubborn. We might get an offer of a buyout before the 23rd, who knows. They have money in the bank till H2, I don't think they can ever raise again at the current price. Such great tech, unfortunately run by compete armatures with not a good salesman among them. This BB was full of people all singing the companies praises, not a single post any more. The rich get richer and the poor .... This was posted on here a couple of days ago, you keep your shares and sell (or buy) through J P Jenkins, just harder to do. Good luck fella. The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-22T21:08:46.907266+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251524-Latino--5725907",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.270407",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yep no shares lost here, shareholders can still sell after delisting via JP Jenkins.",
          "sentiment": 0.0,
          "engagement": "19,349",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-22T21:08:46.907247+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251013-Doppo59--6330412",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.269983",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "I'm staying put. This seems to be oversold, remember delisting was announced months ago. POLX are in partnership with Phillips who already use the product with Xenoview (FDA approved). My money is on Phillips buying us out, or at least a partnership,  POLX have more money in the bank than the current MC, so not going bust. Who knows how many orders are almost ready to be signed, Asia, India, not forgetting US. A couple of bits of good news and J P Jenkins might have to do some work! It seems most have left now, I'll see it through, waited five years, might as well another year! The tech is still sound, and being used. Wish me luck lol Doppo",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-22T21:08:46.907229+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251043-JeniH--1503580",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.269550",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "I'm staying too - it qualifies for 2 bargain stock screens on Stockopedia so I'm happy to hold for the share price recovery or an offer for the whole company  whichever comes first.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.08",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-22T21:08:46.907210+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251135-Lolajamo--7499250",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.269141",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lolajamola",
          "content": "Also sticking it out. Lost so much on this one it\u2019s just not worth selling! Holding out for a miracle\u2026!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-22T21:08:46.907191+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251230-loadofbo-88058918",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.268720",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people buying here? Have I missed something? Be lucky to 1 new share for 100 old when it\u2019s delisted.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-22T21:08:46.907173+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251413-bassman7--3004768",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.268310",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hope your \"knowledgable friend\" didn't give you any other tips Lolajamola \u2620\ufe0f Posted in: POLX Posts: 12 RE: Polx24 Mar 2022 18:53 I know what you mean\u2026. It is unsettling but we are holding tight. For us it\u2019s a long term investment, but hoping our patience will pay off soon! Saw our knowledgeable friend yesterday (that first put us onto Polx) and he is still confident so we are trusting his judgement on this. Lolajamola Posted in: POLX Posts: 12 RE: Here we go21 Mar 2022 16:54 Appreciate reading your recommendations on this one. We have also been tipped by another investor on this one as a good bet but it\u2019s reassuring to hear it from another source! Crossing all the digits\u2026.",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-22T21:08:46.907154+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251606-trunky--7938875",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.267843",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "There are  plenty of wealthy funds and individuals that could buy this company ,show me where there is a company that has such a great product .if this company was listed on the American market investors would be  all over it",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.085",
          "thread_title": "Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-01-22T21:08:46.907135+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251857-Balanced-45670728",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.267429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "We keep hearing it's a great product. Says who. The real proof of a great product is high numbers of sales. Here they have struggled to shift product. It's not all the blame of management. Great products sell themselves to some extent. That hasn't happened here. The product has been marketed for years so those in the sector are well aware of it. It's a poor product and/or doesn't fill a need as was originally expected. Being based in the US the company would have had US based funds or investors at some stage.",
          "sentiment": 0.0,
          "engagement": "1,645",
          "price_at_post": "0.085",
          "thread_title": "RE: Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-01-22T21:08:46.907113+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251956-mr-steve--1699765",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.266995",
        "source": "LSE_CHAT",
        "data": {
          "author": "mr-steve",
          "content": "...I'm not selling. 1) what i have (~500k) is worth close to f-all 2) i still think they could do well 3) even as a private co, I will still hold my shares 4) at some point they will either a) do well and the shares will be worth selling, b) get bought out for a better return than selling now c) relist at a premium to now or d) disappear into a black hole At current prices, d) won't make any difference, the others probably won't but just might. Spin the wheel, my money's on number 26!",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "0.085",
          "thread_title": "For what its worth...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=7E313B47-BF7F-47AF-BEAC-14BA524C82E1"
        },
        "ingested_at": "2026-01-22T21:08:46.907080+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251109-Latino-74804937",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.266551",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Why no RNS..? https://x.com/PolareanImaging/status/2001034816859394174 Congratulations to Robby Thomen, PhD and team on receiving major funding for this exciting asthma research milestone! \ud83c\udf89 We\u2019re thrilled to see new research from the @mumedicine receive a $1.8-million grant from the @NIH to advance understanding of asthma triggers and disease mechanisms. Robby and his team are using Polarean's #XenonMRI platform to visualize regional lung function and investigate whether airway hyperconstriction in asthma also happens in the lung's blood vessels, or vasculature. This long-standing hypothesis in asthma research has been challenging to study, and Xenon MRI offers a new way to explore functional relationships that are not accessible with conventional imaging. This work represents an important step toward more precise, personalized approaches to asthma care and may help explain why some patients respond well to treatment while others continue to experience uncontrolled disease. We look forward to seeing how this research helps move asthma care forward! Learn more: https://medicine.missouri.edu/news/researcher-receives-18-million-study-asthma-triggers #PulmonaryImaging #LungHealth #AsthmaResearch #NIHGrant #ResearchInnovation #Asthma #PrecisionMedicine #Mizzou",
          "sentiment": 0.0,
          "engagement": "19,349",
          "price_at_post": "0.09",
          "thread_title": "X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.907062+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251225-Doppo59--8160677",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.266059",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Good find Latino. You are correct, why no RNS ....  people are actually using Polarean XenonMRI With that news, a buy out and a couple of orders, this could be re-listed on the American market!! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.907044+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251737-Shpunken-73035665",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.265631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Cause it\u2019s now irrelevant, company is no longer public\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.907026+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250732-JeniH--5568098",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.265212",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Still listed until tomorrow and definitely not irrelevant if you still own shares",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.907008+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250806-loadofbo-73400378",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:43.264769",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Great, that should last about a year, then what?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.906990+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo-21449101",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.718400",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.906971+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH--7775035",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.717985",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.906953+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202-90096208",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.717577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,164",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.906935+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202--6123119",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.717152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,164",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.906916+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra-32862802",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.716731",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,244",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-22T21:08:46.906898+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59-62978505",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.716328",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-22T21:08:46.906879+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888-44573209",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.715905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-22T21:08:46.906861+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59--1830453",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.715499",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-22T21:08:46.906843+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202-73702635",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.715072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,164",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-22T21:08:46.906824+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo-14095021",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.714666",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-22T21:08:46.906807+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH-15834989",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.714262",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-22T21:08:46.906789+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59--3241060",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.713846",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-22T21:08:46.906771+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky-48706603",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.713430",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-22T21:08:46.906753+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59--2716221",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.713011",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-22T21:08:46.906735+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59-91362664",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.712595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-22T21:08:46.906717+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu-55430780",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.712181",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-22T21:08:46.906700+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu-70669129",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.711745",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-22T21:08:46.906682+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6--5752810",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.711337",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-22T21:08:46.906664+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan-10879166",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.710917",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-22T21:08:46.906646+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh-20723038",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.710508",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,274",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-22T21:08:46.906628+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23-54374932",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.710072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-22T21:08:46.906609+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261316-Doppo59--3046828",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.709668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hi Aims23, I didn't sell my shares, HL are still holding them. Any trades are made though J P Jenkins who HL deal with on my behalf (sell only) i had to move them out of my stocks and shares ISA as Polarean is now a limited company. Are you still holding? GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-22T21:08:46.906591+00:00"
      },
      {
        "event_id": "SOCIAL-Today1644-rkb007-54399509",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.709248",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Same for me with Charles Stanley - they created an individual director account and moved shares for me \u2026",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-22T21:08:46.906567+00:00"
      },
      {
        "event_id": "SOCIAL-Today1644-rkb007-46904260",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.708818",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Direct",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-22T21:08:46.906547+00:00"
      },
      {
        "event_id": "SOCIAL-Today2043-Doppo59--9170073",
        "event_type": "social_post",
        "date": "2026-01-22T21:08:40.708376",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Rkb007, if you find any news out, can you post in here, i will look. I am a member of a Telegram group also. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-22T21:08:46.906521+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251730-Shpunken-13328483",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.612194",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "There\u2019s no resistance up to 0.4, so we could see the sp double this week if the buying continues.. but I am expecting some profit taking to happen this week as well",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T21:13:45.626367+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251832-Laura202--5512686",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.611783",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Green boxes either quiet or banned ? Not surprised now POLX risen from 0.7p to 0.21p",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T21:13:45.626350+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251858-bassman7-38586747",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.611372",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hmm, in real terms though SP has dropped more than 75% in 3 months hasn't it?",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T21:13:45.626332+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251925-Bahriahe-61467147",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.610961",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bahriaheights",
          "content": "It has and has always been a risk like every other aim share that we pile in. We forget that the pharma is a cash burn, no different from any aim mining company. I had no hope for GDR either when it dropped to 0.25. I do strongly believe someone will step in as tech is a game changer Happy to wait and sit this out as I'm down by 85%.",
          "sentiment": 0.0,
          "engagement": "400",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T21:13:45.626314+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251132-Shpunken--3828260",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.610554",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Buying pressure building up again, this has to explode now, if it doesn\u2019t get to 0.4 it\u2019s only thanks to mms, the book looks overloaded with buys and there\u2019s no resistance till 0.4",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.215",
          "thread_title": "Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=60AA89D0-70DE-46A8-96CB-D03B9D4E3928"
        },
        "ingested_at": "2026-01-21T21:13:45.626297+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251144-RayNR-83262099",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.610146",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayNR",
          "content": "Shpunken, what does mms mean?",
          "sentiment": 0.0,
          "engagement": "14",
          "price_at_post": "0.215",
          "thread_title": "RE: Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=60AA89D0-70DE-46A8-96CB-D03B9D4E3928"
        },
        "ingested_at": "2026-01-21T21:13:45.626279+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251308-Giovs-97073806",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.609735",
        "source": "LSE_CHAT",
        "data": {
          "author": "Giovs",
          "content": "Knows something ??",
          "sentiment": 0.0,
          "engagement": "4,872",
          "price_at_post": "0.215",
          "thread_title": "Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626261+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251803-Laura202-39792578",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.609322",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Continuation of the buying I've mentioned for 4weks now Ita Just that they're willing to pay higher now all the cheap stock has gone :)",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626244+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250858-Apeirogo--5304131",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.608906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Apeirogon",
          "content": "Doesn\u2019t all this buying mean that the people who want to take it private have more votes to enable that to happen ?",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626226+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250910-Jimmy198--3793976",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.608502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jimmy1981",
          "content": "Yeah or could be the people that want to vote against have more votes to do that",
          "sentiment": 0.0,
          "engagement": "63",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626208+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251006-Umaz--2698318",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.608081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Umaz",
          "content": "What happens when someone held shares and voted, and subsequently sold the shares. Buy it again and votes again?",
          "sentiment": 0.0,
          "engagement": "454",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626190+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251200-Safi123--4695740",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.607673",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "I don\u2019t believe any official votes have taken place, just proxy instructions. So it would depend on the instructions given by the shareholders at the time of the vote I noticed the current price is hovering at 0.2p. I wonder if they are raising at 0.2p - could potentially raise 10 million with 5 billion new shares. Would be a big dilution but even still, if business valued at 60 million (which is realistically could be), would equate to 1p per share. I\u2019m hoping with momentum and more news they may be able to raise at 0.5p+ though",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.21",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626172+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251231-Doppo59--1902432",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.607255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "My buys are showing up as sells .... GL",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.195",
          "thread_title": "Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E6F35A1F-D640-4CE8-8A2D-4BDCAB87B314"
        },
        "ingested_at": "2026-01-21T21:13:45.626155+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251258-Shpunken-92646961",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.606836",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Profit taking as expected..",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.195",
          "thread_title": "RE: Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E6F35A1F-D640-4CE8-8A2D-4BDCAB87B314"
        },
        "ingested_at": "2026-01-21T21:13:45.626137+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251322-Laura202-50249820",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.606434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Very steady here Also having done 300% on WHI AYM and almost 100% here thus far Bought EQT",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.195",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626119+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251521-Jimmy198-26723069",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.606009",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jimmy1981",
          "content": "EQT at 600k market cap should bag easily.",
          "sentiment": 0.0,
          "engagement": "63",
          "price_at_post": "0.17",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626091+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251539-Apeirogo--5406303",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.605596",
        "source": "LSE_CHAT",
        "data": {
          "author": "Apeirogon",
          "content": "Only people holding shares at a specific time get to vote. If you have instructed your broker how to vote it still doesn\u2019t happen until the time stamp.",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "0.17",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626073+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251542-RayNR--4393202",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.605184",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayNR",
          "content": "Laura, did you do a massive dump?",
          "sentiment": 0.0,
          "engagement": "14",
          "price_at_post": "0.165",
          "thread_title": "I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-21T21:13:45.626056+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251548-loadofbo--6742630",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.604767",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You mean sell",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.165",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T21:13:45.626037+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251903-Laura202--3159173",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.604353",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Amblast Even more odd is to havw an account since 2015,lurk around, pop up many years later Lose out on 400% gains WHI where you first gave me abuse (.out of 1000s LSE posters ) What  a life u have Xx",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-21T21:13:45.626019+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251911-AmBastei--7059046",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.603916",
        "source": "LSE_CHAT",
        "data": {
          "author": "AmBasteir",
          "content": "Lurk around? You made an arse of yourself with that comment, clearly posts every year. That's just you, I guess.",
          "sentiment": 0.0,
          "engagement": "547",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-21T21:13:45.626002+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251915-Laura202-90504599",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.603499",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Have a good one You've not posted anything of worth for over 10yrs it seems Filtered You enjoy xx",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-21T21:13:45.625984+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251200-Doppo59-29364007",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.603061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "We are back to where we were, SP dropping and no volume. Has everyone now taken their position and waiting to see what happens next? GL",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.16",
          "thread_title": "Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-21T21:13:45.625966+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251212-Shpunken--7536051",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.602645",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Some ppl were on +150%, so it\u2019s normal to take profit and then jump back in at a lower price, that way no risk if things don\u2019t go our way",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.16",
          "thread_title": "RE: Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-21T21:13:45.625949+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251219-bootnk19-58989125",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:45.602214",
        "source": "LSE_CHAT",
        "data": {
          "author": "bootnk19222",
          "content": "This pump and dump is normal before a share delists",
          "sentiment": 0.0,
          "engagement": "381",
          "price_at_post": "0.16",
          "thread_title": "RE: Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-21T21:13:45.625931+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251239-Doppo59-36721033",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.772682",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Bootnk ...... they need 75% before that happens!!",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.16",
          "thread_title": "RE: Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-21T21:13:45.625913+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251244-tuan6-66100422",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.772280",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "There is no RNS yes so nothing change  but  small volume so MM drop  the price.  it is normal that way of life so if you believe that   after  15/12  so hold it for better return  as now if you sell your holding you will lose  your money . Only someone bought this share when it is 0.10  but at that price not many buy huge number  but small one and end of the day someone collect huge number of shares. PI bought this share when it was higher than now  so there is no point for sell it now  as if you sell  now MM will drop more",
          "sentiment": 0.0,
          "engagement": "3,948",
          "price_at_post": "0.16",
          "thread_title": "RE: Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-21T21:13:45.625895+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251254-Balanced--2324387",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.771858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "It's dropping because the Laura poster has moved on pump and dump achieved. She's now on the next great undiscovered investment story called Eqteq.",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "0.16",
          "thread_title": "RE: Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-21T21:13:45.625878+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251301-loadofbo--2929473",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.771453",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You really think people invest because of her it them he, come mate really?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.16",
          "thread_title": "RE: Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-21T21:13:45.625860+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251306-tuan6-15762800",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.771032",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "If someone buy share  base on post in here and if they lose thier money just  dont blame   as that is not the way  PIs  buy or sell share. Blaming for someone in here cause share drop is someone crazy  as  nobody have power to do that  and if that person can  do that act they will never post anything in here  but instead buy or sell share to get his owe gain. It is very starnge when you will money you keep  quite  but when people lose thier money they are sereaching  to blame for someone else but  not themself.",
          "sentiment": 0.0,
          "engagement": "3,948",
          "price_at_post": "0.155",
          "thread_title": "RE: Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-21T21:13:45.625842+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251518-Balanced--5810394",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.770619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "Have you not heard of pump and dumps?",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "0.155",
          "thread_title": "RE: Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-21T21:13:45.625825+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251644-AntoNaz--4113965",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.770217",
        "source": "LSE_CHAT",
        "data": {
          "author": "AntoNaz",
          "content": "Proxy count could come out tomorrow if they don't have enough votes.",
          "sentiment": 0.0,
          "engagement": "343",
          "price_at_post": "0.155",
          "thread_title": "Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625807+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20252018-Laura202-78429664",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.769802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "If they feel they dont have enough they will do what WHI did ( see their early Nov rns)",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625789+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251015-Shpunken--3583144",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.769401",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "We should get an update next week, hopefully ppl have voted to keep the company public..",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625772+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251016-Laura202-91500623",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.768978",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "I have with over 25mln",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625754+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251100-Shpunken-77915111",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.768571",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "We need ppl with combined 400m shares to be on the safe side",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625736+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251121-HideInPl--8490278",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.768169",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "This situation doesn't seem the same as the WHI comparison. There, an announcement was made in advance about the GM votes not likely to meet threshold. There's been no such RNS here about lack of confidence in getting the required votes. Deadline to vote was 2pm yesterday. GM is 2pm Monday. They would have RNS'd something today if they didn't think this was going their way... Surely? Am I missing something? This feels a dead cert delist.",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625718+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251317-AntoNaz--5678938",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.767743",
        "source": "LSE_CHAT",
        "data": {
          "author": "AntoNaz",
          "content": "WHI proxy count arrived one day before the GM. They released it early because of media speculation. Otherwise they would have left it till next day.",
          "sentiment": 0.0,
          "engagement": "343",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625701+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251418-tuan6-81778032",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.767338",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "It is not long to wait and see what the end result. even they delist there is still value in this share   so  we can say it is ok",
          "sentiment": 0.0,
          "engagement": "3,948",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625683+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251441-Shpunken-36793260",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.766919",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "I think If that was the case we wouldve had a leak and a lot of sells today.. so it looks like no one knows anything yet.. but Monday will be a good indicator if something has leaked",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625665+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251501-HideInPl-44277560",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.766515",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "OK, thank all for the replies",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625648+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251640-tuan6-78162297",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.766105",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Waiting at 8 AM on next Monday to see what can bring to this share.",
          "sentiment": 0.0,
          "engagement": "3,948",
          "price_at_post": "0.155",
          "thread_title": "RE: Proxy count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=2FF548EA-F1CA-4488-B87B-6CA53B1223E7"
        },
        "ingested_at": "2026-01-21T21:13:45.625630+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20250719-DYM...Tu--5325807",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.765691",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Polarean De-Listing Meeting on Monday, 15 December at 2pm https://us06web.zoom.us/j/85786652462?pwd=kOezA1tL0b1os8xC77Rj8kDGJ5nEPt.1&from=addon Meeting ID: 857 8665 2462 Passcode: 490834",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.155",
          "thread_title": "Today\u2019s De-Listing Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=F1228374-7A47-4EE5-BA31-F377C72331F3"
        },
        "ingested_at": "2026-01-21T21:13:45.625612+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251128-Laura202-39595025",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.765263",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks DYM",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.145",
          "thread_title": "RE: Today\u2019s De-Listing Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=F1228374-7A47-4EE5-BA31-F377C72331F3"
        },
        "ingested_at": "2026-01-21T21:13:45.625594+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251157-Shpunken-68461595",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.764837",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Just 2 hrs to go, still nothing to see trades wise..",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.145",
          "thread_title": "RE: Today\u2019s De-Listing Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=F1228374-7A47-4EE5-BA31-F377C72331F3"
        },
        "ingested_at": "2026-01-21T21:13:45.625576+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251236-Doppo59-80304160",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.764429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "What you will see, is this BB busy in two hours time! GL",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.145",
          "thread_title": "RE: Today\u2019s De-Listing Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=F1228374-7A47-4EE5-BA31-F377C72331F3"
        },
        "ingested_at": "2026-01-21T21:13:45.625558+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251247-PYUECK--4546196",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.764002",
        "source": "LSE_CHAT",
        "data": {
          "author": "PYUECK",
          "content": "The vote will sail though, no way they would have done this without knowing enough large shareholders onside. Unfortunately again proves AIM is investable for small shareholders, at any time you can just get a notice that the company is being taken private.",
          "sentiment": 0.0,
          "engagement": "773",
          "price_at_post": "0.145",
          "thread_title": "RE: Today\u2019s De-Listing Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=F1228374-7A47-4EE5-BA31-F377C72331F3"
        },
        "ingested_at": "2026-01-21T21:13:45.625533+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251348-Shpunken-22405852",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.763589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "There are plenty of examples when it didn\u2019t happen, so let\u2019s just wait\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.135",
          "thread_title": "RE: Today\u2019s De-Listing Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=F1228374-7A47-4EE5-BA31-F377C72331F3"
        },
        "ingested_at": "2026-01-21T21:13:45.625499+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251350-loadofbo--4522976",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.763163",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Judging by the sp, already leaked, 100% de listing.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.135",
          "thread_title": "RE: Today\u2019s De-Listing Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=F1228374-7A47-4EE5-BA31-F377C72331F3"
        },
        "ingested_at": "2026-01-21T21:13:45.625464+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251354-loadofbo-19859976",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:41.762718",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "7m buy! Maybe I was wrong, unless it\u2019s a sell.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.13",
          "thread_title": "RE: Today\u2019s De-Listing Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=F1228374-7A47-4EE5-BA31-F377C72331F3"
        },
        "ingested_at": "2026-01-21T21:13:45.625444+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251400-bassman7-27242226",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.298945",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Only 17 participants so far",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.13",
          "thread_title": "Anyone else on the call?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4EDF23D9-5E88-42A6-B7D4-43A9B840768A"
        },
        "ingested_at": "2026-01-21T21:13:45.625426+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251402-bassman7-85380011",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.298536",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Apparently no questions submitted by investors. 21 participants now on call.",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.13",
          "thread_title": "RE: Anyone else on the call?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4EDF23D9-5E88-42A6-B7D4-43A9B840768A"
        },
        "ingested_at": "2026-01-21T21:13:45.625409+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251404-bassman7-48517745",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.298134",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Did you think it would be any other way?",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.13",
          "thread_title": "And... delisted from AIM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=8E783F9A-4C63-461E-ACA1-4513E80D78C0"
        },
        "ingested_at": "2026-01-21T21:13:45.625391+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251405-loadofbo--7111302",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.297715",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why on earth would someone buy 7m shares when its de listing?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.13",
          "thread_title": "RE: And... delisted from AIM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=8E783F9A-4C63-461E-ACA1-4513E80D78C0"
        },
        "ingested_at": "2026-01-21T21:13:45.625374+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251406-Doppo59--4274460",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.297312",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Such a shame, but no surprise! GL",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.13",
          "thread_title": "No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-21T21:13:45.625356+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-bassman7-61038854",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.296890",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Judging by your recent comments Doppo, you seemed to think this would come good, even congratulating otheres on their holdings just a week ago... \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-21T21:13:45.625338+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-Shpunken-85977928",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.296483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Yep it is a shame that ppl will miss out on this and big companies again will be the winners",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-21T21:13:45.625321+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251437-Ilovesus-64577447",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.296066",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Down 99.8% over the last 5 years. Even though some may have just made 100% . Often these type of rises are meaningless for most. Who honestly got in on the bottom and how long have they been invested? As the company can no longer get away with another placing it would have to issue too many shares and then only raise small amounts. That it now wants to delist is very telling. Its reach the end of the road. Its in a place where raising more through selling shares will not work. This is where most companies on AIM delist. They cannot sell any more shares. PYC is a company like this that may also delist. Seems some on that company post here. AIM companies list in order to raise money. PYC has had so many placings and  has a history of raising unlike this company. That too like this one will no doubt delist. Beware guys AIM is a cesspit.",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "0.11",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-21T21:13:45.625303+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251519-2reincar-41845758",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.295647",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Question of only when.",
          "sentiment": 0.0,
          "engagement": "5,816",
          "price_at_post": "0.10",
          "thread_title": "Genedrive will eventually go the same way!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=EF81FBC2-AF85-428C-BBE4-906724917774"
        },
        "ingested_at": "2026-01-21T21:13:45.625285+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251534-share4--1094447",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.295242",
        "source": "LSE_CHAT",
        "data": {
          "author": "share4",
          "content": "These are going to end up being known as \"green box\" shares",
          "sentiment": 0.0,
          "engagement": "1,738",
          "price_at_post": "0.10",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-21T21:13:45.625267+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251535-Laura202-39819381",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.294818",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Confirmation or otherwise This drop is on very low volume Mmmmmm",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.10",
          "thread_title": "Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-21T21:13:45.625249+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251539-bassman7--2371995",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.294393",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Did you not zoom the meeting? They said information would be up on their website \"in due course\".  The meeting was about 5 mins long. It was agreed the company is being delisted. Hearing it from the company live in a zoom call (jiopning details below) was enough confirmation for me \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-21T21:13:45.625232+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251541-loadofbo--2415933",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.293978",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people still buying here?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-21T21:13:45.625214+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251545-shamI89--6761743",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.293569",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Managed to get another \"p&d\" away......",
          "sentiment": 0.0,
          "engagement": "5,435",
          "price_at_post": "0.10",
          "thread_title": "Looks like Laura has",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=95DBDD4A-508B-4205-B71E-4DC15152341B"
        },
        "ingested_at": "2026-01-21T21:13:45.625197+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251555-tuan6-15725405",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.293162",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "No RNS is good news as if they pass they have published  it by now.  400% rise next month.",
          "sentiment": 0.0,
          "engagement": "3,948",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-21T21:13:45.625179+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251558-loadofbo-20843492",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.292746",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-21T21:13:45.625161+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-loadofbo--4240141",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.292342",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "If they don\u2019t de list they will go bust because they are out of money, can\u2019t raise anymore and can\u2019t sell the company.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-21T21:13:45.625143+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-bassman7--8241304",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.291924",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "I mean... they announced it live in an advertised public call. Are you honestly putting your posts through googletranslate and back. You know those translation programmes don't make spelling mistakes?",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-21T21:13:45.625118+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-tuan6-89039191",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.291518",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Dont worry  as peoples dont sell when they are  reading in .  only sell when they dont see any value left .  this comoany have more money in its bank account  than its market CAP so there are still  pretty  things left for sell .  even  someone  will jump in  to buy this company  so dont worry  for shareholders as this is thier money and they dont give up that easy.",
          "sentiment": 0.0,
          "engagement": "3,948",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-21T21:13:45.625084+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-Laura202-46376030",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.291103",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected but the 20% tried Will the 80% continue to buy ?",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.10",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-01-21T21:13:45.625066+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-loadofbo-71076377",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.290684",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-21T21:13:45.625048+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251617-loadofbo--9071811",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.290268",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "This is de listing in 8 days, why are people still buying?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-01-21T21:13:45.625031+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251636-Safi123-87371999",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.289834",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "We were close, certainly winning the vote was on the cards but it seems a large number of PIs were apathetic. Does anyone know if any large stakeholders opposed the move to going private? This company is growing, with international expansion, upcoming trial and proven technology. It will have no issue raising cash. In my view a much better chance of success than most small med tech businesses (some of whom valued in 10s of millions) I\u2019m not convinced ultradilution as a private business is inevitable. For one thing, there\u2019s no guarantee either Nukem or Bracco are willing to fully finance this business further to the tune of 20 million, already owning healthy portions. If a third party wants a stake it will be at a much higher valuation (business is realistically worth at the very least 10-20 million looking at similar AIM businesses) Secondly, 524 million votes in favour suggests Nukem and Bracco somehow obtained the support of other large shareholders. These shareholders would never agree to going private if it means their stakes are obliterated.",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.105",
          "thread_title": "Company valuation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=43B57842-8C07-4F9A-B3B1-1EE524148282"
        },
        "ingested_at": "2026-01-21T21:13:45.625013+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251650-trunky-12189949",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.289396",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will this mean we lose all our investment ?or will we be allocated new shares in the private company?",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.105",
          "thread_title": "Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-21T21:13:45.624995+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251656-Mikewinv-78657962",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:37.288951",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikewinvest",
          "content": "TR1s...the dogs that haven't barked!",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "0.105",
          "thread_title": "TR1s",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=698AFB22-A50E-487C-B919-75F58340736B"
        },
        "ingested_at": "2026-01-21T21:13:45.624976+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251720-loadofbo--7383161",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.558859",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Yes, probably 1 new share for every 100 old ones, that\u2019s the usual practice.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-21T21:13:45.624958+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251845-shamI89-67247934",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.558455",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Company has been survining on placings and would do so in near future, so you can imagine what will happen.It is a trend where share holders spend the money and company uses that money to develop a technology to get delisted at the end leaving shareholders high and dry.",
          "sentiment": 0.0,
          "engagement": "5,435",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-21T21:13:45.624941+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251947-Doppo59--6578888",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.558023",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunky. I believe that any shares you own, remain yours. It will be harder to trade them though.However I did hear a rumour that polx are setting up something on their website to help. Maybe stick around and hope they don't go bust!",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-21T21:13:45.624923+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252025-Jacobjoh-14524135",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.557616",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "In a sad old death threesome here.  Dopper and spunky has to admit and apologise now and they should have listened to me and saved some money.  I tried....you can lead a dopper to water lop .. You nasty people deserve every misfortune you get here.",
          "sentiment": -0.5,
          "engagement": "1,274",
          "price_at_post": "0.105",
          "thread_title": "Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-21T21:13:45.624905+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252026-Jacobjoh-44508373",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.557210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "With laura.",
          "sentiment": -0.5,
          "engagement": "1,274",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-21T21:13:45.624888+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252113-shamI89-11601037",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.556797",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "There will be other mini spikes to let traped traders out , although I believe last \"p&d\" was orchestrated to let Laura excape with a profit.",
          "sentiment": 0.0,
          "engagement": "5,435",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-21T21:13:45.624870+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250815-Laura202-83090173",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.556395",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The matched bargain facilty is at bottom of yesterday RNS",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-21T21:13:45.624852+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250921-2reincar--5916182",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.555975",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Say hello to Genedrive when you meet in hell!",
          "sentiment": 0.0,
          "engagement": "5,816",
          "price_at_post": "0.09",
          "thread_title": "Goodbye Polarean",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=28001004-0D99-46D9-AF63-BB068E80A726"
        },
        "ingested_at": "2026-01-21T21:13:45.624834+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251015-Latino-45550876",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.555575",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yesterday RNS extract: The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "19,336",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-21T21:13:45.624816+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251111-Doppo59-73540826",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.555142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Thanks Latino. I did speak to my broker (HL) this morning who confirmed those details. They will be writing to me in the next few days to confirm my holding and advising the next step with J P Jenkins. POLX have funds until H2, lets see what happens next. GL",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-21T21:13:45.624798+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251141-ironknut-11595400",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.554720",
        "source": "LSE_CHAT",
        "data": {
          "author": "ironknut",
          "content": "At last we mugs who invested here are put out of our misery. At least the losses will reduce capital gains tax donations to Westminster.",
          "sentiment": 0.0,
          "engagement": "1,659",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-21T21:13:45.624781+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251259-bassman7--7145516",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.554314",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "What happened to the poster here who said he bought in after a tip from his Harley St eye surgeon's mate? \ud83d\ude02 Hope he didn't lose too much",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.075",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-21T21:13:45.624763+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-PYUECK-77893130",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.553890",
        "source": "LSE_CHAT",
        "data": {
          "author": "PYUECK",
          "content": "I am assuming everybody is now just selling their shares before the 23rd. If you hold in a nominee account I suspect they wont even hold these shares for you in a private company so effectively they will be lost. Even if you keep, assuming the company survives any future fundraising is going to almost completely wipe out existing shareholders anyway. Even if this company has a rosey future, which I doubt, existing shareholders wont be part of it.",
          "sentiment": 0.0,
          "engagement": "773",
          "price_at_post": "0.08",
          "thread_title": "Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-21T21:13:45.624745+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251437-Doppo59-64251642",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.553482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Pyueck, I'm not selling yet, I'm too stubborn. We might get an offer of a buyout before the 23rd, who knows. They have money in the bank till H2, I don't think they can ever raise again at the current price. Such great tech, unfortunately run by compete armatures with not a good salesman among them. This BB was full of people all singing the companies praises, not a single post any more. The rich get richer and the poor .... This was posted on here a couple of days ago, you keep your shares and sell (or buy) through J P Jenkins, just harder to do. Good luck fella. The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-21T21:13:45.624728+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251524-Latino--7133532",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.553042",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yep no shares lost here, shareholders can still sell after delisting via JP Jenkins.",
          "sentiment": 0.0,
          "engagement": "19,336",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-21T21:13:45.624710+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251013-Doppo59-77791059",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.552636",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "I'm staying put. This seems to be oversold, remember delisting was announced months ago. POLX are in partnership with Phillips who already use the product with Xenoview (FDA approved). My money is on Phillips buying us out, or at least a partnership,  POLX have more money in the bank than the current MC, so not going bust. Who knows how many orders are almost ready to be signed, Asia, India, not forgetting US. A couple of bits of good news and J P Jenkins might have to do some work! It seems most have left now, I'll see it through, waited five years, might as well another year! The tech is still sound, and being used. Wish me luck lol Doppo",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.08",
          "thread_title": "For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-21T21:13:45.624693+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251043-JeniH--5663267",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.552206",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "I'm staying too - it qualifies for 2 bargain stock screens on Stockopedia so I'm happy to hold for the share price recovery or an offer for the whole company  whichever comes first.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.08",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-21T21:13:45.624675+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251135-Lolajamo-84270922",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.551786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lolajamola",
          "content": "Also sticking it out. Lost so much on this one it\u2019s just not worth selling! Holding out for a miracle\u2026!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-21T21:13:45.624657+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251230-loadofbo-42508040",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.551382",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people buying here? Have I missed something? Be lucky to 1 new share for 100 old when it\u2019s delisted.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-21T21:13:45.624640+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251413-bassman7-20626154",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.550954",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hope your \"knowledgable friend\" didn't give you any other tips Lolajamola \u2620\ufe0f Posted in: POLX Posts: 12 RE: Polx24 Mar 2022 18:53 I know what you mean\u2026. It is unsettling but we are holding tight. For us it\u2019s a long term investment, but hoping our patience will pay off soon! Saw our knowledgeable friend yesterday (that first put us onto Polx) and he is still confident so we are trusting his judgement on this. Lolajamola Posted in: POLX Posts: 12 RE: Here we go21 Mar 2022 16:54 Appreciate reading your recommendations on this one. We have also been tipped by another investor on this one as a good bet but it\u2019s reassuring to hear it from another source! Crossing all the digits\u2026.",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-21T21:13:45.624621+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251606-trunky-33570009",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.550469",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "There are  plenty of wealthy funds and individuals that could buy this company ,show me where there is a company that has such a great product .if this company was listed on the American market investors would be  all over it",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.085",
          "thread_title": "Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-01-21T21:13:45.624603+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251857-Balanced--5382992",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.550051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "We keep hearing it's a great product. Says who. The real proof of a great product is high numbers of sales. Here they have struggled to shift product. It's not all the blame of management. Great products sell themselves to some extent. That hasn't happened here. The product has been marketed for years so those in the sector are well aware of it. It's a poor product and/or doesn't fill a need as was originally expected. Being based in the US the company would have had US based funds or investors at some stage.",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "0.085",
          "thread_title": "RE: Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-01-21T21:13:45.624585+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251956-mr-steve--2835277",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.549625",
        "source": "LSE_CHAT",
        "data": {
          "author": "mr-steve",
          "content": "...I'm not selling. 1) what i have (~500k) is worth close to f-all 2) i still think they could do well 3) even as a private co, I will still hold my shares 4) at some point they will either a) do well and the shares will be worth selling, b) get bought out for a better return than selling now c) relist at a premium to now or d) disappear into a black hole At current prices, d) won't make any difference, the others probably won't but just might. Spin the wheel, my money's on number 26!",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "0.085",
          "thread_title": "For what its worth...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=7E313B47-BF7F-47AF-BEAC-14BA524C82E1"
        },
        "ingested_at": "2026-01-21T21:13:45.624567+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251109-Latino--5694268",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.549190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Why no RNS..? https://x.com/PolareanImaging/status/2001034816859394174 Congratulations to Robby Thomen, PhD and team on receiving major funding for this exciting asthma research milestone! \ud83c\udf89 We\u2019re thrilled to see new research from the @mumedicine receive a $1.8-million grant from the @NIH to advance understanding of asthma triggers and disease mechanisms. Robby and his team are using Polarean's #XenonMRI platform to visualize regional lung function and investigate whether airway hyperconstriction in asthma also happens in the lung's blood vessels, or vasculature. This long-standing hypothesis in asthma research has been challenging to study, and Xenon MRI offers a new way to explore functional relationships that are not accessible with conventional imaging. This work represents an important step toward more precise, personalized approaches to asthma care and may help explain why some patients respond well to treatment while others continue to experience uncontrolled disease. We look forward to seeing how this research helps move asthma care forward! Learn more: https://medicine.missouri.edu/news/researcher-receives-18-million-study-asthma-triggers #PulmonaryImaging #LungHealth #AsthmaResearch #NIHGrant #ResearchInnovation #Asthma #PrecisionMedicine #Mizzou",
          "sentiment": 0.0,
          "engagement": "19,336",
          "price_at_post": "0.09",
          "thread_title": "X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624549+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251225-Doppo59--2460488",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:34.548692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Good find Latino. You are correct, why no RNS ....  people are actually using Polarean XenonMRI With that news, a buy out and a couple of orders, this could be re-listed on the American market!! GL",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624531+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251737-Shpunken--2953275",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.206327",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Cause it\u2019s now irrelevant, company is no longer public\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624513+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250732-JeniH-51872941",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.205908",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Still listed until tomorrow and definitely not irrelevant if you still own shares",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624495+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250806-loadofbo-10654641",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.205503",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Great, that should last about a year, then what?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624478+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo--6879973",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.205083",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624459+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH-16042740",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.204678",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624442+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202-69323994",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.204266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624424+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202--5599093",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.203835",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624406+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra--7247221",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.203425",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,244",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-21T21:13:45.624388+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59-28795359",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.203011",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-21T21:13:45.624370+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888-27360321",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.202599",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T21:13:45.624352+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59-19955509",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.202194",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T21:13:45.624335+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202-16421490",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.201771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T21:13:45.624317+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo-57846190",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.201363",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T21:13:45.624300+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH-13309496",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.200929",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-21T21:13:45.624282+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59--2802542",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.200520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T21:13:45.624264+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky--3691555",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.200091",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T21:13:45.624247+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59--2866105",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.199690",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T21:13:45.624229+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59-58793040",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.199272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T21:13:45.624211+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu-27513296",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.198858",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T21:13:45.624194+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu--9216596",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.198421",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T21:13:45.624176+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6-47928511",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.197999",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,948",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T21:13:45.624157+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan-25296440",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.197585",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T21:13:45.624139+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh-46446285",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.197177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,274",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T21:13:45.624117+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23--4983411",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.196746",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-21T21:13:45.624085+00:00"
      },
      {
        "event_id": "SOCIAL-Today1316-Doppo59--2913864",
        "event_type": "social_post",
        "date": "2026-01-21T21:13:29.196319",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hi Aims23, I didn't sell my shares, HL are still holding them. Any trades are made though J P Jenkins who HL deal with on my behalf (sell only) i had to move them out of my stocks and shares ISA as Polarean is now a limited company. Are you still holding? GL",
          "sentiment": 0.0,
          "engagement": "238",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-21T21:13:45.624062+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251109-Latino-35994335",
        "event_type": "social_post",
        "date": "2026-01-21T00:48:02.136467",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Why no RNS..? https://x.com/PolareanImaging/status/2001034816859394174 Congratulations to Robby Thomen, PhD and team on receiving major funding for this exciting asthma research milestone! \ud83c\udf89 We\u2019re thrilled to see new research from the @mumedicine receive a $1.8-million grant from the @NIH to advance understanding of asthma triggers and disease mechanisms. Robby and his team are using Polarean's #XenonMRI platform to visualize regional lung function and investigate whether airway hyperconstriction in asthma also happens in the lung's blood vessels, or vasculature. This long-standing hypothesis in asthma research has been challenging to study, and Xenon MRI offers a new way to explore functional relationships that are not accessible with conventional imaging. This work represents an important step toward more precise, personalized approaches to asthma care and may help explain why some patients respond well to treatment while others continue to experience uncontrolled disease. We look forward to seeing how this research helps move asthma care forward! Learn more: https://medicine.missouri.edu/news/researcher-receives-18-million-study-asthma-triggers #PulmonaryImaging #LungHealth #AsthmaResearch #NIHGrant #ResearchInnovation #Asthma #PrecisionMedicine #Mizzou",
          "sentiment": 0.0,
          "engagement": "19,317",
          "price_at_post": "0.09",
          "thread_title": "X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518730Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251225-Doppo59-34406366",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.706420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Good find Latino. You are correct, why no RNS ....  people are actually using Polarean XenonMRI With that news, a buy out and a couple of orders, this could be re-listed on the American market!! GL",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518705Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251737-Shpunken-91062528",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.705987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Cause it\u2019s now irrelevant, company is no longer public\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518679Z"
      },
      {
        "event_id": "SOCIAL-22Dec20250732-JeniH-69955951",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.705576",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Still listed until tomorrow and definitely not irrelevant if you still own shares",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518653Z"
      },
      {
        "event_id": "SOCIAL-22Dec20250806-loadofbo-87966258",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.705169",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Great, that should last about a year, then what?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518628Z"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo--3830374",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.704749",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518602Z"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH--7362543",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.704343",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518576Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202-84841572",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.703923",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,139",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518550Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202-80026270",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.703503",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,139",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518524Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra-68884043",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.703078",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,243",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-21T00:48:13.518498Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59--3721111",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.702671",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-21T00:48:13.518472Z"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888-61185580",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.702259",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "108",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-21T00:48:13.518446Z"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59-27801813",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.701847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T00:48:13.518420Z"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202-76888978",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.701436",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,139",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T00:48:13.518394Z"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo--3281308",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.701018",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T00:48:13.518368Z"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH--4794066",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.700610",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-21T00:48:13.518342Z"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59--1587521",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.700201",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T00:48:13.518316Z"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky-49504391",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.699768",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T00:48:13.518288Z"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59--7088272",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.699361",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T00:48:13.518262Z"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59--3381602",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.698931",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-21T00:48:13.518236Z"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu--4748599",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.698523",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T00:48:13.518210Z"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu-38821934",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.698072",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T00:48:13.518184Z"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6-21756822",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.697661",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,946",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T00:48:13.518157Z"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan--7982460",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.697246",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T00:48:13.518126Z"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh--8265152",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.696821",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,273",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-21T00:48:13.518076Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23--5563727",
        "event_type": "social_post",
        "date": "2026-01-21T00:47:58.696393",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-21T00:48:13.518044Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251702-loadofbo-39493447",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.400351",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Guess we\u2019ll find out soon",
          "sentiment": 0.0,
          "engagement": "262",
          "price_at_post": "0.22",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-12T21:58:27.052896Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251702-loadofbo-85358500",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.400351",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Guess we\u2019ll find out soon",
          "sentiment": 0.0,
          "engagement": "262",
          "price_at_post": "0.22",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-16T22:19:47.077539Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251702-loadofbo--2846998",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.400351",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Guess we\u2019ll find out soon",
          "sentiment": 0.0,
          "engagement": "262",
          "price_at_post": "0.22",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T00:48:13.521368Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251704-Laura202--9999016",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.399936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "EasyP See previous posts I will wait till 20-22nd Dec then decide The situation was always to buy cheap while the buyer was at work",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.22",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-12T21:58:27.052870Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251704-Laura202--6540856",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.399936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "EasyP See previous posts I will wait till 20-22nd Dec then decide The situation was always to buy cheap while the buyer was at work",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.22",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-16T22:19:47.077513Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251704-Laura202--5674927",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.399936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "EasyP See previous posts I will wait till 20-22nd Dec then decide The situation was always to buy cheap while the buyer was at work",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.22",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T00:48:13.521341Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251730-Shpunken--8779429",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.399515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "There\u2019s no resistance up to 0.4, so we could see the sp double this week if the buying continues.. but I am expecting some profit taking to happen this week as well",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-12T21:58:27.052843Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251730-Shpunken-77967026",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.399515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "There\u2019s no resistance up to 0.4, so we could see the sp double this week if the buying continues.. but I am expecting some profit taking to happen this week as well",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-16T22:19:47.077486Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251730-Shpunken--8298817",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.399515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "There\u2019s no resistance up to 0.4, so we could see the sp double this week if the buying continues.. but I am expecting some profit taking to happen this week as well",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T00:48:13.521316Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251832-Laura202-66794666",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.399114",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Green boxes either quiet or banned ? Not surprised now POLX risen from 0.7p to 0.21p",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-12T21:58:27.052816Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251832-Laura202--3981922",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.399114",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Green boxes either quiet or banned ? Not surprised now POLX risen from 0.7p to 0.21p",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-16T22:19:47.077460Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251832-Laura202-20302620",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.399114",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Green boxes either quiet or banned ? Not surprised now POLX risen from 0.7p to 0.21p",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T00:48:13.521290Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251858-bassman7--7755993",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.398699",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hmm, in real terms though SP has dropped more than 75% in 3 months hasn't it?",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-12T21:58:27.052790Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251858-bassman7--3623528",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.398699",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hmm, in real terms though SP has dropped more than 75% in 3 months hasn't it?",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-16T22:19:47.077434Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251858-bassman7--7256052",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.398699",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hmm, in real terms though SP has dropped more than 75% in 3 months hasn't it?",
          "sentiment": 0.0,
          "engagement": "1,065",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T00:48:13.521264Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251925-Bahriahe-16998694",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.398294",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bahriaheights",
          "content": "It has and has always been a risk like every other aim share that we pile in. We forget that the pharma is a cash burn, no different from any aim mining company. I had no hope for GDR either when it dropped to 0.25. I do strongly believe someone will step in as tech is a game changer Happy to wait and sit this out as I'm down by 85%.",
          "sentiment": 0.0,
          "engagement": "400",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-12T21:58:27.052763Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251925-Bahriahe--2862915",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.398294",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bahriaheights",
          "content": "It has and has always been a risk like every other aim share that we pile in. We forget that the pharma is a cash burn, no different from any aim mining company. I had no hope for GDR either when it dropped to 0.25. I do strongly believe someone will step in as tech is a game changer Happy to wait and sit this out as I'm down by 85%.",
          "sentiment": 0.0,
          "engagement": "400",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-16T22:19:47.077407Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251925-Bahriahe--5120335",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.398294",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bahriaheights",
          "content": "It has and has always been a risk like every other aim share that we pile in. We forget that the pharma is a cash burn, no different from any aim mining company. I had no hope for GDR either when it dropped to 0.25. I do strongly believe someone will step in as tech is a game changer Happy to wait and sit this out as I'm down by 85%.",
          "sentiment": 0.0,
          "engagement": "400",
          "price_at_post": "0.215",
          "thread_title": "RE: Keep hold of your shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=335DFFAE-D04B-426D-9D92-BD65F11CB04E"
        },
        "ingested_at": "2026-01-21T00:48:13.521238Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251132-Shpunken-44741502",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.397877",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Buying pressure building up again, this has to explode now, if it doesn\u2019t get to 0.4 it\u2019s only thanks to mms, the book looks overloaded with buys and there\u2019s no resistance till 0.4",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.215",
          "thread_title": "Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=60AA89D0-70DE-46A8-96CB-D03B9D4E3928"
        },
        "ingested_at": "2026-01-12T21:58:27.052736Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251132-Shpunken-31693591",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.397877",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Buying pressure building up again, this has to explode now, if it doesn\u2019t get to 0.4 it\u2019s only thanks to mms, the book looks overloaded with buys and there\u2019s no resistance till 0.4",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.215",
          "thread_title": "Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=60AA89D0-70DE-46A8-96CB-D03B9D4E3928"
        },
        "ingested_at": "2026-01-16T22:19:47.077381Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251132-Shpunken-66675932",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.397877",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Buying pressure building up again, this has to explode now, if it doesn\u2019t get to 0.4 it\u2019s only thanks to mms, the book looks overloaded with buys and there\u2019s no resistance till 0.4",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.215",
          "thread_title": "Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=60AA89D0-70DE-46A8-96CB-D03B9D4E3928"
        },
        "ingested_at": "2026-01-21T00:48:13.521212Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251144-RayNR-26905596",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.397474",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayNR",
          "content": "Shpunken, what does mms mean?",
          "sentiment": 0.0,
          "engagement": "14",
          "price_at_post": "0.215",
          "thread_title": "RE: Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=60AA89D0-70DE-46A8-96CB-D03B9D4E3928"
        },
        "ingested_at": "2026-01-12T21:58:27.052709Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251144-RayNR-57228587",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.397474",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayNR",
          "content": "Shpunken, what does mms mean?",
          "sentiment": 0.0,
          "engagement": "14",
          "price_at_post": "0.215",
          "thread_title": "RE: Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=60AA89D0-70DE-46A8-96CB-D03B9D4E3928"
        },
        "ingested_at": "2026-01-16T22:19:47.077354Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251144-RayNR--7857838",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.397474",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayNR",
          "content": "Shpunken, what does mms mean?",
          "sentiment": 0.0,
          "engagement": "14",
          "price_at_post": "0.215",
          "thread_title": "RE: Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=60AA89D0-70DE-46A8-96CB-D03B9D4E3928"
        },
        "ingested_at": "2026-01-21T00:48:13.521185Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251308-Giovs-12295894",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.397060",
        "source": "LSE_CHAT",
        "data": {
          "author": "Giovs",
          "content": "Knows something ??",
          "sentiment": 0.0,
          "engagement": "4,835",
          "price_at_post": "0.215",
          "thread_title": "Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052682Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251308-Giovs--3677020",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.397060",
        "source": "LSE_CHAT",
        "data": {
          "author": "Giovs",
          "content": "Knows something ??",
          "sentiment": 0.0,
          "engagement": "4,835",
          "price_at_post": "0.215",
          "thread_title": "Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077328Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251308-Giovs-48063283",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.397060",
        "source": "LSE_CHAT",
        "data": {
          "author": "Giovs",
          "content": "Knows something ??",
          "sentiment": 0.0,
          "engagement": "4,835",
          "price_at_post": "0.215",
          "thread_title": "Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.521159Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251803-Laura202--2580307",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.396652",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Continuation of the buying I've mentioned for 4weks now Ita Just that they're willing to pay higher now all the cheap stock has gone :)",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052656Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251803-Laura202-43573064",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.396652",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Continuation of the buying I've mentioned for 4weks now Ita Just that they're willing to pay higher now all the cheap stock has gone :)",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077301Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251803-Laura202--2101247",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.396652",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Continuation of the buying I've mentioned for 4weks now Ita Just that they're willing to pay higher now all the cheap stock has gone :)",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.521133Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250858-Apeirogo--5371986",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.396241",
        "source": "LSE_CHAT",
        "data": {
          "author": "Apeirogon",
          "content": "Doesn\u2019t all this buying mean that the people who want to take it private have more votes to enable that to happen ?",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052630Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250858-Apeirogo-35452695",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.396241",
        "source": "LSE_CHAT",
        "data": {
          "author": "Apeirogon",
          "content": "Doesn\u2019t all this buying mean that the people who want to take it private have more votes to enable that to happen ?",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077275Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250858-Apeirogo--2761852",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.396241",
        "source": "LSE_CHAT",
        "data": {
          "author": "Apeirogon",
          "content": "Doesn\u2019t all this buying mean that the people who want to take it private have more votes to enable that to happen ?",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.521105Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250910-Jimmy198-88705116",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.395823",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jimmy1981",
          "content": "Yeah or could be the people that want to vote against have more votes to do that",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052603Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250910-Jimmy198--3762400",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.395823",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jimmy1981",
          "content": "Yeah or could be the people that want to vote against have more votes to do that",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077248Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250910-Jimmy198--4990654",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.395823",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jimmy1981",
          "content": "Yeah or could be the people that want to vote against have more votes to do that",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.521072Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251006-Umaz--8475402",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.395410",
        "source": "LSE_CHAT",
        "data": {
          "author": "Umaz",
          "content": "What happens when someone held shares and voted, and subsequently sold the shares. Buy it again and votes again?",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052576Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251006-Umaz--7454358",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.395410",
        "source": "LSE_CHAT",
        "data": {
          "author": "Umaz",
          "content": "What happens when someone held shares and voted, and subsequently sold the shares. Buy it again and votes again?",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077221Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251006-Umaz--1407182",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.395410",
        "source": "LSE_CHAT",
        "data": {
          "author": "Umaz",
          "content": "What happens when someone held shares and voted, and subsequently sold the shares. Buy it again and votes again?",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "0.215",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.521045Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251200-Safi123--8532056",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.394990",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "I don\u2019t believe any official votes have taken place, just proxy instructions. So it would depend on the instructions given by the shareholders at the time of the vote I noticed the current price is hovering at 0.2p. I wonder if they are raising at 0.2p - could potentially raise 10 million with 5 billion new shares. Would be a big dilution but even still, if business valued at 60 million (which is realistically could be), would equate to 1p per share. I\u2019m hoping with momentum and more news they may be able to raise at 0.5p+ though",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.21",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052550Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251200-Safi123--5451594",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.394990",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "I don\u2019t believe any official votes have taken place, just proxy instructions. So it would depend on the instructions given by the shareholders at the time of the vote I noticed the current price is hovering at 0.2p. I wonder if they are raising at 0.2p - could potentially raise 10 million with 5 billion new shares. Would be a big dilution but even still, if business valued at 60 million (which is realistically could be), would equate to 1p per share. I\u2019m hoping with momentum and more news they may be able to raise at 0.5p+ though",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.21",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077194Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251200-Safi123--8944798",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.394990",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "I don\u2019t believe any official votes have taken place, just proxy instructions. So it would depend on the instructions given by the shareholders at the time of the vote I noticed the current price is hovering at 0.2p. I wonder if they are raising at 0.2p - could potentially raise 10 million with 5 billion new shares. Would be a big dilution but even still, if business valued at 60 million (which is realistically could be), would equate to 1p per share. I\u2019m hoping with momentum and more news they may be able to raise at 0.5p+ though",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.21",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.521019Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251231-Doppo59--5034704",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.394581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "My buys are showing up as sells .... GL",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.195",
          "thread_title": "Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E6F35A1F-D640-4CE8-8A2D-4BDCAB87B314"
        },
        "ingested_at": "2026-01-12T21:58:27.052524Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251231-Doppo59--6757568",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.394581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "My buys are showing up as sells .... GL",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.195",
          "thread_title": "Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E6F35A1F-D640-4CE8-8A2D-4BDCAB87B314"
        },
        "ingested_at": "2026-01-16T22:19:47.077168Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251231-Doppo59-45559361",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.394581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "My buys are showing up as sells .... GL",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.195",
          "thread_title": "Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E6F35A1F-D640-4CE8-8A2D-4BDCAB87B314"
        },
        "ingested_at": "2026-01-21T00:48:13.520993Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251258-Shpunken-44432292",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.394170",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Profit taking as expected..",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.195",
          "thread_title": "RE: Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E6F35A1F-D640-4CE8-8A2D-4BDCAB87B314"
        },
        "ingested_at": "2026-01-12T21:58:27.052497Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251258-Shpunken-58287719",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.394170",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Profit taking as expected..",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.195",
          "thread_title": "RE: Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E6F35A1F-D640-4CE8-8A2D-4BDCAB87B314"
        },
        "ingested_at": "2026-01-16T22:19:47.077141Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251258-Shpunken--8702804",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.394170",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Profit taking as expected..",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.195",
          "thread_title": "RE: Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E6F35A1F-D640-4CE8-8A2D-4BDCAB87B314"
        },
        "ingested_at": "2026-01-21T00:48:13.520967Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251322-Laura202-35967072",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.393750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Very steady here Also having done 300% on WHI AYM and almost 100% here thus far Bought EQT",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.195",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052471Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251322-Laura202--4133012",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.393750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Very steady here Also having done 300% on WHI AYM and almost 100% here thus far Bought EQT",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.195",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077114Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251322-Laura202--6964467",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.393750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Very steady here Also having done 300% on WHI AYM and almost 100% here thus far Bought EQT",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.195",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.520941Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251521-Jimmy198--6082621",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.393334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jimmy1981",
          "content": "EQT at 600k market cap should bag easily.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "0.17",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052445Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251521-Jimmy198--5247933",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.393334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jimmy1981",
          "content": "EQT at 600k market cap should bag easily.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "0.17",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077079Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251521-Jimmy198-87312459",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.393334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jimmy1981",
          "content": "EQT at 600k market cap should bag easily.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "0.17",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.520915Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251539-Apeirogo-43455580",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.392915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Apeirogon",
          "content": "Only people holding shares at a specific time get to vote. If you have instructed your broker how to vote it still doesn\u2019t happen until the time stamp.",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "0.17",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052418Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251539-Apeirogo--6593782",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.392915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Apeirogon",
          "content": "Only people holding shares at a specific time get to vote. If you have instructed your broker how to vote it still doesn\u2019t happen until the time stamp.",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "0.17",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077053Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251539-Apeirogo--1222273",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.392915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Apeirogon",
          "content": "Only people holding shares at a specific time get to vote. If you have instructed your broker how to vote it still doesn\u2019t happen until the time stamp.",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "0.17",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.520889Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251542-RayNR--2178657",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.392504",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayNR",
          "content": "Laura, did you do a massive dump?",
          "sentiment": 0.0,
          "engagement": "14",
          "price_at_post": "0.165",
          "thread_title": "I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-12T21:58:27.052392Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251542-RayNR--2027509",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.392504",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayNR",
          "content": "Laura, did you do a massive dump?",
          "sentiment": 0.0,
          "engagement": "14",
          "price_at_post": "0.165",
          "thread_title": "I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-16T22:19:47.077026Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251542-RayNR-57718614",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.392504",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayNR",
          "content": "Laura, did you do a massive dump?",
          "sentiment": 0.0,
          "engagement": "14",
          "price_at_post": "0.165",
          "thread_title": "I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-21T00:48:13.520863Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251548-loadofbo-77445460",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.392076",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You mean sell",
          "sentiment": 0.0,
          "engagement": "262",
          "price_at_post": "0.165",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-12T21:58:27.052365Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251548-loadofbo--8688689",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.392076",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You mean sell",
          "sentiment": 0.0,
          "engagement": "262",
          "price_at_post": "0.165",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-16T22:19:47.077000Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251548-loadofbo--3127377",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.392076",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You mean sell",
          "sentiment": 0.0,
          "engagement": "262",
          "price_at_post": "0.165",
          "thread_title": "RE: Nice 10k buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=905AA793-9A38-418A-92A8-4B167001E2F0"
        },
        "ingested_at": "2026-01-21T00:48:13.520837Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251903-Laura202--7418052",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.391659",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Amblast Even more odd is to havw an account since 2015,lurk around, pop up many years later Lose out on 400% gains WHI where you first gave me abuse (.out of 1000s LSE posters ) What  a life u have Xx",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-12T21:58:27.052339Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251903-Laura202-26364196",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.391659",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Amblast Even more odd is to havw an account since 2015,lurk around, pop up many years later Lose out on 400% gains WHI where you first gave me abuse (.out of 1000s LSE posters ) What  a life u have Xx",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-16T22:19:47.076974Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251903-Laura202-65836683",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.391659",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Amblast Even more odd is to havw an account since 2015,lurk around, pop up many years later Lose out on 400% gains WHI where you first gave me abuse (.out of 1000s LSE posters ) What  a life u have Xx",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-21T00:48:13.520812Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251911-AmBastei--1611522",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.391225",
        "source": "LSE_CHAT",
        "data": {
          "author": "AmBasteir",
          "content": "Lurk around? You made an arse of yourself with that comment, clearly posts every year. That's just you, I guess.",
          "sentiment": 0.0,
          "engagement": "541",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-12T21:58:27.052312Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251911-AmBastei--5972869",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.391225",
        "source": "LSE_CHAT",
        "data": {
          "author": "AmBasteir",
          "content": "Lurk around? You made an arse of yourself with that comment, clearly posts every year. That's just you, I guess.",
          "sentiment": 0.0,
          "engagement": "541",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-16T22:19:47.076947Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251911-AmBastei--8027795",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.391225",
        "source": "LSE_CHAT",
        "data": {
          "author": "AmBasteir",
          "content": "Lurk around? You made an arse of yourself with that comment, clearly posts every year. That's just you, I guess.",
          "sentiment": 0.0,
          "engagement": "541",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-21T00:48:13.520786Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251915-Laura202--1288249",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.390800",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Have a good one You've not posted anything of worth for over 10yrs it seems Filtered You enjoy xx",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-12T21:58:27.052285Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251915-Laura202-50158405",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.390800",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Have a good one You've not posted anything of worth for over 10yrs it seems Filtered You enjoy xx",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-16T22:19:47.076921Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251915-Laura202--7861962",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.390800",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Have a good one You've not posted anything of worth for over 10yrs it seems Filtered You enjoy xx",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "0.165",
          "thread_title": "RE: I don\u2019t know how to phrase it politely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=BC54FA77-3075-4175-91D9-E116476D75DB"
        },
        "ingested_at": "2026-01-21T00:48:13.520760Z"
      },
      {
        "event_id": "SOCIAL-11Dec20251200-Doppo59-46170096",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.390349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "We are back to where we were, SP dropping and no volume. Has everyone now taken their position and waiting to see what happens next? GL",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.16",
          "thread_title": "Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-12T21:58:27.052259Z"
      },
      {
        "event_id": "SOCIAL-11Dec20251200-Doppo59--2984512",
        "event_type": "social_post",
        "date": "2026-01-09T22:54:35.390349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "We are back to where we were, SP dropping and no volume. Has everyone now taken their position and waiting to see what happens next? GL",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.16",
          "thread_title": "Time running out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=1992A94E-82D0-4F8B-8779-4439FCD4E779"
        },
        "ingested_at": "2026-01-16T22:19:47.076894Z"
      },
      {
        "event_id": "SOCIAL-22Jan20262043-Doppo59--8035989",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611356",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Rkb007, if you find any news out, can you post in here, i will look. I am a member of a Telegram group also. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-24T01:32:52.626942+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007-68349186",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611798",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Direct",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-24T01:32:52.626964+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007--9123392",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612234",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Same for me with Charles Stanley - they created an individual director account and moved shares for me \u2026",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-24T01:32:52.626984+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261316-Doppo59--4621937",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hi Aims23, I didn't sell my shares, HL are still holding them. Any trades are made though J P Jenkins who HL deal with on my behalf (sell only) i had to move them out of my stocks and shares ISA as Polarean is now a limited company. Are you still holding? GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-24T01:32:52.627006+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23--3944350",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-24T01:32:52.627024+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh--2311267",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613495",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,274",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-24T01:32:52.627043+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan-40102783",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613908",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-24T01:32:52.627061+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6-78939578",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614336",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-24T01:32:52.627079+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu--4459836",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614743",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-24T01:32:52.627108+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu--3508659",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615184",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-24T01:32:52.627128+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59-19948576",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-24T01:32:52.627145+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59-56477928",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-24T01:32:52.627163+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky--5731791",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616436",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-24T01:32:52.627181+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59-97773337",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616860",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-24T01:32:52.627199+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH--3782752",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617280",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-24T01:32:52.627216+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo-81089555",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617687",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-24T01:32:52.627235+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202--6750861",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618105",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-24T01:32:52.627269+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59--1681657",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618523",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-24T01:32:52.627298+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888-33511792",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-24T01:32:52.627316+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59--8574603",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619359",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-24T01:32:52.627334+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra-68483889",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619832",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,244",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-24T01:32:52.627353+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202--8082565",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-24T01:32:52.627371+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202--7970128",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-24T01:32:52.627389+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH-61429477",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621090",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-24T01:32:52.627408+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo--3408373",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621514",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-24T01:32:52.627426+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250806-loadofbo--5543008",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229293",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Great, that should last about a year, then what?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.414412+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250732-JeniH-26746463",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229904",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Still listed until tomorrow and definitely not irrelevant if you still own shares",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.414463+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251737-Shpunken-31804859",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.230631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Cause it\u2019s now irrelevant, company is no longer public\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.414500+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251225-Doppo59--3151176",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.231490",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Good find Latino. You are correct, why no RNS ....  people are actually using Polarean XenonMRI With that news, a buy out and a couple of orders, this could be re-listed on the American market!! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.414535+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251109-Latino-84561663",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Why no RNS..? https://x.com/PolareanImaging/status/2001034816859394174 Congratulations to Robby Thomen, PhD and team on receiving major funding for this exciting asthma research milestone! \ud83c\udf89 We\u2019re thrilled to see new research from the @mumedicine receive a $1.8-million grant from the @NIH to advance understanding of asthma triggers and disease mechanisms. Robby and his team are using Polarean's #XenonMRI platform to visualize regional lung function and investigate whether airway hyperconstriction in asthma also happens in the lung's blood vessels, or vasculature. This long-standing hypothesis in asthma research has been challenging to study, and Xenon MRI offers a new way to explore functional relationships that are not accessible with conventional imaging. This work represents an important step toward more precise, personalized approaches to asthma care and may help explain why some patients respond well to treatment while others continue to experience uncontrolled disease. We look forward to seeing how this research helps move asthma care forward! Learn more: https://medicine.missouri.edu/news/researcher-receives-18-million-study-asthma-triggers #PulmonaryImaging #LungHealth #AsthmaResearch #NIHGrant #ResearchInnovation #Asthma #PrecisionMedicine #Mizzou",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.414571+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251956-mr-steve--1542484",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232831",
        "source": "LSE_CHAT",
        "data": {
          "author": "mr-steve",
          "content": "...I'm not selling. 1) what i have (~500k) is worth close to f-all 2) i still think they could do well 3) even as a private co, I will still hold my shares 4) at some point they will either a) do well and the shares will be worth selling, b) get bought out for a better return than selling now c) relist at a premium to now or d) disappear into a black hole At current prices, d) won't make any difference, the others probably won't but just might. Spin the wheel, my money's on number 26!",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "0.085",
          "thread_title": "For what its worth...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=7E313B47-BF7F-47AF-BEAC-14BA524C82E1"
        },
        "ingested_at": "2026-01-29T09:42:57.414610+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251857-Balanced-38677703",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.233482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "We keep hearing it's a great product. Says who. The real proof of a great product is high numbers of sales. Here they have struggled to shift product. It's not all the blame of management. Great products sell themselves to some extent. That hasn't happened here. The product has been marketed for years so those in the sector are well aware of it. It's a poor product and/or doesn't fill a need as was originally expected. Being based in the US the company would have had US based funds or investors at some stage.",
          "sentiment": 0.0,
          "engagement": "1,653",
          "price_at_post": "0.085",
          "thread_title": "RE: Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-01-29T09:42:57.414654+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251606-trunky-21697162",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234129",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "There are  plenty of wealthy funds and individuals that could buy this company ,show me where there is a company that has such a great product .if this company was listed on the American market investors would be  all over it",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.085",
          "thread_title": "Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-01-29T09:42:57.414673+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251413-bassman7--2576099",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234709",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hope your \"knowledgable friend\" didn't give you any other tips Lolajamola \u2620\ufe0f Posted in: POLX Posts: 12 RE: Polx24 Mar 2022 18:53 I know what you mean\u2026. It is unsettling but we are holding tight. For us it\u2019s a long term investment, but hoping our patience will pay off soon! Saw our knowledgeable friend yesterday (that first put us onto Polx) and he is still confident so we are trusting his judgement on this. Lolajamola Posted in: POLX Posts: 12 RE: Here we go21 Mar 2022 16:54 Appreciate reading your recommendations on this one. We have also been tipped by another investor on this one as a good bet but it\u2019s reassuring to hear it from another source! Crossing all the digits\u2026.",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-29T09:42:57.414692+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251230-loadofbo-50958177",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235225",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people buying here? Have I missed something? Be lucky to 1 new share for 100 old when it\u2019s delisted.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-29T09:42:57.414711+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251135-Lolajamo-66955552",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lolajamola",
          "content": "Also sticking it out. Lost so much on this one it\u2019s just not worth selling! Holding out for a miracle\u2026!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-29T09:42:57.414730+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251043-JeniH-88271627",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236264",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "I'm staying too - it qualifies for 2 bargain stock screens on Stockopedia so I'm happy to hold for the share price recovery or an offer for the whole company  whichever comes first.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.08",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-29T09:42:57.414749+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251013-Doppo59-24583033",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236801",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "I'm staying put. This seems to be oversold, remember delisting was announced months ago. POLX are in partnership with Phillips who already use the product with Xenoview (FDA approved). My money is on Phillips buying us out, or at least a partnership,  POLX have more money in the bank than the current MC, so not going bust. Who knows how many orders are almost ready to be signed, Asia, India, not forgetting US. A couple of bits of good news and J P Jenkins might have to do some work! It seems most have left now, I'll see it through, waited five years, might as well another year! The tech is still sound, and being used. Wish me luck lol Doppo",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-29T09:42:57.414767+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251524-Latino-91969220",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yep no shares lost here, shareholders can still sell after delisting via JP Jenkins.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-29T09:42:57.414786+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251437-Doppo59-45413461",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Pyueck, I'm not selling yet, I'm too stubborn. We might get an offer of a buyout before the 23rd, who knows. They have money in the bank till H2, I don't think they can ever raise again at the current price. Such great tech, unfortunately run by compete armatures with not a good salesman among them. This BB was full of people all singing the companies praises, not a single post any more. The rich get richer and the poor .... This was posted on here a couple of days ago, you keep your shares and sell (or buy) through J P Jenkins, just harder to do. Good luck fella. The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-29T09:42:57.414805+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-PYUECK--9042707",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238302",
        "source": "LSE_CHAT",
        "data": {
          "author": "PYUECK",
          "content": "I am assuming everybody is now just selling their shares before the 23rd. If you hold in a nominee account I suspect they wont even hold these shares for you in a private company so effectively they will be lost. Even if you keep, assuming the company survives any future fundraising is going to almost completely wipe out existing shareholders anyway. Even if this company has a rosey future, which I doubt, existing shareholders wont be part of it.",
          "sentiment": 0.0,
          "engagement": "773",
          "price_at_post": "0.08",
          "thread_title": "Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-29T09:42:57.414829+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251259-bassman7-40936615",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238717",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "What happened to the poster here who said he bought in after a tip from his Harley St eye surgeon's mate? \ud83d\ude02 Hope he didn't lose too much",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.075",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-29T09:42:57.414872+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251141-ironknut-72159337",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239147",
        "source": "LSE_CHAT",
        "data": {
          "author": "ironknut",
          "content": "At last we mugs who invested here are put out of our misery. At least the losses will reduce capital gains tax donations to Westminster.",
          "sentiment": 0.0,
          "engagement": "1,665",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-29T09:42:57.414892+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251111-Doppo59-76202850",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Thanks Latino. I did speak to my broker (HL) this morning who confirmed those details. They will be writing to me in the next few days to confirm my holding and advising the next step with J P Jenkins. POLX have funds until H2, lets see what happens next. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-29T09:42:57.414913+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251015-Latino--1689009",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240018",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yesterday RNS extract: The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-29T09:42:57.414938+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250921-2reincar-40817038",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240438",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Say hello to Genedrive when you meet in hell!",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.09",
          "thread_title": "Goodbye Polarean",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=28001004-0D99-46D9-AF63-BB068E80A726"
        },
        "ingested_at": "2026-01-29T09:42:57.414972+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250815-Laura202--5856331",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240850",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The matched bargain facilty is at bottom of yesterday RNS",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-29T09:42:57.414992+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252113-shamI89-68385993",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241280",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "There will be other mini spikes to let traped traders out , although I believe last \"p&d\" was orchestrated to let Laura excape with a profit.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-29T09:42:57.415011+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252026-Jacobjoh-14207963",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "With laura.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-29T09:42:57.415029+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252025-Jacobjoh-33516542",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.242119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "In a sad old death threesome here.  Dopper and spunky has to admit and apologise now and they should have listened to me and saved some money.  I tried....you can lead a dopper to water lop .. You nasty people deserve every misfortune you get here.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-29T09:42:57.415048+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251947-Doppo59--4251265",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384442",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunky. I believe that any shares you own, remain yours. It will be harder to trade them though.However I did hear a rumour that polx are setting up something on their website to help. Maybe stick around and hope they don't go bust!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-29T09:42:57.415089+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251845-shamI89--4320843",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384975",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Company has been survining on placings and would do so in near future, so you can imagine what will happen.It is a trend where share holders spend the money and company uses that money to develop a technology to get delisted at the end leaving shareholders high and dry.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-29T09:42:57.415136+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251720-loadofbo-94854389",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.385526",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Yes, probably 1 new share for every 100 old ones, that\u2019s the usual practice.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-29T09:42:57.415156+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251656-Mikewinv-33927835",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikewinvest",
          "content": "TR1s...the dogs that haven't barked!",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "0.105",
          "thread_title": "TR1s",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=698AFB22-A50E-487C-B919-75F58340736B"
        },
        "ingested_at": "2026-01-29T09:42:57.415175+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251650-trunky-52397908",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386636",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will this mean we lose all our investment ?or will we be allocated new shares in the private company?",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.105",
          "thread_title": "Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-29T09:42:57.415194+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251636-Safi123-28503239",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "We were close, certainly winning the vote was on the cards but it seems a large number of PIs were apathetic. Does anyone know if any large stakeholders opposed the move to going private? This company is growing, with international expansion, upcoming trial and proven technology. It will have no issue raising cash. In my view a much better chance of success than most small med tech businesses (some of whom valued in 10s of millions) I\u2019m not convinced ultradilution as a private business is inevitable. For one thing, there\u2019s no guarantee either Nukem or Bracco are willing to fully finance this business further to the tune of 20 million, already owning healthy portions. If a third party wants a stake it will be at a much higher valuation (business is realistically worth at the very least 10-20 million looking at similar AIM businesses) Secondly, 524 million votes in favour suggests Nukem and Bracco somehow obtained the support of other large shareholders. These shareholders would never agree to going private if it means their stakes are obliterated.",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.105",
          "thread_title": "Company valuation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=43B57842-8C07-4F9A-B3B1-1EE524148282"
        },
        "ingested_at": "2026-01-29T09:42:57.415212+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251617-loadofbo-46402567",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387696",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "This is de listing in 8 days, why are people still buying?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-01-29T09:42:57.415240+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-loadofbo--3978823",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388224",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-29T09:42:57.415275+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-Laura202--7015029",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388744",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected but the 20% tried Will the 80% continue to buy ?",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-01-29T09:42:57.415313+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-tuan6--3533334",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389269",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Dont worry  as peoples dont sell when they are  reading in .  only sell when they dont see any value left .  this comoany have more money in its bank account  than its market CAP so there are still  pretty  things left for sell .  even  someone  will jump in  to buy this company  so dont worry  for shareholders as this is thier money and they dont give up that easy.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-29T09:42:57.415351+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-bassman7-25665808",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389791",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "I mean... they announced it live in an advertised public call. Are you honestly putting your posts through googletranslate and back. You know those translation programmes don't make spelling mistakes?",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-29T09:42:57.415390+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-loadofbo-64354181",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390312",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "If they don\u2019t de list they will go bust because they are out of money, can\u2019t raise anymore and can\u2019t sell the company.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-29T09:42:57.415429+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251558-loadofbo-71760524",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390804",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-29T09:42:57.415467+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251555-tuan6--1661186",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391467",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "No RNS is good news as if they pass they have published  it by now.  400% rise next month.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-29T09:42:57.415505+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251545-shamI89-16494512",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391981",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Managed to get another \"p&d\" away......",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.10",
          "thread_title": "Looks like Laura has",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=95DBDD4A-508B-4205-B71E-4DC15152341B"
        },
        "ingested_at": "2026-01-29T09:42:57.415544+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251541-loadofbo-79921930",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.392503",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people still buying here?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-29T09:42:57.415583+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251539-bassman7--5149912",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393006",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Did you not zoom the meeting? They said information would be up on their website \"in due course\".  The meeting was about 5 mins long. It was agreed the company is being delisted. Hearing it from the company live in a zoom call (jiopning details below) was enough confirmation for me \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-29T09:42:57.415622+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251535-Laura202--6208818",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Confirmation or otherwise This drop is on very low volume Mmmmmm",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-29T09:42:57.415660+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251534-share4--7239764",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394027",
        "source": "LSE_CHAT",
        "data": {
          "author": "share4",
          "content": "These are going to end up being known as \"green box\" shares",
          "sentiment": 0.0,
          "engagement": "1,738",
          "price_at_post": "0.10",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-29T09:42:57.415698+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251519-2reincar--8201469",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394469",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Question of only when.",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.10",
          "thread_title": "Genedrive will eventually go the same way!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=EF81FBC2-AF85-428C-BBE4-906724917774"
        },
        "ingested_at": "2026-01-29T09:42:57.415737+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251437-Ilovesus-30637131",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Down 99.8% over the last 5 years. Even though some may have just made 100% . Often these type of rises are meaningless for most. Who honestly got in on the bottom and how long have they been invested? As the company can no longer get away with another placing it would have to issue too many shares and then only raise small amounts. That it now wants to delist is very telling. Its reach the end of the road. Its in a place where raising more through selling shares will not work. This is where most companies on AIM delist. They cannot sell any more shares. PYC is a company like this that may also delist. Seems some on that company post here. AIM companies list in order to raise money. PYC has had so many placings and  has a history of raising unlike this company. That too like this one will no doubt delist. Beware guys AIM is a cesspit.",
          "sentiment": 0.0,
          "engagement": "7,727",
          "price_at_post": "0.11",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-29T09:42:57.415788+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-Shpunken-26994260",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395328",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Yep it is a shame that ppl will miss out on this and big companies again will be the winners",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-29T09:42:57.415827+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-bassman7--7545873",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395735",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Judging by your recent comments Doppo, you seemed to think this would come good, even congratulating otheres on their holdings just a week ago... \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-29T09:42:57.415865+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251406-Doppo59--7757399",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Such a shame, but no surprise! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.13",
          "thread_title": "No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-29T09:42:57.415912+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251405-loadofbo-18534409",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396667",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why on earth would someone buy 7m shares when its de listing?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.13",
          "thread_title": "RE: And... delisted from AIM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=8E783F9A-4C63-461E-ACA1-4513E80D78C0"
        },
        "ingested_at": "2026-01-29T09:42:57.415951+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262043-Doppo59-86060922",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611356",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Rkb007, if you find any news out, can you post in here, i will look. I am a member of a Telegram group also. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-29T09:42:57.415992+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007--2437156",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611798",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Direct",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-29T09:42:57.416033+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007-62735304",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612234",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Same for me with Charles Stanley - they created an individual director account and moved shares for me \u2026",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-29T09:42:57.416072+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261316-Doppo59-54041691",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hi Aims23, I didn't sell my shares, HL are still holding them. Any trades are made though J P Jenkins who HL deal with on my behalf (sell only) i had to move them out of my stocks and shares ISA as Polarean is now a limited company. Are you still holding? GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-29T09:42:57.416126+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23-60390417",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-29T09:42:57.416163+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh--8585721",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613495",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,274",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-29T09:42:57.416203+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan--6887532",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613908",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-29T09:42:57.416241+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6-50522157",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614336",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-29T09:42:57.416280+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu-25565182",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614743",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-29T09:42:57.416320+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu-13997876",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615184",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-29T09:42:57.416347+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59--1384498",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-29T09:42:57.416381+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59--8647578",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-29T09:42:57.416419+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky-20374662",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616436",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-29T09:42:57.416457+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59-24103317",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616860",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-29T09:42:57.416496+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH-89625482",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617280",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-29T09:42:57.416542+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo-21381758",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617687",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-29T09:42:57.416584+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202--4812767",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618105",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-29T09:42:57.416623+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59--2585584",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618523",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-29T09:42:57.416663+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888-57466567",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.416702+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59-62214395",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619359",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-29T09:42:57.416740+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra--1638415",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619832",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,244",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-29T09:42:57.416778+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202--2602873",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.416816+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202--5473705",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.416853+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH--1745990",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621090",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.416892+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo--4037672",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621514",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-29T09:42:57.416949+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250806-loadofbo-83646107",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229293",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Great, that should last about a year, then what?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.359466+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250732-JeniH--4016835",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229904",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Still listed until tomorrow and definitely not irrelevant if you still own shares",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.359489+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251737-Shpunken--7062944",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.230631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Cause it\u2019s now irrelevant, company is no longer public\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.359509+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251225-Doppo59-81096381",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.231490",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Good find Latino. You are correct, why no RNS ....  people are actually using Polarean XenonMRI With that news, a buy out and a couple of orders, this could be re-listed on the American market!! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.359528+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251109-Latino-14646661",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Why no RNS..? https://x.com/PolareanImaging/status/2001034816859394174 Congratulations to Robby Thomen, PhD and team on receiving major funding for this exciting asthma research milestone! \ud83c\udf89 We\u2019re thrilled to see new research from the @mumedicine receive a $1.8-million grant from the @NIH to advance understanding of asthma triggers and disease mechanisms. Robby and his team are using Polarean's #XenonMRI platform to visualize regional lung function and investigate whether airway hyperconstriction in asthma also happens in the lung's blood vessels, or vasculature. This long-standing hypothesis in asthma research has been challenging to study, and Xenon MRI offers a new way to explore functional relationships that are not accessible with conventional imaging. This work represents an important step toward more precise, personalized approaches to asthma care and may help explain why some patients respond well to treatment while others continue to experience uncontrolled disease. We look forward to seeing how this research helps move asthma care forward! Learn more: https://medicine.missouri.edu/news/researcher-receives-18-million-study-asthma-triggers #PulmonaryImaging #LungHealth #AsthmaResearch #NIHGrant #ResearchInnovation #Asthma #PrecisionMedicine #Mizzou",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.359546+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251956-mr-steve--5933177",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232831",
        "source": "LSE_CHAT",
        "data": {
          "author": "mr-steve",
          "content": "...I'm not selling. 1) what i have (~500k) is worth close to f-all 2) i still think they could do well 3) even as a private co, I will still hold my shares 4) at some point they will either a) do well and the shares will be worth selling, b) get bought out for a better return than selling now c) relist at a premium to now or d) disappear into a black hole At current prices, d) won't make any difference, the others probably won't but just might. Spin the wheel, my money's on number 26!",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "0.085",
          "thread_title": "For what its worth...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=7E313B47-BF7F-47AF-BEAC-14BA524C82E1"
        },
        "ingested_at": "2026-01-30T22:33:35.359565+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251857-Balanced--3617431",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.233482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "We keep hearing it's a great product. Says who. The real proof of a great product is high numbers of sales. Here they have struggled to shift product. It's not all the blame of management. Great products sell themselves to some extent. That hasn't happened here. The product has been marketed for years so those in the sector are well aware of it. It's a poor product and/or doesn't fill a need as was originally expected. Being based in the US the company would have had US based funds or investors at some stage.",
          "sentiment": 0.0,
          "engagement": "1,653",
          "price_at_post": "0.085",
          "thread_title": "RE: Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-01-30T22:33:35.359583+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251606-trunky--3377992",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234129",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "There are  plenty of wealthy funds and individuals that could buy this company ,show me where there is a company that has such a great product .if this company was listed on the American market investors would be  all over it",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.085",
          "thread_title": "Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-01-30T22:33:35.359606+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251413-bassman7--7790635",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234709",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hope your \"knowledgable friend\" didn't give you any other tips Lolajamola \u2620\ufe0f Posted in: POLX Posts: 12 RE: Polx24 Mar 2022 18:53 I know what you mean\u2026. It is unsettling but we are holding tight. For us it\u2019s a long term investment, but hoping our patience will pay off soon! Saw our knowledgeable friend yesterday (that first put us onto Polx) and he is still confident so we are trusting his judgement on this. Lolajamola Posted in: POLX Posts: 12 RE: Here we go21 Mar 2022 16:54 Appreciate reading your recommendations on this one. We have also been tipped by another investor on this one as a good bet but it\u2019s reassuring to hear it from another source! Crossing all the digits\u2026.",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-30T22:33:35.359625+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251230-loadofbo-69734069",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235225",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people buying here? Have I missed something? Be lucky to 1 new share for 100 old when it\u2019s delisted.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-30T22:33:35.359643+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251135-Lolajamo--4278894",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lolajamola",
          "content": "Also sticking it out. Lost so much on this one it\u2019s just not worth selling! Holding out for a miracle\u2026!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-30T22:33:35.359661+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251043-JeniH-58578735",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236264",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "I'm staying too - it qualifies for 2 bargain stock screens on Stockopedia so I'm happy to hold for the share price recovery or an offer for the whole company  whichever comes first.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.08",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-30T22:33:35.359679+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251013-Doppo59-68735908",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236801",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "I'm staying put. This seems to be oversold, remember delisting was announced months ago. POLX are in partnership with Phillips who already use the product with Xenoview (FDA approved). My money is on Phillips buying us out, or at least a partnership,  POLX have more money in the bank than the current MC, so not going bust. Who knows how many orders are almost ready to be signed, Asia, India, not forgetting US. A couple of bits of good news and J P Jenkins might have to do some work! It seems most have left now, I'll see it through, waited five years, might as well another year! The tech is still sound, and being used. Wish me luck lol Doppo",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-01-30T22:33:35.359697+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251524-Latino-52892863",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yep no shares lost here, shareholders can still sell after delisting via JP Jenkins.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-30T22:33:35.359715+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251437-Doppo59-39531738",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Pyueck, I'm not selling yet, I'm too stubborn. We might get an offer of a buyout before the 23rd, who knows. They have money in the bank till H2, I don't think they can ever raise again at the current price. Such great tech, unfortunately run by compete armatures with not a good salesman among them. This BB was full of people all singing the companies praises, not a single post any more. The rich get richer and the poor .... This was posted on here a couple of days ago, you keep your shares and sell (or buy) through J P Jenkins, just harder to do. Good luck fella. The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-30T22:33:35.359733+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-PYUECK--1810014",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238302",
        "source": "LSE_CHAT",
        "data": {
          "author": "PYUECK",
          "content": "I am assuming everybody is now just selling their shares before the 23rd. If you hold in a nominee account I suspect they wont even hold these shares for you in a private company so effectively they will be lost. Even if you keep, assuming the company survives any future fundraising is going to almost completely wipe out existing shareholders anyway. Even if this company has a rosey future, which I doubt, existing shareholders wont be part of it.",
          "sentiment": 0.0,
          "engagement": "773",
          "price_at_post": "0.08",
          "thread_title": "Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-01-30T22:33:35.359750+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251259-bassman7--8224470",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238717",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "What happened to the poster here who said he bought in after a tip from his Harley St eye surgeon's mate? \ud83d\ude02 Hope he didn't lose too much",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.075",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-30T22:33:35.359769+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251141-ironknut-50848405",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239147",
        "source": "LSE_CHAT",
        "data": {
          "author": "ironknut",
          "content": "At last we mugs who invested here are put out of our misery. At least the losses will reduce capital gains tax donations to Westminster.",
          "sentiment": 0.0,
          "engagement": "1,665",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-30T22:33:35.359787+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251111-Doppo59-51759370",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Thanks Latino. I did speak to my broker (HL) this morning who confirmed those details. They will be writing to me in the next few days to confirm my holding and advising the next step with J P Jenkins. POLX have funds until H2, lets see what happens next. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-30T22:33:35.359806+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251015-Latino--3498098",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240018",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yesterday RNS extract: The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-30T22:33:35.359823+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250921-2reincar--2953872",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240438",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Say hello to Genedrive when you meet in hell!",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.09",
          "thread_title": "Goodbye Polarean",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=28001004-0D99-46D9-AF63-BB068E80A726"
        },
        "ingested_at": "2026-01-30T22:33:35.359842+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250815-Laura202-18630752",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240850",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The matched bargain facilty is at bottom of yesterday RNS",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-30T22:33:35.359859+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252113-shamI89-58939750",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241280",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "There will be other mini spikes to let traped traders out , although I believe last \"p&d\" was orchestrated to let Laura excape with a profit.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-30T22:33:35.359877+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252026-Jacobjoh--7825075",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "With laura.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-30T22:33:35.359895+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252025-Jacobjoh-69774979",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.242119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "In a sad old death threesome here.  Dopper and spunky has to admit and apologise now and they should have listened to me and saved some money.  I tried....you can lead a dopper to water lop .. You nasty people deserve every misfortune you get here.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-01-30T22:33:35.359913+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251947-Doppo59--8381521",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384442",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunky. I believe that any shares you own, remain yours. It will be harder to trade them though.However I did hear a rumour that polx are setting up something on their website to help. Maybe stick around and hope they don't go bust!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-30T22:33:35.359931+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251845-shamI89-17935874",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384975",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Company has been survining on placings and would do so in near future, so you can imagine what will happen.It is a trend where share holders spend the money and company uses that money to develop a technology to get delisted at the end leaving shareholders high and dry.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-30T22:33:35.359949+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251720-loadofbo--7488381",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.385526",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Yes, probably 1 new share for every 100 old ones, that\u2019s the usual practice.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-30T22:33:35.359967+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251656-Mikewinv-73316935",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikewinvest",
          "content": "TR1s...the dogs that haven't barked!",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "0.105",
          "thread_title": "TR1s",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=698AFB22-A50E-487C-B919-75F58340736B"
        },
        "ingested_at": "2026-01-30T22:33:35.359984+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251650-trunky--4134738",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386636",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will this mean we lose all our investment ?or will we be allocated new shares in the private company?",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.105",
          "thread_title": "Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-01-30T22:33:35.360002+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251636-Safi123--7480347",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "We were close, certainly winning the vote was on the cards but it seems a large number of PIs were apathetic. Does anyone know if any large stakeholders opposed the move to going private? This company is growing, with international expansion, upcoming trial and proven technology. It will have no issue raising cash. In my view a much better chance of success than most small med tech businesses (some of whom valued in 10s of millions) I\u2019m not convinced ultradilution as a private business is inevitable. For one thing, there\u2019s no guarantee either Nukem or Bracco are willing to fully finance this business further to the tune of 20 million, already owning healthy portions. If a third party wants a stake it will be at a much higher valuation (business is realistically worth at the very least 10-20 million looking at similar AIM businesses) Secondly, 524 million votes in favour suggests Nukem and Bracco somehow obtained the support of other large shareholders. These shareholders would never agree to going private if it means their stakes are obliterated.",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.105",
          "thread_title": "Company valuation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=43B57842-8C07-4F9A-B3B1-1EE524148282"
        },
        "ingested_at": "2026-01-30T22:33:35.360019+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251617-loadofbo--6061493",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387696",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "This is de listing in 8 days, why are people still buying?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-01-30T22:33:35.360037+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-loadofbo--3830284",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388224",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-30T22:33:35.360055+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-Laura202-22119162",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388744",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected but the 20% tried Will the 80% continue to buy ?",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-01-30T22:33:35.360073+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-tuan6--1035742",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389269",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Dont worry  as peoples dont sell when they are  reading in .  only sell when they dont see any value left .  this comoany have more money in its bank account  than its market CAP so there are still  pretty  things left for sell .  even  someone  will jump in  to buy this company  so dont worry  for shareholders as this is thier money and they dont give up that easy.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-30T22:33:35.360092+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-bassman7--7442717",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389791",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "I mean... they announced it live in an advertised public call. Are you honestly putting your posts through googletranslate and back. You know those translation programmes don't make spelling mistakes?",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-30T22:33:35.360129+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-loadofbo--4761824",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390312",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "If they don\u2019t de list they will go bust because they are out of money, can\u2019t raise anymore and can\u2019t sell the company.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-30T22:33:35.360148+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251558-loadofbo-25821961",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390804",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-30T22:33:35.360165+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251555-tuan6--1594480",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391467",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "No RNS is good news as if they pass they have published  it by now.  400% rise next month.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-30T22:33:35.360184+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251545-shamI89-68044561",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391981",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Managed to get another \"p&d\" away......",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.10",
          "thread_title": "Looks like Laura has",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=95DBDD4A-508B-4205-B71E-4DC15152341B"
        },
        "ingested_at": "2026-01-30T22:33:35.360202+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251541-loadofbo-88890539",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.392503",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people still buying here?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-30T22:33:35.360220+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251539-bassman7--6330278",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393006",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Did you not zoom the meeting? They said information would be up on their website \"in due course\".  The meeting was about 5 mins long. It was agreed the company is being delisted. Hearing it from the company live in a zoom call (jiopning details below) was enough confirmation for me \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-30T22:33:35.360238+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251535-Laura202-29158004",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Confirmation or otherwise This drop is on very low volume Mmmmmm",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-01-30T22:33:35.360257+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251534-share4--2382137",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394027",
        "source": "LSE_CHAT",
        "data": {
          "author": "share4",
          "content": "These are going to end up being known as \"green box\" shares",
          "sentiment": 0.0,
          "engagement": "1,738",
          "price_at_post": "0.10",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-30T22:33:35.360275+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251519-2reincar--6506032",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394469",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Question of only when.",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.10",
          "thread_title": "Genedrive will eventually go the same way!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=EF81FBC2-AF85-428C-BBE4-906724917774"
        },
        "ingested_at": "2026-01-30T22:33:35.360294+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251437-Ilovesus--2296436",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Down 99.8% over the last 5 years. Even though some may have just made 100% . Often these type of rises are meaningless for most. Who honestly got in on the bottom and how long have they been invested? As the company can no longer get away with another placing it would have to issue too many shares and then only raise small amounts. That it now wants to delist is very telling. Its reach the end of the road. Its in a place where raising more through selling shares will not work. This is where most companies on AIM delist. They cannot sell any more shares. PYC is a company like this that may also delist. Seems some on that company post here. AIM companies list in order to raise money. PYC has had so many placings and  has a history of raising unlike this company. That too like this one will no doubt delist. Beware guys AIM is a cesspit.",
          "sentiment": 0.0,
          "engagement": "7,727",
          "price_at_post": "0.11",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-30T22:33:35.360312+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-Shpunken-92039757",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395328",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Yep it is a shame that ppl will miss out on this and big companies again will be the winners",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-30T22:33:35.360331+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-bassman7--3522872",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395735",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Judging by your recent comments Doppo, you seemed to think this would come good, even congratulating otheres on their holdings just a week ago... \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-30T22:33:35.360350+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251406-Doppo59--4539034",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Such a shame, but no surprise! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.13",
          "thread_title": "No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-01-30T22:33:35.360368+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251405-loadofbo--4562198",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396667",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why on earth would someone buy 7m shares when its de listing?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.13",
          "thread_title": "RE: And... delisted from AIM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=8E783F9A-4C63-461E-ACA1-4513E80D78C0"
        },
        "ingested_at": "2026-01-30T22:33:35.360387+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262043-Doppo59--4117872",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611356",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Rkb007, if you find any news out, can you post in here, i will look. I am a member of a Telegram group also. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-30T22:33:35.360405+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007--2109208",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611798",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Direct",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-30T22:33:35.360423+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007--4857484",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612234",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Same for me with Charles Stanley - they created an individual director account and moved shares for me \u2026",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-30T22:33:35.360441+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261316-Doppo59--4699542",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hi Aims23, I didn't sell my shares, HL are still holding them. Any trades are made though J P Jenkins who HL deal with on my behalf (sell only) i had to move them out of my stocks and shares ISA as Polarean is now a limited company. Are you still holding? GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-30T22:33:35.360460+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23--2732569",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-01-30T22:33:35.360478+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh-46190135",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613495",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,274",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-30T22:33:35.360496+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan--1730278",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613908",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-30T22:33:35.360514+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6--5904936",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614336",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-30T22:33:35.360532+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu-90661124",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614743",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-30T22:33:35.360550+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu-30045940",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615184",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-01-30T22:33:35.360569+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59--5878951",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-30T22:33:35.360587+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59--8399137",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-30T22:33:35.360605+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky-71655865",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616436",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-30T22:33:35.360623+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59--3704487",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616860",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-30T22:33:35.360641+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH-84295487",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617280",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-30T22:33:35.360659+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo-66583882",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617687",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-30T22:33:35.360678+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202--6393730",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618105",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-30T22:33:35.360697+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59-38595582",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618523",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-01-30T22:33:35.360715+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888--3574764",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.360733+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59--9272132",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619359",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-30T22:33:35.360752+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra-16964120",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619832",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,244",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-01-30T22:33:35.360770+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202-74418641",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.360791+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202-55393059",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.360809+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH-65758043",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621090",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.360828+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo-41606046",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621514",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-01-30T22:33:35.360846+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250806-loadofbo--6473803",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229293",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Great, that should last about a year, then what?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.688886+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250732-JeniH-72758056",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229904",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Still listed until tomorrow and definitely not irrelevant if you still own shares",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.688918+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251737-Shpunken-45535172",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.230631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Cause it\u2019s now irrelevant, company is no longer public\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.688938+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251225-Doppo59-49966911",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.231490",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Good find Latino. You are correct, why no RNS ....  people are actually using Polarean XenonMRI With that news, a buy out and a couple of orders, this could be re-listed on the American market!! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.688957+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251109-Latino-80935316",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Why no RNS..? https://x.com/PolareanImaging/status/2001034816859394174 Congratulations to Robby Thomen, PhD and team on receiving major funding for this exciting asthma research milestone! \ud83c\udf89 We\u2019re thrilled to see new research from the @mumedicine receive a $1.8-million grant from the @NIH to advance understanding of asthma triggers and disease mechanisms. Robby and his team are using Polarean's #XenonMRI platform to visualize regional lung function and investigate whether airway hyperconstriction in asthma also happens in the lung's blood vessels, or vasculature. This long-standing hypothesis in asthma research has been challenging to study, and Xenon MRI offers a new way to explore functional relationships that are not accessible with conventional imaging. This work represents an important step toward more precise, personalized approaches to asthma care and may help explain why some patients respond well to treatment while others continue to experience uncontrolled disease. We look forward to seeing how this research helps move asthma care forward! Learn more: https://medicine.missouri.edu/news/researcher-receives-18-million-study-asthma-triggers #PulmonaryImaging #LungHealth #AsthmaResearch #NIHGrant #ResearchInnovation #Asthma #PrecisionMedicine #Mizzou",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.688975+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251956-mr-steve-81110131",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232831",
        "source": "LSE_CHAT",
        "data": {
          "author": "mr-steve",
          "content": "...I'm not selling. 1) what i have (~500k) is worth close to f-all 2) i still think they could do well 3) even as a private co, I will still hold my shares 4) at some point they will either a) do well and the shares will be worth selling, b) get bought out for a better return than selling now c) relist at a premium to now or d) disappear into a black hole At current prices, d) won't make any difference, the others probably won't but just might. Spin the wheel, my money's on number 26!",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "0.085",
          "thread_title": "For what its worth...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=7E313B47-BF7F-47AF-BEAC-14BA524C82E1"
        },
        "ingested_at": "2026-02-06T22:28:38.688995+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251857-Balanced--4404567",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.233482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "We keep hearing it's a great product. Says who. The real proof of a great product is high numbers of sales. Here they have struggled to shift product. It's not all the blame of management. Great products sell themselves to some extent. That hasn't happened here. The product has been marketed for years so those in the sector are well aware of it. It's a poor product and/or doesn't fill a need as was originally expected. Being based in the US the company would have had US based funds or investors at some stage.",
          "sentiment": 0.0,
          "engagement": "1,653",
          "price_at_post": "0.085",
          "thread_title": "RE: Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-02-06T22:28:38.689013+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251606-trunky--8344515",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234129",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "There are  plenty of wealthy funds and individuals that could buy this company ,show me where there is a company that has such a great product .if this company was listed on the American market investors would be  all over it",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.085",
          "thread_title": "Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-02-06T22:28:38.689031+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251413-bassman7--3703971",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234709",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hope your \"knowledgable friend\" didn't give you any other tips Lolajamola \u2620\ufe0f Posted in: POLX Posts: 12 RE: Polx24 Mar 2022 18:53 I know what you mean\u2026. It is unsettling but we are holding tight. For us it\u2019s a long term investment, but hoping our patience will pay off soon! Saw our knowledgeable friend yesterday (that first put us onto Polx) and he is still confident so we are trusting his judgement on this. Lolajamola Posted in: POLX Posts: 12 RE: Here we go21 Mar 2022 16:54 Appreciate reading your recommendations on this one. We have also been tipped by another investor on this one as a good bet but it\u2019s reassuring to hear it from another source! Crossing all the digits\u2026.",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-06T22:28:38.689049+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251230-loadofbo-45306420",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235225",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people buying here? Have I missed something? Be lucky to 1 new share for 100 old when it\u2019s delisted.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-06T22:28:38.689067+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251135-Lolajamo-79484932",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lolajamola",
          "content": "Also sticking it out. Lost so much on this one it\u2019s just not worth selling! Holding out for a miracle\u2026!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-06T22:28:38.689085+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251043-JeniH--2344798",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236264",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "I'm staying too - it qualifies for 2 bargain stock screens on Stockopedia so I'm happy to hold for the share price recovery or an offer for the whole company  whichever comes first.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.08",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-06T22:28:38.689130+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251013-Doppo59--2428347",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236801",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "I'm staying put. This seems to be oversold, remember delisting was announced months ago. POLX are in partnership with Phillips who already use the product with Xenoview (FDA approved). My money is on Phillips buying us out, or at least a partnership,  POLX have more money in the bank than the current MC, so not going bust. Who knows how many orders are almost ready to be signed, Asia, India, not forgetting US. A couple of bits of good news and J P Jenkins might have to do some work! It seems most have left now, I'll see it through, waited five years, might as well another year! The tech is still sound, and being used. Wish me luck lol Doppo",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-06T22:28:38.689151+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251524-Latino-17488421",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yep no shares lost here, shareholders can still sell after delisting via JP Jenkins.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-06T22:28:38.689169+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251437-Doppo59--4363150",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Pyueck, I'm not selling yet, I'm too stubborn. We might get an offer of a buyout before the 23rd, who knows. They have money in the bank till H2, I don't think they can ever raise again at the current price. Such great tech, unfortunately run by compete armatures with not a good salesman among them. This BB was full of people all singing the companies praises, not a single post any more. The rich get richer and the poor .... This was posted on here a couple of days ago, you keep your shares and sell (or buy) through J P Jenkins, just harder to do. Good luck fella. The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-06T22:28:38.689187+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-PYUECK-30654640",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238302",
        "source": "LSE_CHAT",
        "data": {
          "author": "PYUECK",
          "content": "I am assuming everybody is now just selling their shares before the 23rd. If you hold in a nominee account I suspect they wont even hold these shares for you in a private company so effectively they will be lost. Even if you keep, assuming the company survives any future fundraising is going to almost completely wipe out existing shareholders anyway. Even if this company has a rosey future, which I doubt, existing shareholders wont be part of it.",
          "sentiment": 0.0,
          "engagement": "773",
          "price_at_post": "0.08",
          "thread_title": "Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-06T22:28:38.689205+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251259-bassman7-87690322",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238717",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "What happened to the poster here who said he bought in after a tip from his Harley St eye surgeon's mate? \ud83d\ude02 Hope he didn't lose too much",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.075",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-06T22:28:38.689222+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251141-ironknut-20233982",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239147",
        "source": "LSE_CHAT",
        "data": {
          "author": "ironknut",
          "content": "At last we mugs who invested here are put out of our misery. At least the losses will reduce capital gains tax donations to Westminster.",
          "sentiment": 0.0,
          "engagement": "1,665",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-06T22:28:38.689240+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251111-Doppo59-76460050",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Thanks Latino. I did speak to my broker (HL) this morning who confirmed those details. They will be writing to me in the next few days to confirm my holding and advising the next step with J P Jenkins. POLX have funds until H2, lets see what happens next. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-06T22:28:38.689258+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251015-Latino--1956223",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240018",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yesterday RNS extract: The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-06T22:28:38.689276+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250921-2reincar--3853234",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240438",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Say hello to Genedrive when you meet in hell!",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.09",
          "thread_title": "Goodbye Polarean",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=28001004-0D99-46D9-AF63-BB068E80A726"
        },
        "ingested_at": "2026-02-06T22:28:38.689294+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250815-Laura202--7176846",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240850",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The matched bargain facilty is at bottom of yesterday RNS",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-06T22:28:38.689312+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252113-shamI89--3408564",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241280",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "There will be other mini spikes to let traped traders out , although I believe last \"p&d\" was orchestrated to let Laura excape with a profit.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-06T22:28:38.689330+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252026-Jacobjoh--8094060",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "With laura.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-06T22:28:38.689349+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252025-Jacobjoh-20428148",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.242119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "In a sad old death threesome here.  Dopper and spunky has to admit and apologise now and they should have listened to me and saved some money.  I tried....you can lead a dopper to water lop .. You nasty people deserve every misfortune you get here.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-06T22:28:38.689368+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251947-Doppo59--1030993",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384442",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunky. I believe that any shares you own, remain yours. It will be harder to trade them though.However I did hear a rumour that polx are setting up something on their website to help. Maybe stick around and hope they don't go bust!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-06T22:28:38.689386+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251845-shamI89--8530303",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384975",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Company has been survining on placings and would do so in near future, so you can imagine what will happen.It is a trend where share holders spend the money and company uses that money to develop a technology to get delisted at the end leaving shareholders high and dry.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-06T22:28:38.689405+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251720-loadofbo-79349958",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.385526",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Yes, probably 1 new share for every 100 old ones, that\u2019s the usual practice.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-06T22:28:38.689423+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251656-Mikewinv-84258207",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikewinvest",
          "content": "TR1s...the dogs that haven't barked!",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "0.105",
          "thread_title": "TR1s",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=698AFB22-A50E-487C-B919-75F58340736B"
        },
        "ingested_at": "2026-02-06T22:28:38.689441+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251650-trunky--7158458",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386636",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will this mean we lose all our investment ?or will we be allocated new shares in the private company?",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.105",
          "thread_title": "Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-06T22:28:38.689459+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251636-Safi123-85481448",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "We were close, certainly winning the vote was on the cards but it seems a large number of PIs were apathetic. Does anyone know if any large stakeholders opposed the move to going private? This company is growing, with international expansion, upcoming trial and proven technology. It will have no issue raising cash. In my view a much better chance of success than most small med tech businesses (some of whom valued in 10s of millions) I\u2019m not convinced ultradilution as a private business is inevitable. For one thing, there\u2019s no guarantee either Nukem or Bracco are willing to fully finance this business further to the tune of 20 million, already owning healthy portions. If a third party wants a stake it will be at a much higher valuation (business is realistically worth at the very least 10-20 million looking at similar AIM businesses) Secondly, 524 million votes in favour suggests Nukem and Bracco somehow obtained the support of other large shareholders. These shareholders would never agree to going private if it means their stakes are obliterated.",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.105",
          "thread_title": "Company valuation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=43B57842-8C07-4F9A-B3B1-1EE524148282"
        },
        "ingested_at": "2026-02-06T22:28:38.689477+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251617-loadofbo--3560227",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387696",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "This is de listing in 8 days, why are people still buying?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-02-06T22:28:38.689495+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-loadofbo--4788959",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388224",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-06T22:28:38.689513+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-Laura202-32142712",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388744",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected but the 20% tried Will the 80% continue to buy ?",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-02-06T22:28:38.689531+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-tuan6-43050293",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389269",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Dont worry  as peoples dont sell when they are  reading in .  only sell when they dont see any value left .  this comoany have more money in its bank account  than its market CAP so there are still  pretty  things left for sell .  even  someone  will jump in  to buy this company  so dont worry  for shareholders as this is thier money and they dont give up that easy.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-06T22:28:38.689548+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-bassman7--4914417",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389791",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "I mean... they announced it live in an advertised public call. Are you honestly putting your posts through googletranslate and back. You know those translation programmes don't make spelling mistakes?",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-06T22:28:38.689566+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-loadofbo-34278018",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390312",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "If they don\u2019t de list they will go bust because they are out of money, can\u2019t raise anymore and can\u2019t sell the company.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-06T22:28:38.689584+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251558-loadofbo--8395124",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390804",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-06T22:28:38.689601+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251555-tuan6--9144551",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391467",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "No RNS is good news as if they pass they have published  it by now.  400% rise next month.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-06T22:28:38.689619+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251545-shamI89-24433884",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391981",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Managed to get another \"p&d\" away......",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.10",
          "thread_title": "Looks like Laura has",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=95DBDD4A-508B-4205-B71E-4DC15152341B"
        },
        "ingested_at": "2026-02-06T22:28:38.689636+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251541-loadofbo-90278697",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.392503",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people still buying here?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-06T22:28:38.689654+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251539-bassman7--1608576",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393006",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Did you not zoom the meeting? They said information would be up on their website \"in due course\".  The meeting was about 5 mins long. It was agreed the company is being delisted. Hearing it from the company live in a zoom call (jiopning details below) was enough confirmation for me \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-06T22:28:38.689673+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251535-Laura202-81143495",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Confirmation or otherwise This drop is on very low volume Mmmmmm",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-06T22:28:38.689692+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251534-share4--1912456",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394027",
        "source": "LSE_CHAT",
        "data": {
          "author": "share4",
          "content": "These are going to end up being known as \"green box\" shares",
          "sentiment": 0.0,
          "engagement": "1,738",
          "price_at_post": "0.10",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-06T22:28:38.689710+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251519-2reincar-48362402",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394469",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Question of only when.",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.10",
          "thread_title": "Genedrive will eventually go the same way!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=EF81FBC2-AF85-428C-BBE4-906724917774"
        },
        "ingested_at": "2026-02-06T22:28:38.689729+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251437-Ilovesus--6082093",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Down 99.8% over the last 5 years. Even though some may have just made 100% . Often these type of rises are meaningless for most. Who honestly got in on the bottom and how long have they been invested? As the company can no longer get away with another placing it would have to issue too many shares and then only raise small amounts. That it now wants to delist is very telling. Its reach the end of the road. Its in a place where raising more through selling shares will not work. This is where most companies on AIM delist. They cannot sell any more shares. PYC is a company like this that may also delist. Seems some on that company post here. AIM companies list in order to raise money. PYC has had so many placings and  has a history of raising unlike this company. That too like this one will no doubt delist. Beware guys AIM is a cesspit.",
          "sentiment": 0.0,
          "engagement": "7,727",
          "price_at_post": "0.11",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-06T22:28:38.689748+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-Shpunken-15508676",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395328",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Yep it is a shame that ppl will miss out on this and big companies again will be the winners",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-06T22:28:38.689767+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-bassman7--9029771",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395735",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Judging by your recent comments Doppo, you seemed to think this would come good, even congratulating otheres on their holdings just a week ago... \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-06T22:28:38.689785+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251406-Doppo59--9022327",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Such a shame, but no surprise! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.13",
          "thread_title": "No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-06T22:28:38.689803+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251405-loadofbo--2766821",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396667",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why on earth would someone buy 7m shares when its de listing?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.13",
          "thread_title": "RE: And... delisted from AIM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=8E783F9A-4C63-461E-ACA1-4513E80D78C0"
        },
        "ingested_at": "2026-02-06T22:28:38.689821+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262043-Doppo59--2315834",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611356",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Rkb007, if you find any news out, can you post in here, i will look. I am a member of a Telegram group also. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-06T22:28:38.689840+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007--7961224",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611798",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Direct",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-06T22:28:38.689858+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007--1686042",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612234",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Same for me with Charles Stanley - they created an individual director account and moved shares for me \u2026",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-06T22:28:38.689876+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261316-Doppo59-80039804",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hi Aims23, I didn't sell my shares, HL are still holding them. Any trades are made though J P Jenkins who HL deal with on my behalf (sell only) i had to move them out of my stocks and shares ISA as Polarean is now a limited company. Are you still holding? GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-06T22:28:38.689894+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23-19837665",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-06T22:28:38.689913+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh-40113050",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613495",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,274",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-06T22:28:38.689931+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan-63635068",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613908",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-06T22:28:38.689949+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6-31632081",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614336",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-06T22:28:38.689967+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu-36727629",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614743",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-06T22:28:38.689985+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu--1730845",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615184",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-06T22:28:38.690003+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59-81676520",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-06T22:28:38.690021+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59--2169982",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-06T22:28:38.690039+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky--8078757",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616436",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-06T22:28:38.690057+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59--2460948",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616860",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-06T22:28:38.690075+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH-91074021",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617280",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-06T22:28:38.690093+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo--3812884",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617687",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-06T22:28:38.690127+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202-80841882",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618105",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-06T22:28:38.690145+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59--8095616",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618523",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-06T22:28:38.690164+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888--5994970",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.690188+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59--7033571",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619359",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-06T22:28:38.690207+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra-12986827",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619832",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,244",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-06T22:28:38.690225+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202-45650553",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.690243+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202--7513949",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.690262+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH--7567452",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621090",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.690280+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo-52084931",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621514",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-06T22:28:38.690299+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250806-loadofbo-16649307",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229293",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Great, that should last about a year, then what?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.363874+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250732-JeniH--7049284",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229904",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Still listed until tomorrow and definitely not irrelevant if you still own shares",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.363913+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251737-Shpunken-18727317",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.230631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Cause it\u2019s now irrelevant, company is no longer public\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.363945+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251225-Doppo59-91593064",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.231490",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Good find Latino. You are correct, why no RNS ....  people are actually using Polarean XenonMRI With that news, a buy out and a couple of orders, this could be re-listed on the American market!! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.363977+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251109-Latino--3837382",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Why no RNS..? https://x.com/PolareanImaging/status/2001034816859394174 Congratulations to Robby Thomen, PhD and team on receiving major funding for this exciting asthma research milestone! \ud83c\udf89 We\u2019re thrilled to see new research from the @mumedicine receive a $1.8-million grant from the @NIH to advance understanding of asthma triggers and disease mechanisms. Robby and his team are using Polarean's #XenonMRI platform to visualize regional lung function and investigate whether airway hyperconstriction in asthma also happens in the lung's blood vessels, or vasculature. This long-standing hypothesis in asthma research has been challenging to study, and Xenon MRI offers a new way to explore functional relationships that are not accessible with conventional imaging. This work represents an important step toward more precise, personalized approaches to asthma care and may help explain why some patients respond well to treatment while others continue to experience uncontrolled disease. We look forward to seeing how this research helps move asthma care forward! Learn more: https://medicine.missouri.edu/news/researcher-receives-18-million-study-asthma-triggers #PulmonaryImaging #LungHealth #AsthmaResearch #NIHGrant #ResearchInnovation #Asthma #PrecisionMedicine #Mizzou",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.364010+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251956-mr-steve-40624089",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232831",
        "source": "LSE_CHAT",
        "data": {
          "author": "mr-steve",
          "content": "...I'm not selling. 1) what i have (~500k) is worth close to f-all 2) i still think they could do well 3) even as a private co, I will still hold my shares 4) at some point they will either a) do well and the shares will be worth selling, b) get bought out for a better return than selling now c) relist at a premium to now or d) disappear into a black hole At current prices, d) won't make any difference, the others probably won't but just might. Spin the wheel, my money's on number 26!",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "0.085",
          "thread_title": "For what its worth...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=7E313B47-BF7F-47AF-BEAC-14BA524C82E1"
        },
        "ingested_at": "2026-02-09T22:49:32.364044+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251857-Balanced--9021880",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.233482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "We keep hearing it's a great product. Says who. The real proof of a great product is high numbers of sales. Here they have struggled to shift product. It's not all the blame of management. Great products sell themselves to some extent. That hasn't happened here. The product has been marketed for years so those in the sector are well aware of it. It's a poor product and/or doesn't fill a need as was originally expected. Being based in the US the company would have had US based funds or investors at some stage.",
          "sentiment": 0.0,
          "engagement": "1,653",
          "price_at_post": "0.085",
          "thread_title": "RE: Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-02-09T22:49:32.364076+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251606-trunky--6854968",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234129",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "There are  plenty of wealthy funds and individuals that could buy this company ,show me where there is a company that has such a great product .if this company was listed on the American market investors would be  all over it",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.085",
          "thread_title": "Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-02-09T22:49:32.364136+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251413-bassman7-68564518",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234709",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hope your \"knowledgable friend\" didn't give you any other tips Lolajamola \u2620\ufe0f Posted in: POLX Posts: 12 RE: Polx24 Mar 2022 18:53 I know what you mean\u2026. It is unsettling but we are holding tight. For us it\u2019s a long term investment, but hoping our patience will pay off soon! Saw our knowledgeable friend yesterday (that first put us onto Polx) and he is still confident so we are trusting his judgement on this. Lolajamola Posted in: POLX Posts: 12 RE: Here we go21 Mar 2022 16:54 Appreciate reading your recommendations on this one. We have also been tipped by another investor on this one as a good bet but it\u2019s reassuring to hear it from another source! Crossing all the digits\u2026.",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-09T22:49:32.364175+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251230-loadofbo-30806630",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235225",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people buying here? Have I missed something? Be lucky to 1 new share for 100 old when it\u2019s delisted.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-09T22:49:32.364211+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251135-Lolajamo-35676039",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lolajamola",
          "content": "Also sticking it out. Lost so much on this one it\u2019s just not worth selling! Holding out for a miracle\u2026!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-09T22:49:32.364232+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251043-JeniH-58329980",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236264",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "I'm staying too - it qualifies for 2 bargain stock screens on Stockopedia so I'm happy to hold for the share price recovery or an offer for the whole company  whichever comes first.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.08",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-09T22:49:32.364250+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251013-Doppo59-27105186",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236801",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "I'm staying put. This seems to be oversold, remember delisting was announced months ago. POLX are in partnership with Phillips who already use the product with Xenoview (FDA approved). My money is on Phillips buying us out, or at least a partnership,  POLX have more money in the bank than the current MC, so not going bust. Who knows how many orders are almost ready to be signed, Asia, India, not forgetting US. A couple of bits of good news and J P Jenkins might have to do some work! It seems most have left now, I'll see it through, waited five years, might as well another year! The tech is still sound, and being used. Wish me luck lol Doppo",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-09T22:49:32.364268+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251524-Latino-83291115",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yep no shares lost here, shareholders can still sell after delisting via JP Jenkins.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-09T22:49:32.364287+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251437-Doppo59--8630446",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Pyueck, I'm not selling yet, I'm too stubborn. We might get an offer of a buyout before the 23rd, who knows. They have money in the bank till H2, I don't think they can ever raise again at the current price. Such great tech, unfortunately run by compete armatures with not a good salesman among them. This BB was full of people all singing the companies praises, not a single post any more. The rich get richer and the poor .... This was posted on here a couple of days ago, you keep your shares and sell (or buy) through J P Jenkins, just harder to do. Good luck fella. The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-09T22:49:32.364305+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-PYUECK-82585772",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238302",
        "source": "LSE_CHAT",
        "data": {
          "author": "PYUECK",
          "content": "I am assuming everybody is now just selling their shares before the 23rd. If you hold in a nominee account I suspect they wont even hold these shares for you in a private company so effectively they will be lost. Even if you keep, assuming the company survives any future fundraising is going to almost completely wipe out existing shareholders anyway. Even if this company has a rosey future, which I doubt, existing shareholders wont be part of it.",
          "sentiment": 0.0,
          "engagement": "773",
          "price_at_post": "0.08",
          "thread_title": "Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-09T22:49:32.364323+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251259-bassman7-89525924",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238717",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "What happened to the poster here who said he bought in after a tip from his Harley St eye surgeon's mate? \ud83d\ude02 Hope he didn't lose too much",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.075",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-09T22:49:32.364341+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251141-ironknut-88328382",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239147",
        "source": "LSE_CHAT",
        "data": {
          "author": "ironknut",
          "content": "At last we mugs who invested here are put out of our misery. At least the losses will reduce capital gains tax donations to Westminster.",
          "sentiment": 0.0,
          "engagement": "1,665",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-09T22:49:32.364359+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251111-Doppo59--3635990",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Thanks Latino. I did speak to my broker (HL) this morning who confirmed those details. They will be writing to me in the next few days to confirm my holding and advising the next step with J P Jenkins. POLX have funds until H2, lets see what happens next. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-09T22:49:32.364377+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251015-Latino-19336347",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240018",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yesterday RNS extract: The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-09T22:49:32.364395+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250921-2reincar-32425693",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240438",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Say hello to Genedrive when you meet in hell!",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.09",
          "thread_title": "Goodbye Polarean",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=28001004-0D99-46D9-AF63-BB068E80A726"
        },
        "ingested_at": "2026-02-09T22:49:32.364413+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250815-Laura202-45244156",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240850",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The matched bargain facilty is at bottom of yesterday RNS",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-09T22:49:32.364432+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252113-shamI89--8166707",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241280",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "There will be other mini spikes to let traped traders out , although I believe last \"p&d\" was orchestrated to let Laura excape with a profit.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-09T22:49:32.364449+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252026-Jacobjoh--5711182",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "With laura.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-09T22:49:32.364468+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252025-Jacobjoh-11015025",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.242119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "In a sad old death threesome here.  Dopper and spunky has to admit and apologise now and they should have listened to me and saved some money.  I tried....you can lead a dopper to water lop .. You nasty people deserve every misfortune you get here.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-09T22:49:32.364485+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251947-Doppo59-37880644",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384442",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunky. I believe that any shares you own, remain yours. It will be harder to trade them though.However I did hear a rumour that polx are setting up something on their website to help. Maybe stick around and hope they don't go bust!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-09T22:49:32.364504+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251845-shamI89-61701154",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384975",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Company has been survining on placings and would do so in near future, so you can imagine what will happen.It is a trend where share holders spend the money and company uses that money to develop a technology to get delisted at the end leaving shareholders high and dry.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-09T22:49:32.364523+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251720-loadofbo-15634014",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.385526",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Yes, probably 1 new share for every 100 old ones, that\u2019s the usual practice.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-09T22:49:32.364541+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251656-Mikewinv--4262480",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikewinvest",
          "content": "TR1s...the dogs that haven't barked!",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "0.105",
          "thread_title": "TR1s",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=698AFB22-A50E-487C-B919-75F58340736B"
        },
        "ingested_at": "2026-02-09T22:49:32.364559+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251650-trunky--9941046",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386636",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will this mean we lose all our investment ?or will we be allocated new shares in the private company?",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.105",
          "thread_title": "Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-09T22:49:32.364576+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251636-Safi123--8316985",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "We were close, certainly winning the vote was on the cards but it seems a large number of PIs were apathetic. Does anyone know if any large stakeholders opposed the move to going private? This company is growing, with international expansion, upcoming trial and proven technology. It will have no issue raising cash. In my view a much better chance of success than most small med tech businesses (some of whom valued in 10s of millions) I\u2019m not convinced ultradilution as a private business is inevitable. For one thing, there\u2019s no guarantee either Nukem or Bracco are willing to fully finance this business further to the tune of 20 million, already owning healthy portions. If a third party wants a stake it will be at a much higher valuation (business is realistically worth at the very least 10-20 million looking at similar AIM businesses) Secondly, 524 million votes in favour suggests Nukem and Bracco somehow obtained the support of other large shareholders. These shareholders would never agree to going private if it means their stakes are obliterated.",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.105",
          "thread_title": "Company valuation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=43B57842-8C07-4F9A-B3B1-1EE524148282"
        },
        "ingested_at": "2026-02-09T22:49:32.364594+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251617-loadofbo-60333418",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387696",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "This is de listing in 8 days, why are people still buying?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-02-09T22:49:32.364612+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-loadofbo--6412909",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388224",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-09T22:49:32.364630+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-Laura202--2526322",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388744",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected but the 20% tried Will the 80% continue to buy ?",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-02-09T22:49:32.364648+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-tuan6-36676077",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389269",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Dont worry  as peoples dont sell when they are  reading in .  only sell when they dont see any value left .  this comoany have more money in its bank account  than its market CAP so there are still  pretty  things left for sell .  even  someone  will jump in  to buy this company  so dont worry  for shareholders as this is thier money and they dont give up that easy.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-09T22:49:32.364666+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-bassman7-60281986",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389791",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "I mean... they announced it live in an advertised public call. Are you honestly putting your posts through googletranslate and back. You know those translation programmes don't make spelling mistakes?",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-09T22:49:32.364684+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-loadofbo--5919663",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390312",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "If they don\u2019t de list they will go bust because they are out of money, can\u2019t raise anymore and can\u2019t sell the company.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-09T22:49:32.364701+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251558-loadofbo--2157266",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390804",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-09T22:49:32.364719+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251555-tuan6--7957017",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391467",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "No RNS is good news as if they pass they have published  it by now.  400% rise next month.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-09T22:49:32.364737+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251545-shamI89-52732367",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391981",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Managed to get another \"p&d\" away......",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.10",
          "thread_title": "Looks like Laura has",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=95DBDD4A-508B-4205-B71E-4DC15152341B"
        },
        "ingested_at": "2026-02-09T22:49:32.364755+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251541-loadofbo-69651386",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.392503",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people still buying here?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-09T22:49:32.364773+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251539-bassman7--8233396",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393006",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Did you not zoom the meeting? They said information would be up on their website \"in due course\".  The meeting was about 5 mins long. It was agreed the company is being delisted. Hearing it from the company live in a zoom call (jiopning details below) was enough confirmation for me \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-09T22:49:32.364792+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251535-Laura202--2920300",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Confirmation or otherwise This drop is on very low volume Mmmmmm",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-09T22:49:32.364811+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251534-share4--9140497",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394027",
        "source": "LSE_CHAT",
        "data": {
          "author": "share4",
          "content": "These are going to end up being known as \"green box\" shares",
          "sentiment": 0.0,
          "engagement": "1,738",
          "price_at_post": "0.10",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-09T22:49:32.364830+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251519-2reincar-10349685",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394469",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Question of only when.",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.10",
          "thread_title": "Genedrive will eventually go the same way!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=EF81FBC2-AF85-428C-BBE4-906724917774"
        },
        "ingested_at": "2026-02-09T22:49:32.364849+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251437-Ilovesus--8457803",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Down 99.8% over the last 5 years. Even though some may have just made 100% . Often these type of rises are meaningless for most. Who honestly got in on the bottom and how long have they been invested? As the company can no longer get away with another placing it would have to issue too many shares and then only raise small amounts. That it now wants to delist is very telling. Its reach the end of the road. Its in a place where raising more through selling shares will not work. This is where most companies on AIM delist. They cannot sell any more shares. PYC is a company like this that may also delist. Seems some on that company post here. AIM companies list in order to raise money. PYC has had so many placings and  has a history of raising unlike this company. That too like this one will no doubt delist. Beware guys AIM is a cesspit.",
          "sentiment": 0.0,
          "engagement": "7,727",
          "price_at_post": "0.11",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-09T22:49:32.364868+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-Shpunken-40718476",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395328",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Yep it is a shame that ppl will miss out on this and big companies again will be the winners",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-09T22:49:32.364887+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-bassman7-88195030",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395735",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Judging by your recent comments Doppo, you seemed to think this would come good, even congratulating otheres on their holdings just a week ago... \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-09T22:49:32.364905+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251406-Doppo59--7720887",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Such a shame, but no surprise! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.13",
          "thread_title": "No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-09T22:49:32.364923+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251405-loadofbo--3970532",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396667",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why on earth would someone buy 7m shares when its de listing?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.13",
          "thread_title": "RE: And... delisted from AIM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=8E783F9A-4C63-461E-ACA1-4513E80D78C0"
        },
        "ingested_at": "2026-02-09T22:49:32.364941+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262043-Doppo59-24476904",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611356",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Rkb007, if you find any news out, can you post in here, i will look. I am a member of a Telegram group also. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-09T22:49:32.364960+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007-55659224",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611798",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Direct",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-09T22:49:32.364978+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007-64227329",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612234",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Same for me with Charles Stanley - they created an individual director account and moved shares for me \u2026",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-09T22:49:32.364996+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261316-Doppo59--7457213",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hi Aims23, I didn't sell my shares, HL are still holding them. Any trades are made though J P Jenkins who HL deal with on my behalf (sell only) i had to move them out of my stocks and shares ISA as Polarean is now a limited company. Are you still holding? GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-09T22:49:32.365014+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23--8450148",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-09T22:49:32.365033+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh--6592675",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613495",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,274",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-09T22:49:32.365051+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan-40883515",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613908",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-09T22:49:32.365070+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6-52174680",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614336",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-09T22:49:32.365087+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu-25355315",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614743",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-09T22:49:32.365172+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu--8028153",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615184",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-09T22:49:32.365207+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59-69700417",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-09T22:49:32.365244+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59-77437891",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-09T22:49:32.365280+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky-90903535",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616436",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-09T22:49:32.365318+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59-84328298",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616860",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-09T22:49:32.365341+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH--6032375",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617280",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-09T22:49:32.365378+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo--8050802",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617687",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-09T22:49:32.365416+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202-77985973",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618105",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-09T22:49:32.365454+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59--7756763",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618523",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-09T22:49:32.365491+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888-72351464",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.365528+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59--5386281",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619359",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-09T22:49:32.365564+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra-18735477",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619832",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,244",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-09T22:49:32.365603+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202-87091655",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.365639+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202--5488181",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.365673+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH--1114321",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621090",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.365719+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo-52338039",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621514",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-09T22:49:32.365756+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250806-loadofbo--7901542",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229293",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Great, that should last about a year, then what?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.233400+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250732-JeniH--7330306",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229904",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Still listed until tomorrow and definitely not irrelevant if you still own shares",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.233435+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251737-Shpunken-97509874",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.230631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Cause it\u2019s now irrelevant, company is no longer public\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.233456+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251225-Doppo59--2927843",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.231490",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Good find Latino. You are correct, why no RNS ....  people are actually using Polarean XenonMRI With that news, a buy out and a couple of orders, this could be re-listed on the American market!! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.233475+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251109-Latino--3617582",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Why no RNS..? https://x.com/PolareanImaging/status/2001034816859394174 Congratulations to Robby Thomen, PhD and team on receiving major funding for this exciting asthma research milestone! \ud83c\udf89 We\u2019re thrilled to see new research from the @mumedicine receive a $1.8-million grant from the @NIH to advance understanding of asthma triggers and disease mechanisms. Robby and his team are using Polarean's #XenonMRI platform to visualize regional lung function and investigate whether airway hyperconstriction in asthma also happens in the lung's blood vessels, or vasculature. This long-standing hypothesis in asthma research has been challenging to study, and Xenon MRI offers a new way to explore functional relationships that are not accessible with conventional imaging. This work represents an important step toward more precise, personalized approaches to asthma care and may help explain why some patients respond well to treatment while others continue to experience uncontrolled disease. We look forward to seeing how this research helps move asthma care forward! Learn more: https://medicine.missouri.edu/news/researcher-receives-18-million-study-asthma-triggers #PulmonaryImaging #LungHealth #AsthmaResearch #NIHGrant #ResearchInnovation #Asthma #PrecisionMedicine #Mizzou",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.233494+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251956-mr-steve-70294464",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232831",
        "source": "LSE_CHAT",
        "data": {
          "author": "mr-steve",
          "content": "...I'm not selling. 1) what i have (~500k) is worth close to f-all 2) i still think they could do well 3) even as a private co, I will still hold my shares 4) at some point they will either a) do well and the shares will be worth selling, b) get bought out for a better return than selling now c) relist at a premium to now or d) disappear into a black hole At current prices, d) won't make any difference, the others probably won't but just might. Spin the wheel, my money's on number 26!",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "0.085",
          "thread_title": "For what its worth...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=7E313B47-BF7F-47AF-BEAC-14BA524C82E1"
        },
        "ingested_at": "2026-02-10T22:27:07.233512+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251857-Balanced--7412163",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.233482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "We keep hearing it's a great product. Says who. The real proof of a great product is high numbers of sales. Here they have struggled to shift product. It's not all the blame of management. Great products sell themselves to some extent. That hasn't happened here. The product has been marketed for years so those in the sector are well aware of it. It's a poor product and/or doesn't fill a need as was originally expected. Being based in the US the company would have had US based funds or investors at some stage.",
          "sentiment": 0.0,
          "engagement": "1,653",
          "price_at_post": "0.085",
          "thread_title": "RE: Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-02-10T22:27:07.233532+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251606-trunky--6479468",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234129",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "There are  plenty of wealthy funds and individuals that could buy this company ,show me where there is a company that has such a great product .if this company was listed on the American market investors would be  all over it",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.085",
          "thread_title": "Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-02-10T22:27:07.233550+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251413-bassman7--7077165",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234709",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hope your \"knowledgable friend\" didn't give you any other tips Lolajamola \u2620\ufe0f Posted in: POLX Posts: 12 RE: Polx24 Mar 2022 18:53 I know what you mean\u2026. It is unsettling but we are holding tight. For us it\u2019s a long term investment, but hoping our patience will pay off soon! Saw our knowledgeable friend yesterday (that first put us onto Polx) and he is still confident so we are trusting his judgement on this. Lolajamola Posted in: POLX Posts: 12 RE: Here we go21 Mar 2022 16:54 Appreciate reading your recommendations on this one. We have also been tipped by another investor on this one as a good bet but it\u2019s reassuring to hear it from another source! Crossing all the digits\u2026.",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-10T22:27:07.233568+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251230-loadofbo--4751355",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235225",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people buying here? Have I missed something? Be lucky to 1 new share for 100 old when it\u2019s delisted.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-10T22:27:07.233586+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251135-Lolajamo-51189864",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lolajamola",
          "content": "Also sticking it out. Lost so much on this one it\u2019s just not worth selling! Holding out for a miracle\u2026!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-10T22:27:07.233605+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251043-JeniH-49293472",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236264",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "I'm staying too - it qualifies for 2 bargain stock screens on Stockopedia so I'm happy to hold for the share price recovery or an offer for the whole company  whichever comes first.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.08",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-10T22:27:07.233623+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251013-Doppo59-20294000",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236801",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "I'm staying put. This seems to be oversold, remember delisting was announced months ago. POLX are in partnership with Phillips who already use the product with Xenoview (FDA approved). My money is on Phillips buying us out, or at least a partnership,  POLX have more money in the bank than the current MC, so not going bust. Who knows how many orders are almost ready to be signed, Asia, India, not forgetting US. A couple of bits of good news and J P Jenkins might have to do some work! It seems most have left now, I'll see it through, waited five years, might as well another year! The tech is still sound, and being used. Wish me luck lol Doppo",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-10T22:27:07.233641+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251524-Latino-65957513",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yep no shares lost here, shareholders can still sell after delisting via JP Jenkins.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-10T22:27:07.233659+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251437-Doppo59-18995007",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Pyueck, I'm not selling yet, I'm too stubborn. We might get an offer of a buyout before the 23rd, who knows. They have money in the bank till H2, I don't think they can ever raise again at the current price. Such great tech, unfortunately run by compete armatures with not a good salesman among them. This BB was full of people all singing the companies praises, not a single post any more. The rich get richer and the poor .... This was posted on here a couple of days ago, you keep your shares and sell (or buy) through J P Jenkins, just harder to do. Good luck fella. The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-10T22:27:07.233677+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-PYUECK--7632750",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238302",
        "source": "LSE_CHAT",
        "data": {
          "author": "PYUECK",
          "content": "I am assuming everybody is now just selling their shares before the 23rd. If you hold in a nominee account I suspect they wont even hold these shares for you in a private company so effectively they will be lost. Even if you keep, assuming the company survives any future fundraising is going to almost completely wipe out existing shareholders anyway. Even if this company has a rosey future, which I doubt, existing shareholders wont be part of it.",
          "sentiment": 0.0,
          "engagement": "773",
          "price_at_post": "0.08",
          "thread_title": "Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-10T22:27:07.233695+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251259-bassman7-61345552",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238717",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "What happened to the poster here who said he bought in after a tip from his Harley St eye surgeon's mate? \ud83d\ude02 Hope he didn't lose too much",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.075",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-10T22:27:07.233713+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251141-ironknut-66847203",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239147",
        "source": "LSE_CHAT",
        "data": {
          "author": "ironknut",
          "content": "At last we mugs who invested here are put out of our misery. At least the losses will reduce capital gains tax donations to Westminster.",
          "sentiment": 0.0,
          "engagement": "1,665",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-10T22:27:07.233731+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251111-Doppo59-36903281",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Thanks Latino. I did speak to my broker (HL) this morning who confirmed those details. They will be writing to me in the next few days to confirm my holding and advising the next step with J P Jenkins. POLX have funds until H2, lets see what happens next. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-10T22:27:07.233750+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251015-Latino-23603407",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240018",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yesterday RNS extract: The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-10T22:27:07.233768+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250921-2reincar-46489466",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240438",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Say hello to Genedrive when you meet in hell!",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.09",
          "thread_title": "Goodbye Polarean",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=28001004-0D99-46D9-AF63-BB068E80A726"
        },
        "ingested_at": "2026-02-10T22:27:07.233786+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250815-Laura202--1217377",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240850",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The matched bargain facilty is at bottom of yesterday RNS",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-10T22:27:07.233804+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252113-shamI89--1752087",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241280",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "There will be other mini spikes to let traped traders out , although I believe last \"p&d\" was orchestrated to let Laura excape with a profit.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-10T22:27:07.233822+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252026-Jacobjoh-92030445",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "With laura.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-10T22:27:07.233840+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252025-Jacobjoh--3206152",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.242119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "In a sad old death threesome here.  Dopper and spunky has to admit and apologise now and they should have listened to me and saved some money.  I tried....you can lead a dopper to water lop .. You nasty people deserve every misfortune you get here.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-10T22:27:07.233858+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251947-Doppo59-79916975",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384442",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunky. I believe that any shares you own, remain yours. It will be harder to trade them though.However I did hear a rumour that polx are setting up something on their website to help. Maybe stick around and hope they don't go bust!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-10T22:27:07.233876+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251845-shamI89-74171079",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384975",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Company has been survining on placings and would do so in near future, so you can imagine what will happen.It is a trend where share holders spend the money and company uses that money to develop a technology to get delisted at the end leaving shareholders high and dry.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-10T22:27:07.233894+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251720-loadofbo-79393647",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.385526",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Yes, probably 1 new share for every 100 old ones, that\u2019s the usual practice.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-10T22:27:07.233911+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251656-Mikewinv--2800181",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikewinvest",
          "content": "TR1s...the dogs that haven't barked!",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "0.105",
          "thread_title": "TR1s",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=698AFB22-A50E-487C-B919-75F58340736B"
        },
        "ingested_at": "2026-02-10T22:27:07.233929+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251650-trunky--1969237",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386636",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will this mean we lose all our investment ?or will we be allocated new shares in the private company?",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.105",
          "thread_title": "Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-10T22:27:07.233947+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251636-Safi123-35059070",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "We were close, certainly winning the vote was on the cards but it seems a large number of PIs were apathetic. Does anyone know if any large stakeholders opposed the move to going private? This company is growing, with international expansion, upcoming trial and proven technology. It will have no issue raising cash. In my view a much better chance of success than most small med tech businesses (some of whom valued in 10s of millions) I\u2019m not convinced ultradilution as a private business is inevitable. For one thing, there\u2019s no guarantee either Nukem or Bracco are willing to fully finance this business further to the tune of 20 million, already owning healthy portions. If a third party wants a stake it will be at a much higher valuation (business is realistically worth at the very least 10-20 million looking at similar AIM businesses) Secondly, 524 million votes in favour suggests Nukem and Bracco somehow obtained the support of other large shareholders. These shareholders would never agree to going private if it means their stakes are obliterated.",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.105",
          "thread_title": "Company valuation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=43B57842-8C07-4F9A-B3B1-1EE524148282"
        },
        "ingested_at": "2026-02-10T22:27:07.233965+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251617-loadofbo--5137638",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387696",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "This is de listing in 8 days, why are people still buying?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-02-10T22:27:07.233983+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-loadofbo-85487715",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388224",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-10T22:27:07.234001+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-Laura202-67752650",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388744",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected but the 20% tried Will the 80% continue to buy ?",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-02-10T22:27:07.234019+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-tuan6-61885588",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389269",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Dont worry  as peoples dont sell when they are  reading in .  only sell when they dont see any value left .  this comoany have more money in its bank account  than its market CAP so there are still  pretty  things left for sell .  even  someone  will jump in  to buy this company  so dont worry  for shareholders as this is thier money and they dont give up that easy.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-10T22:27:07.234037+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-bassman7-51024958",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389791",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "I mean... they announced it live in an advertised public call. Are you honestly putting your posts through googletranslate and back. You know those translation programmes don't make spelling mistakes?",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-10T22:27:07.234055+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-loadofbo--1588456",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390312",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "If they don\u2019t de list they will go bust because they are out of money, can\u2019t raise anymore and can\u2019t sell the company.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-10T22:27:07.234073+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251558-loadofbo--5401605",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390804",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-10T22:27:07.234091+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251555-tuan6-50784868",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391467",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "No RNS is good news as if they pass they have published  it by now.  400% rise next month.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-10T22:27:07.234134+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251545-shamI89--2754907",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391981",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Managed to get another \"p&d\" away......",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.10",
          "thread_title": "Looks like Laura has",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=95DBDD4A-508B-4205-B71E-4DC15152341B"
        },
        "ingested_at": "2026-02-10T22:27:07.234152+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251541-loadofbo-30351919",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.392503",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people still buying here?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-10T22:27:07.234171+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251539-bassman7-77668084",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393006",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Did you not zoom the meeting? They said information would be up on their website \"in due course\".  The meeting was about 5 mins long. It was agreed the company is being delisted. Hearing it from the company live in a zoom call (jiopning details below) was enough confirmation for me \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-10T22:27:07.234190+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251535-Laura202-35063486",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Confirmation or otherwise This drop is on very low volume Mmmmmm",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-10T22:27:07.234208+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251534-share4-75558800",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394027",
        "source": "LSE_CHAT",
        "data": {
          "author": "share4",
          "content": "These are going to end up being known as \"green box\" shares",
          "sentiment": 0.0,
          "engagement": "1,738",
          "price_at_post": "0.10",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-10T22:27:07.234227+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251519-2reincar-18494514",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394469",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Question of only when.",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.10",
          "thread_title": "Genedrive will eventually go the same way!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=EF81FBC2-AF85-428C-BBE4-906724917774"
        },
        "ingested_at": "2026-02-10T22:27:07.234245+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251437-Ilovesus--2646560",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Down 99.8% over the last 5 years. Even though some may have just made 100% . Often these type of rises are meaningless for most. Who honestly got in on the bottom and how long have they been invested? As the company can no longer get away with another placing it would have to issue too many shares and then only raise small amounts. That it now wants to delist is very telling. Its reach the end of the road. Its in a place where raising more through selling shares will not work. This is where most companies on AIM delist. They cannot sell any more shares. PYC is a company like this that may also delist. Seems some on that company post here. AIM companies list in order to raise money. PYC has had so many placings and  has a history of raising unlike this company. That too like this one will no doubt delist. Beware guys AIM is a cesspit.",
          "sentiment": 0.0,
          "engagement": "7,727",
          "price_at_post": "0.11",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-10T22:27:07.234263+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-Shpunken--1934121",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395328",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Yep it is a shame that ppl will miss out on this and big companies again will be the winners",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-10T22:27:07.234282+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-bassman7-59076264",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395735",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Judging by your recent comments Doppo, you seemed to think this would come good, even congratulating otheres on their holdings just a week ago... \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-10T22:27:07.234301+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251406-Doppo59--8096901",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Such a shame, but no surprise! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.13",
          "thread_title": "No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-10T22:27:07.234319+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251405-loadofbo--3783700",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396667",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why on earth would someone buy 7m shares when its de listing?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.13",
          "thread_title": "RE: And... delisted from AIM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=8E783F9A-4C63-461E-ACA1-4513E80D78C0"
        },
        "ingested_at": "2026-02-10T22:27:07.234338+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262043-Doppo59-59269938",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611356",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Rkb007, if you find any news out, can you post in here, i will look. I am a member of a Telegram group also. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-10T22:27:07.234356+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007-31069963",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611798",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Direct",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-10T22:27:07.234375+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007--6731426",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612234",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Same for me with Charles Stanley - they created an individual director account and moved shares for me \u2026",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-10T22:27:07.234393+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261316-Doppo59--8641025",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hi Aims23, I didn't sell my shares, HL are still holding them. Any trades are made though J P Jenkins who HL deal with on my behalf (sell only) i had to move them out of my stocks and shares ISA as Polarean is now a limited company. Are you still holding? GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-10T22:27:07.234411+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23--8458070",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-10T22:27:07.234429+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh--7468158",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613495",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,274",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-10T22:27:07.234448+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan-56745017",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613908",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-10T22:27:07.234466+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6--1975307",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614336",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-10T22:27:07.234484+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu--3417572",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614743",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-10T22:27:07.234502+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu-26681967",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615184",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-10T22:27:07.234521+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59-79907982",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-10T22:27:07.234538+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59-20422548",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-10T22:27:07.234557+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky--8180792",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616436",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-10T22:27:07.234574+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59--1528910",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616860",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-10T22:27:07.234593+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH-42421253",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617280",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-10T22:27:07.234612+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo--3555891",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617687",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-10T22:27:07.234630+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202-58104476",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618105",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-10T22:27:07.234648+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59-26046784",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618523",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-10T22:27:07.234666+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888-31147284",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.234684+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59-29667410",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619359",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-10T22:27:07.234702+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra--1938874",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619832",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,244",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-10T22:27:07.234721+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202--1374619",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.234739+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202--6612815",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.234757+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH-28717204",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621090",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.234775+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo--5500922",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621514",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-10T22:27:07.234793+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250806-loadofbo--2840759",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229293",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Great, that should last about a year, then what?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.719985+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250732-JeniH-39365807",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.229904",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Still listed until tomorrow and definitely not irrelevant if you still own shares",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.720009+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251737-Shpunken-78274021",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.230631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Cause it\u2019s now irrelevant, company is no longer public\u2026",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.720029+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251225-Doppo59--5830533",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.231490",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Good find Latino. You are correct, why no RNS ....  people are actually using Polarean XenonMRI With that news, a buy out and a couple of orders, this could be re-listed on the American market!! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.720048+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251109-Latino--5704415",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Why no RNS..? https://x.com/PolareanImaging/status/2001034816859394174 Congratulations to Robby Thomen, PhD and team on receiving major funding for this exciting asthma research milestone! \ud83c\udf89 We\u2019re thrilled to see new research from the @mumedicine receive a $1.8-million grant from the @NIH to advance understanding of asthma triggers and disease mechanisms. Robby and his team are using Polarean's #XenonMRI platform to visualize regional lung function and investigate whether airway hyperconstriction in asthma also happens in the lung's blood vessels, or vasculature. This long-standing hypothesis in asthma research has been challenging to study, and Xenon MRI offers a new way to explore functional relationships that are not accessible with conventional imaging. This work represents an important step toward more precise, personalized approaches to asthma care and may help explain why some patients respond well to treatment while others continue to experience uncontrolled disease. We look forward to seeing how this research helps move asthma care forward! Learn more: https://medicine.missouri.edu/news/researcher-receives-18-million-study-asthma-triggers #PulmonaryImaging #LungHealth #AsthmaResearch #NIHGrant #ResearchInnovation #Asthma #PrecisionMedicine #Mizzou",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.720066+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251956-mr-steve-39908178",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.232831",
        "source": "LSE_CHAT",
        "data": {
          "author": "mr-steve",
          "content": "...I'm not selling. 1) what i have (~500k) is worth close to f-all 2) i still think they could do well 3) even as a private co, I will still hold my shares 4) at some point they will either a) do well and the shares will be worth selling, b) get bought out for a better return than selling now c) relist at a premium to now or d) disappear into a black hole At current prices, d) won't make any difference, the others probably won't but just might. Spin the wheel, my money's on number 26!",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "0.085",
          "thread_title": "For what its worth...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=7E313B47-BF7F-47AF-BEAC-14BA524C82E1"
        },
        "ingested_at": "2026-02-11T16:51:14.720085+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251857-Balanced--7476003",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.233482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Balanced66",
          "content": "We keep hearing it's a great product. Says who. The real proof of a great product is high numbers of sales. Here they have struggled to shift product. It's not all the blame of management. Great products sell themselves to some extent. That hasn't happened here. The product has been marketed for years so those in the sector are well aware of it. It's a poor product and/or doesn't fill a need as was originally expected. Being based in the US the company would have had US based funds or investors at some stage.",
          "sentiment": 0.0,
          "engagement": "1,653",
          "price_at_post": "0.085",
          "thread_title": "RE: Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-02-11T16:51:14.720121+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251606-trunky--4110460",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234129",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "There are  plenty of wealthy funds and individuals that could buy this company ,show me where there is a company that has such a great product .if this company was listed on the American market investors would be  all over it",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.085",
          "thread_title": "Risk capital",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=5FBAD33F-E22D-4038-9AA2-BBCB169775F6"
        },
        "ingested_at": "2026-02-11T16:51:14.720142+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251413-bassman7-41360126",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.234709",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Hope your \"knowledgable friend\" didn't give you any other tips Lolajamola \u2620\ufe0f Posted in: POLX Posts: 12 RE: Polx24 Mar 2022 18:53 I know what you mean\u2026. It is unsettling but we are holding tight. For us it\u2019s a long term investment, but hoping our patience will pay off soon! Saw our knowledgeable friend yesterday (that first put us onto Polx) and he is still confident so we are trusting his judgement on this. Lolajamola Posted in: POLX Posts: 12 RE: Here we go21 Mar 2022 16:54 Appreciate reading your recommendations on this one. We have also been tipped by another investor on this one as a good bet but it\u2019s reassuring to hear it from another source! Crossing all the digits\u2026.",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-11T16:51:14.720161+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251230-loadofbo--5491830",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235225",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people buying here? Have I missed something? Be lucky to 1 new share for 100 old when it\u2019s delisted.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-11T16:51:14.720179+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251135-Lolajamo-92361156",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.235739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lolajamola",
          "content": "Also sticking it out. Lost so much on this one it\u2019s just not worth selling! Holding out for a miracle\u2026!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "0.085",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-11T16:51:14.720198+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251043-JeniH-40403750",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236264",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "I'm staying too - it qualifies for 2 bargain stock screens on Stockopedia so I'm happy to hold for the share price recovery or an offer for the whole company  whichever comes first.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.08",
          "thread_title": "RE: For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-11T16:51:14.720222+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251013-Doppo59--1094409",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.236801",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "I'm staying put. This seems to be oversold, remember delisting was announced months ago. POLX are in partnership with Phillips who already use the product with Xenoview (FDA approved). My money is on Phillips buying us out, or at least a partnership,  POLX have more money in the bank than the current MC, so not going bust. Who knows how many orders are almost ready to be signed, Asia, India, not forgetting US. A couple of bits of good news and J P Jenkins might have to do some work! It seems most have left now, I'll see it through, waited five years, might as well another year! The tech is still sound, and being used. Wish me luck lol Doppo",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "For what it's worth",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=439BA32B-A40D-4DAA-ABE6-5468C85E3592"
        },
        "ingested_at": "2026-02-11T16:51:14.720241+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251524-Latino--9098353",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yep no shares lost here, shareholders can still sell after delisting via JP Jenkins.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-11T16:51:14.720259+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251437-Doppo59--3961383",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.237857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Pyueck, I'm not selling yet, I'm too stubborn. We might get an offer of a buyout before the 23rd, who knows. They have money in the bank till H2, I don't think they can ever raise again at the current price. Such great tech, unfortunately run by compete armatures with not a good salesman among them. This BB was full of people all singing the companies praises, not a single post any more. The rich get richer and the poor .... This was posted on here a couple of days ago, you keep your shares and sell (or buy) through J P Jenkins, just harder to do. Good luck fella. The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.08",
          "thread_title": "RE: Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-11T16:51:14.720276+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-PYUECK-58116357",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238302",
        "source": "LSE_CHAT",
        "data": {
          "author": "PYUECK",
          "content": "I am assuming everybody is now just selling their shares before the 23rd. If you hold in a nominee account I suspect they wont even hold these shares for you in a private company so effectively they will be lost. Even if you keep, assuming the company survives any future fundraising is going to almost completely wipe out existing shareholders anyway. Even if this company has a rosey future, which I doubt, existing shareholders wont be part of it.",
          "sentiment": 0.0,
          "engagement": "773",
          "price_at_post": "0.08",
          "thread_title": "Is everybody selling up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=E56829BC-8039-4D57-AB0B-A3BFF07C453E"
        },
        "ingested_at": "2026-02-11T16:51:14.720294+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251259-bassman7-91282066",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.238717",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "What happened to the poster here who said he bought in after a tip from his Harley St eye surgeon's mate? \ud83d\ude02 Hope he didn't lose too much",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.075",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-11T16:51:14.720312+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251141-ironknut--7870018",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239147",
        "source": "LSE_CHAT",
        "data": {
          "author": "ironknut",
          "content": "At last we mugs who invested here are put out of our misery. At least the losses will reduce capital gains tax donations to Westminster.",
          "sentiment": 0.0,
          "engagement": "1,665",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-11T16:51:14.720330+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251111-Doppo59-26336660",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.239580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Thanks Latino. I did speak to my broker (HL) this morning who confirmed those details. They will be writing to me in the next few days to confirm my holding and advising the next step with J P Jenkins. POLX have funds until H2, lets see what happens next. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-11T16:51:14.720348+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251015-Latino-70401162",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240018",
        "source": "LSE_CHAT",
        "data": {
          "author": "Latino",
          "content": "Yesterday RNS extract: The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation. Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders. The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.",
          "sentiment": 0.0,
          "engagement": "19,401",
          "price_at_post": "0.09",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-11T16:51:14.720366+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250921-2reincar-24703430",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240438",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Say hello to Genedrive when you meet in hell!",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.09",
          "thread_title": "Goodbye Polarean",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=28001004-0D99-46D9-AF63-BB068E80A726"
        },
        "ingested_at": "2026-02-11T16:51:14.720384+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250815-Laura202-73839491",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.240850",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The matched bargain facilty is at bottom of yesterday RNS",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-11T16:51:14.720417+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252113-shamI89--3357919",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241280",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "There will be other mini spikes to let traped traders out , although I believe last \"p&d\" was orchestrated to let Laura excape with a profit.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-11T16:51:14.720439+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252026-Jacobjoh-89743707",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.241692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "With laura.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "RE: Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-11T16:51:14.720458+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20252025-Jacobjoh--5093547",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:54.242119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "In a sad old death threesome here.  Dopper and spunky has to admit and apologise now and they should have listened to me and saved some money.  I tried....you can lead a dopper to water lop .. You nasty people deserve every misfortune you get here.",
          "sentiment": -0.5,
          "engagement": "1,281",
          "price_at_post": "0.105",
          "thread_title": "Dopper and spunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=76E974FC-5B2B-4E54-B87D-1F3B26F91F8C"
        },
        "ingested_at": "2026-02-11T16:51:14.720476+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251947-Doppo59--2653542",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384442",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunky. I believe that any shares you own, remain yours. It will be harder to trade them though.However I did hear a rumour that polx are setting up something on their website to help. Maybe stick around and hope they don't go bust!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-11T16:51:14.720494+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251845-shamI89--1134993",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.384975",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Company has been survining on placings and would do so in near future, so you can imagine what will happen.It is a trend where share holders spend the money and company uses that money to develop a technology to get delisted at the end leaving shareholders high and dry.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-11T16:51:14.720512+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251720-loadofbo--1531213",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.385526",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Yes, probably 1 new share for every 100 old ones, that\u2019s the usual practice.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.105",
          "thread_title": "RE: Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-11T16:51:14.720530+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251656-Mikewinv-57589838",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikewinvest",
          "content": "TR1s...the dogs that haven't barked!",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "0.105",
          "thread_title": "TR1s",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=698AFB22-A50E-487C-B919-75F58340736B"
        },
        "ingested_at": "2026-02-11T16:51:14.720547+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251650-trunky--1734567",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.386636",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will this mean we lose all our investment ?or will we be allocated new shares in the private company?",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.105",
          "thread_title": "Shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=75ABD2D8-B461-4C1A-B973-11CFF7603D09"
        },
        "ingested_at": "2026-02-11T16:51:14.720565+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251636-Safi123-90350317",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Safi123",
          "content": "We were close, certainly winning the vote was on the cards but it seems a large number of PIs were apathetic. Does anyone know if any large stakeholders opposed the move to going private? This company is growing, with international expansion, upcoming trial and proven technology. It will have no issue raising cash. In my view a much better chance of success than most small med tech businesses (some of whom valued in 10s of millions) I\u2019m not convinced ultradilution as a private business is inevitable. For one thing, there\u2019s no guarantee either Nukem or Bracco are willing to fully finance this business further to the tune of 20 million, already owning healthy portions. If a third party wants a stake it will be at a much higher valuation (business is realistically worth at the very least 10-20 million looking at similar AIM businesses) Secondly, 524 million votes in favour suggests Nukem and Bracco somehow obtained the support of other large shareholders. These shareholders would never agree to going private if it means their stakes are obliterated.",
          "sentiment": 0.0,
          "engagement": "124",
          "price_at_post": "0.105",
          "thread_title": "Company valuation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=43B57842-8C07-4F9A-B3B1-1EE524148282"
        },
        "ingested_at": "2026-02-11T16:51:14.720584+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251617-loadofbo--5096981",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.387696",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "This is de listing in 8 days, why are people still buying?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-02-11T16:51:14.720602+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-loadofbo--2699353",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388224",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-11T16:51:14.720620+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-Laura202-68553871",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.388744",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected but the 20% tried Will the 80% continue to buy ?",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=3F2A7B3B-AE3E-4639-A934-240BBB204D8B"
        },
        "ingested_at": "2026-02-11T16:51:14.720638+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251606-tuan6--6025225",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389269",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Dont worry  as peoples dont sell when they are  reading in .  only sell when they dont see any value left .  this comoany have more money in its bank account  than its market CAP so there are still  pretty  things left for sell .  even  someone  will jump in  to buy this company  so dont worry  for shareholders as this is thier money and they dont give up that easy.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-11T16:51:14.720655+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-bassman7-69250264",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.389791",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "I mean... they announced it live in an advertised public call. Are you honestly putting your posts through googletranslate and back. You know those translation programmes don't make spelling mistakes?",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-11T16:51:14.720673+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251600-loadofbo--7399572",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390312",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "If they don\u2019t de list they will go bust because they are out of money, can\u2019t raise anymore and can\u2019t sell the company.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-11T16:51:14.720691+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251558-loadofbo-81195102",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.390804",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-11T16:51:14.720708+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251555-tuan6-64200085",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391467",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "No RNS is good news as if they pass they have published  it by now.  400% rise next month.",
          "sentiment": 0.0,
          "engagement": "3,965",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-11T16:51:14.720726+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251545-shamI89-48606909",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.391981",
        "source": "LSE_CHAT",
        "data": {
          "author": "shamI89",
          "content": "Managed to get another \"p&d\" away......",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.10",
          "thread_title": "Looks like Laura has",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=95DBDD4A-508B-4205-B71E-4DC15152341B"
        },
        "ingested_at": "2026-02-11T16:51:14.720744+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251541-loadofbo--5336811",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.392503",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why are people still buying here?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-11T16:51:14.720762+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251539-bassman7-47497446",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393006",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Did you not zoom the meeting? They said information would be up on their website \"in due course\".  The meeting was about 5 mins long. It was agreed the company is being delisted. Hearing it from the company live in a zoom call (jiopning details below) was enough confirmation for me \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.10",
          "thread_title": "RE: Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-11T16:51:14.720781+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251535-Laura202--8200275",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.393535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Confirmation or otherwise This drop is on very low volume Mmmmmm",
          "sentiment": 0.0,
          "engagement": "15,330",
          "price_at_post": "0.10",
          "thread_title": "Still no",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=9089B43B-45C6-4C71-BC31-95302BCC59EA"
        },
        "ingested_at": "2026-02-11T16:51:14.720800+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251534-share4--3392034",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394027",
        "source": "LSE_CHAT",
        "data": {
          "author": "share4",
          "content": "These are going to end up being known as \"green box\" shares",
          "sentiment": 0.0,
          "engagement": "1,738",
          "price_at_post": "0.10",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-11T16:51:14.720818+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251519-2reincar--3806135",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394469",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Question of only when.",
          "sentiment": 0.0,
          "engagement": "5,840",
          "price_at_post": "0.10",
          "thread_title": "Genedrive will eventually go the same way!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=EF81FBC2-AF85-428C-BBE4-906724917774"
        },
        "ingested_at": "2026-02-11T16:51:14.720837+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251437-Ilovesus--7501064",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.394897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Down 99.8% over the last 5 years. Even though some may have just made 100% . Often these type of rises are meaningless for most. Who honestly got in on the bottom and how long have they been invested? As the company can no longer get away with another placing it would have to issue too many shares and then only raise small amounts. That it now wants to delist is very telling. Its reach the end of the road. Its in a place where raising more through selling shares will not work. This is where most companies on AIM delist. They cannot sell any more shares. PYC is a company like this that may also delist. Seems some on that company post here. AIM companies list in order to raise money. PYC has had so many placings and  has a history of raising unlike this company. That too like this one will no doubt delist. Beware guys AIM is a cesspit.",
          "sentiment": 0.0,
          "engagement": "7,727",
          "price_at_post": "0.11",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-11T16:51:14.720855+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-Shpunken-58457943",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395328",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shpunken",
          "content": "Yep it is a shame that ppl will miss out on this and big companies again will be the winners",
          "sentiment": 0.0,
          "engagement": "4,326",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-11T16:51:14.720874+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251408-bassman7--7289286",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.395735",
        "source": "LSE_CHAT",
        "data": {
          "author": "bassman72",
          "content": "Judging by your recent comments Doppo, you seemed to think this would come good, even congratulating otheres on their holdings just a week ago... \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.13",
          "thread_title": "RE: No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-11T16:51:14.720892+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251406-Doppo59-24801736",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Such a shame, but no surprise! GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.13",
          "thread_title": "No Suprise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=609FF30E-F48D-4911-9450-FFC0AE00770D"
        },
        "ingested_at": "2026-02-11T16:51:14.720910+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251405-loadofbo-15718261",
        "event_type": "social_post",
        "date": "2026-01-29T09:42:57.396667",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "Why on earth would someone buy 7m shares when its de listing?",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.13",
          "thread_title": "RE: And... delisted from AIM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&share=POLX&thread=8E783F9A-4C63-461E-ACA1-4513E80D78C0"
        },
        "ingested_at": "2026-02-11T16:51:14.720928+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262043-Doppo59--4200449",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611356",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Rkb007, if you find any news out, can you post in here, i will look. I am a member of a Telegram group also. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-11T16:51:14.720945+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007-35567086",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.611798",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Direct",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-11T16:51:14.720964+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261644-rkb007--9414247",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612234",
        "source": "LSE_CHAT",
        "data": {
          "author": "rkb007",
          "content": "Same for me with Charles Stanley - they created an individual director account and moved shares for me \u2026",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-11T16:51:14.720982+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261316-Doppo59-25647000",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.612661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hi Aims23, I didn't sell my shares, HL are still holding them. Any trades are made though J P Jenkins who HL deal with on my behalf (sell only) i had to move them out of my stocks and shares ISA as Polarean is now a limited company. Are you still holding? GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.00",
          "thread_title": "RE: POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-11T16:51:14.721000+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261714-Aims23-76953988",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aims23",
          "content": "What happens to any share holders now? Does anyone know?",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "0.00",
          "thread_title": "POLX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=BAFE3FA4-F586-497E-8804-37C74E3E72CA"
        },
        "ingested_at": "2026-02-11T16:51:14.721018+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250958-Jacobjoh--1952706",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613495",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jacobjohn7",
          "content": "Who is going to instigate the class action here?",
          "sentiment": 0.0,
          "engagement": "1,274",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-11T16:51:14.721036+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251247-agakhan-33537463",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.613908",
        "source": "LSE_CHAT",
        "data": {
          "author": "agakhan",
          "content": "This is nothing short of CRIMINALITY.",
          "sentiment": 0.0,
          "engagement": "150",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-11T16:51:14.721054+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251023-tuan6--7850157",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614336",
        "source": "LSE_CHAT",
        "data": {
          "author": "tuan6",
          "content": "Looking bach history  of CEO and he have make two other company delist.  That show all of us how   behavior  from peoson who  management  your money. This delist is intend  so they can take all public shareholders off value and sell them with only them get benefit.   Some how FCA  letting whole AIMs  doingvthis for years and nothing  happens  to CEOs yes.  .  CEOs are daylight  robbers and they take all money.",
          "sentiment": 0.0,
          "engagement": "3,951",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-11T16:51:14.721072+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250957-DYM...Tu-71176277",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.614743",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "* company to be sold!",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "RE: Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-11T16:51:14.721091+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250918-DYM...Tu--2690646",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615184",
        "source": "LSE_CHAT",
        "data": {
          "author": "DYM...Turbo",
          "content": "Thanks for the info Doppo. Have a look at the link below, the major Gas Exchange trail was compete a couple of weeks ago. Obviously, this will have to be submitted to the FDA for approval but it would make things very interesting if we can get Gas Exchange approved before the next raise. FWiW, IMO, the company will be sold when the Gas Exchange is approved. https://clinicaltrials.gov/study/NCT04855305?a=11&tab=table Maybe the delisting is the first step in the chain for the to be sold?",
          "sentiment": 0.0,
          "engagement": "235",
          "price_at_post": "0.00",
          "thread_title": "Gas Exchange",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=07A6397C-C735-4572-941F-DE14EB830269"
        },
        "ingested_at": "2026-02-11T16:51:14.721131+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251512-Doppo59--7131856",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.615595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Sorry Trunky  ..... but yes I  believe is the answer to your question.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-11T16:51:14.721150+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251510-Doppo59--5180912",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Trunks, my shares were with HL who are listed on JP Jenkins site as a partner. POLX is now shown on there. They charge 1.5% for a trade along with a one off transaction fee of \u00a325. I believe you make the request to sell through HL but I'm still waiting for confirmation in the new year. Don't be mistaken, it is harder to trade though. Having said that POLX has to be in a prime position to be bought out. I think, keeping up with any news might be hard as they do not have to release an RNS. I'm holding 2.5 million so let's see what happens. The market is huge. GL",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-11T16:51:14.721168+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251442-trunky-60137236",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616436",
        "source": "LSE_CHAT",
        "data": {
          "author": "trunky",
          "content": "Will you be offered share certificates if you hold shares on crest",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-11T16:51:14.721187+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251436-Doppo59-17358746",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.616860",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Hey Loadof, I'm pleased that your not involved with this company any more, it's clearly not for you. Get yourself in with a steady Blue-chip company. By the way, what BB are you on now, just so that I know to stay away! Merry Christmas to us all x",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-11T16:51:14.721205+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-JeniH--8451859",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617280",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Three of us it is - thanks for the info on the share price Doppo - I won't be selling for a while.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-11T16:51:14.721223+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251133-loadofbo-23197435",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.617687",
        "source": "LSE_CHAT",
        "data": {
          "author": "loadofbollox",
          "content": "You\u2019ll be lucky to be offered 100:1 old for new, this garbage is finished for investors, just getting started for directors.",
          "sentiment": 0.0,
          "engagement": "269",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-11T16:51:14.721241+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251058-Laura202-24574944",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618105",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks Doppo",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.10",
          "thread_title": "RE: To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-11T16:51:14.721259+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251057-Doppo59--8328542",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618523",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "POLX is now listed on J P Jenkins at  0.1 GBX. Which is 0.001p .... I just wanted to be clear. Thank you and good luck, I guess we need to keep an eye on the POLX website from now on.",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "To be clear",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=E7124414-05F7-4E24-A9E6-CE4D4EFC45F6"
        },
        "ingested_at": "2026-02-11T16:51:14.721277+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250708-Nova888--2191404",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.618938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nova888",
          "content": "How did you eventually sell your shares Laura?",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "0.10",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.721294+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251846-Doppo59-44551359",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619359",
        "source": "LSE_CHAT",
        "data": {
          "author": "Doppo59",
          "content": "Can we make it the three of us! Im in!",
          "sentiment": 0.0,
          "engagement": "239",
          "price_at_post": "0.10",
          "thread_title": "RE: The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-11T16:51:14.721312+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251624-pjmcgra--6284835",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.619832",
        "source": "LSE_CHAT",
        "data": {
          "author": "pjmcgra",
          "content": "Laura and Jeni , love the enthusiasm,, keep it going well into the New Year . Thanks .",
          "sentiment": 0.5,
          "engagement": "1,244",
          "price_at_post": "0.10",
          "thread_title": "The two of us!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4AB8D2D8-863B-4C1F-80D9-C9F915D42D98"
        },
        "ingested_at": "2026-02-11T16:51:14.721330+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251045-Laura202-79302516",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "The medical.one was Verona",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.721348+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251041-Laura202--4505377",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.620684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Yes I'm happy to keep mine I've had 6 shares like this , and 4 have done well once.private, 2 less so But there was one that was then taken over x 10 after 3yrs of leaving AIM (a medical one ) Also tempted with INDI",
          "sentiment": 0.0,
          "engagement": "15,179",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.721366+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250928-JeniH-62880434",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621090",
        "source": "LSE_CHAT",
        "data": {
          "author": "JeniH",
          "content": "Very well put",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.721384+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250915-HPCFollo--8609540",
        "event_type": "social_post",
        "date": "2026-01-24T01:32:52.621514",
        "source": "LSE_CHAT",
        "data": {
          "author": "HPCFollower",
          "content": "I topped up & averaged down... companies who leave AIM with a solid business, perhaps in a lull or care & maintenance, save \u00a30.5 million p.a. and won't suffer high volatility of the share price when new investors buy in or provide loans. POLX have a good, unique product & will do well eventually. Doubt many will sell now.",
          "sentiment": 0.5,
          "engagement": "13",
          "price_at_post": "0.085",
          "thread_title": "RE: X - Major Funding $1.8M Grant!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLX&thread=4B96C180-01AF-47B2-9599-EB1921FA89F7"
        },
        "ingested_at": "2026-02-11T16:51:14.721402+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2025-12-08"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [],
    "narrative_summary": "POLX.L presents a standard crash recovery setup without unusual patterns detected. Monitor for catalyst developments and trend shifts.",
    "_is_real": false
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 66.0,
      "signal": "HIGH_PANIC",
      "interpretation": "\ud83d\udfe0 Fear dominant - watch for reversal signs",
      "breakdown": {
        "price_destruction": 40.0,
        "volume_death": 10,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": true,
      "opportunity_reason": "\u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 40/40 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 169% proven capacity"
      ],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "HIGH_PANIC",
        "icon": "\ud83d\udfe0",
        "text": "Fear 66/100",
        "color": "#f59e0b"
      },
      {
        "type": "EARLY",
        "icon": "\u23f0",
        "text": "Too Early",
        "color": "#3b82f6"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 52",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Cancellation - Polarean Imaging Plc",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Result of General Meeting",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Chest coil passes Philips compatibility testing",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "First Xenon Hyperpolariser in Asia",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Korean distributor agreement with DK Healthcare",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "BUY",
      "reason": "\ud83c\udfaf CrashHunter Signal: \u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "66/100",
          "pass": true,
          "icon": "\ud83d\udd34"
        },
        {
          "criterion": "Timing Regime",
          "value": "TOO_EARLY",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "52/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "3 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "5/5"
    },
    "contrarian_panic": {
      "total_score": 40,
      "band": "\ud83d\udfe2 MILD COMPRESSION (Top 50% - WATCHLIST)",
      "components": {
        "compression": {
          "score": 28,
          "max": 40,
          "signals_30d": 6,
          "signals_60d": 9,
          "signals_90d": 9,
          "signals_per_week": 0.69,
          "total_signals": 53,
          "rsi_extreme_count": 6,
          "rsi_ultra_count": 0,
          "escalation_count": 2,
          "density_score": 8,
          "rsi_score": 10,
          "escalation_score": 7,
          "description": "0.7 signals/week | 6 RSI<20 | 2 escalations | \u26a1 HIGH COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "EXTREME CRASH BOTTOM",
            "EXTREME CRASH BOTTOM",
            "DEEP CRASH BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 2,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 0,
          "max": 15,
          "relative_volume": 1.68,
          "description": "Normal volume"
        },
        "pop_potential": {
          "score": 7,
          "max": 15,
          "best_historical_rally": 168.8,
          "avg_rally": 30.7,
          "signal_count": 53,
          "description": "Moderate performer (169%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "POLX.L",
      "signal_date": "2025-11-27",
      "total_signals_history": 53
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +14 (AI_Technical_Score=11.0/20)",
      "Drawdown reversion potential: +19 (Drawdown_Pct=95.0%)",
      "Volume confirmation: +6 (Relative_Volume=1.7)",
      "Pattern reliability: +5 (Rally_Count=2.0)",
      "Upside history: +8 (best_rally_pct=169%)"
    ],
    "technical_score": {
      "points": 14,
      "ai_score": 11.0,
      "reason": "AI Technical Score 11.0/20 translates to 14/25 points"
    },
    "drawdown_score": {
      "points": 19,
      "drawdown_pct": 95.0,
      "reason": "Drawdown of 95.0% gives 19/20 points"
    },
    "volume_score": {
      "points": 6,
      "rel_volume": 1.68,
      "reason": "Relative volume 1.68x gives 6 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 2.0,
      "reason": "2.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 8,
      "best_rally_pct": 168.75,
      "reason": "Best rally of 169% gives 8/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=TOO_EARLY",
          "current_return_pct=-0.0%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2025-11-27"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "TOO_EARLY",
    "run_multiple": -0.0,
    "current_run_pct": -0.0,
    "avg_historical_run_pct": 168.75
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows TOO_EARLY timing with 52/100 APEX score. Historical data shows 2 rallies averaging 169% upside. Current position: -0.0%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "TOO_EARLY means you can get chopped before real move"
    ],
    "timing_translation": "It might be starting, but not proven yet. Wait for base + volume + catalysts.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  },
  "report_version": "5.0",
  "comprehensive_apex": {
    "score": 52,
    "rating": "MODERATE",
    "color": "#f59e0b",
    "calculation": "APEX Score: 52/100",
    "components": {
      "setup": {
        "score": 52,
        "weight": 0.25
      },
      "trust": {
        "score": 40,
        "weight": 0.2
      },
      "panic": {
        "score": 66.0,
        "weight": 0.3
      },
      "compression": {
        "score": 40,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "TOO_EARLY",
      "multiplier": 1.0
    }
  }
};</script>
  <script src="../../apex_trust_panel.js"></script>
</body>
</html>
